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	Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis 
(M.tuberculosis), a small aerobic bacillus, with a unique high lipid-content cell wall 
that plays an important role in its pathogenicity [1]. The organism affects the lungs 
predominantly, but extrapulmonary involvement is particularly common in young 
children and immune-compromised individuals [2]. Most people infected with 
M.tuberculosis have latent disease and are asymptomatic [3]. However, the smaller 
proportion of people who develop active disease, have significant morbidity and 
mortality. TB is essentially a preventable disease. Tuberculosis is unique in that it is 
transmitted almost exclusively through aerosolized droplets formed by coughing [4]. 
Factors affecting transmission of M.tuberculosis include sputum bacillary load and the 
presence of lung cavitation in the source. Effective anti-tuberculous treatment, 
isolation of sputum-individuals and the wearing of masks provide simple opportunities 
for prevention of mycobacterial transmission [5]. Adequate, well-ventilated, housing 
and the prevention of overcrowding are as effective in preventing transmission but are, 
due to resource limitation, much more difficult to achieve. 
	
In 2013, there was an estimated 9.0 million new TB cases worldwide [6]. From 1990 
to 2013 the incidence of new TB cases in South Africa increased from 301 to 
860/100,000 population. Currently the incidence of TB with human 
immunodeficiency virus (HIV) co-infection is 520/100,000 population, revealing the 
additional strain of the HIV pandemic on the TB burden [6]. Central nervous system 
(CNS) involvement, mostly tuberculous meningitis (TBM), accounts for approximately 
1% of all cases [7]. In the Western Cape Province of South Africa, a TB endemic area 
with routine access to Haemophilus influenza type-B and pneumococcal vaccination, 
TBM was shown to be the most common form of bacterial meningitis in children [8].  
 
In the late nineteenth century, it was thought that TBM resulted from haematogenous 
spread to the meninges, due to the frequent finding of TBM and miliary TB occurring 
in the same patient [9]. In 1933, Rich and McCordock, published their findings that in 
the majority of TBM cases that came to autopsy, a single caseous focus (Rich’s focus) 
could be found from which, when ruptured, bacilli could spread to the subarachnoid 
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space. In addition they found that the Rich focus was histologically more developed 
(“older”) than the granulomas found in concurrently occurring miliary TB [10]. This 
formed the basis of understanding of the pathogenesis of TBM. However, this model 
does not fully explain the frequency of simultaneously occurring miliary TB and TBM 
[11,12], or the mechanism whereby M.tuberculosis spreads from the lungs to the 
meninges and crosses the blood-brain barrier [13]. Animal models have been 
developed to improve understanding of the pathogenesis of CNS tuberculosis but 
findings are frustrated by the poor correlation between human and animal studies 
[13]. Magnetic resonance imaging has detected numerous concurrent leptomeningeal 
granulomas in children with miliary TB, further challenging Rich’s pathogenetic 
model [13,14]. It is likely that early hematogenous spread to the brain occurs, before a 
T-cell mediated immune response is activated. This could explain the vulnerability to 
TBM when T-cell mediated immunity is sub-optimal as in patients with untreated HIV 
disease [15].  
 
The protective role of lymphocytes is essential, including CD4+ and CD8+ T-cells, 
along with macrophages in isolating and engulfing M.tuberculosis to form a 
granuloma. Furthermore, disequilibrium of pro- and anti-inflammatory cytokines 
influence the severity and course of TBM [16,17]. Many of the signs, symptoms, and 
sequelae of TBM result from an immunologically-directed inflammatory response to 
the infection [16,17]. A better understanding of the entry of M.tuberculosis into the 
central nervous system and the immunological mechanisms allowing survival of the 
bacilli is crucial to improve prevention and treatment. Once spread to the brain 
occurs, TBM causes pathology by the formation of a dense basal exudate, initially 
containing erythrocytes, neutrophils and macrophages. When the dense exudate 
surrounds the circle of Willis, especially the perforators of the middle cerebral artery, 
cranial nerves and brainstem this can lead to infarction, cranial nerve palsy and direct 
brainstem parenchymal involvement, respectively.  Obstruction of cerebrospinal fluid 
(CSF) flow can result in hydrocephalus [7]. 
 
While accurate prediction of outcome in childhood TBM is difficult due to the 










	diversity of underlying pathological mechanisms and variation in host immunological 
response and early detection of TBM is onerous, due to a non-specific clinical 
presentation with symptoms such as cough, loss of weight, fever, vomiting and 
malaise. With disease progression, meningism, focal neurological signs and depressed 
level of consciousness become manifest. TBM represents the most severe 
manifestation of TB and is a major cause of death in paediatric TB [18]. The moment 
of initiating treatment is the most critical factor affecting morbidity and mortality, 
highlighting the importance of early diagnosis of TBM [19,20]. 
 
The hypothesis tested is two-fold. Early diagnosis of childhood TBM can be improved 
by 1) applying and refining a uniform case definition 2) enhancing rapid identification 
of M.tuberculosis in CSF. 
 
The clinical objective is to validate the uniform case definition for TBM in clinical 
practice and to test its utility a clinical tool to detect early childhood TBM, with high 
sensitivity and specificity. The laboratory-based objectives are: 
1. To determine the role of CSF volume in obtaining a positive culture of M.tuberculosis.  
2. To determine the diagnostic accuracy, and resistance detection, of the MTBDRplus® 
assay on fresh CSF samples and to compare these results with those obtained from 
cultured specimens. 
3. To determine the diagnostic accuracy, and resistance detection, of the Xpert 
MTB/RIF® assay on fresh CSF samples and to compare these results with those 
obtained from cultured specimens. 
 
With this thesis, the aim is to improve the early and/or more accurate diagnosis of 
childhood TBM by defining predictive clinical criteria, and evaluate the diagnostic 
accuracy of diagnostic methods.  
 
My colleague, Dr Ronald van Toorn, and I were invited to submit an update on the 
diagnosis and management of TBM in children to a 2014 edition of Seminars in 
Pediatric Neurology focusing on key challenges specific to the African continent in 
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the management of children with neurologic diseases. This review, to which both 
authors contributed equally, highlights the importance of TBM as a cause of 
neurologic handicap in resource-poor countries (see chapter 2) [21]. In this review I 
discuss early diagnosis and treatment of TBM as the single most important factor 
determining outcome and prioritization of the development of affordable, accurate 
diagnostic tests for TBM in resource-poor settings. 
 
A definite diagnosis of TBM in meningitis suspects is possible when acid-fast bacilli 
are seen on CSF microscopy, CSF M.tuberculosis culture is positive and/or when M 
tuberculosis antigen is detected in CSF by commercial nucleic acid amplification 
(NAA) tests. Because of the low sensitivity of these tests, diagnosis of TBM in clinical 
practice is based on a combination of clinical, laboratory and radiological findings. 
Typical cerebro-spinal fluid (CSF) features include a moderately increased white cell 
count with lymphocyte predominance, increased protein, and decreased glucose. A 
clinical prediction rule differentiating TBM from other forms of meningitis in adults 
found five useful parameters: young age (<36 yrs), sub-acute presentation (symptom 
duration >5 days), normal peripheral white blood cell count, moderately raised CSF 
white cell count (<500 cells/ml), and lymphocyte predominance (CSF neutrophil 
proportion <50%) [22]. A subsequent study that tested this prediction rule found that 
it had good diagnostic accuracy when using a composite clinical case-definition and 
bacteriologically-confirmed TBM as reference standards [23]. Although 
macroscopically clear CSF with lymphocyte predominance differentiated TBM from 
bacterial meningitis [24], many additional characteristics (sub-acute onset, focal 
neurological deficit, low CSF/serum glucose ratio, and elevated CSF protein) were 
required to differentiate TBM from viral meningitis in adult patients [25].  
 
However data that compare diagnostic criteria of TBM and other causes of meningitis 
in children are limited. No studies describe clinical prediction rules derived from 
comparing childhood TBM to other forms of meningitis. Case definitions for TBM in 
the existing literature include definite and probable cases. There is general agreement 
that definite TBM includes meningitis suspects with acid-fast bacilli seen on CSF 










	microscopy, positive CSF M.tuberculosis culture and/or detection by commercial NAA 
tests. A large number of clinical, CSF, and radiological criteria have been used by 
different authors in different combinations for diagnosis of probable TBM. Clinical 
criteria for TBM included: 1) Prolonged symptoms 2) Recent poor weight gain 3) 
Headache and/or fever and/or night sweats and/or vomiting 4) Recent contact with an 
infectious TB source case or a positive tuberculin skin test 5) Neurological features 
including depressed level of consciousness, focal neurological signs, raised 
intracranial pressure, seizures, or meningism 6) Positive tuberculin skin test 7) Chest 
X-ray compatible with pulmonary TB 8) CT compatible with TBM 9) Other clinical 
specimens positive for acid-fast bacilli. CSF criteria for TBM included clear 
appearance, pleocytosis 10-500/µl, increased protein >1g/dl and decreased glucose 
defined as <2.2mmol/l or CSF to serum ratio of <50% [26-30]. 
 
Since most TBM cases are diagnosed on clinical grounds without bacteriological 
confirmation from CSF, research is impeded by the lack of reliable diagnostic criteria 
and standardized approaches [31,32]. Since attaining adequate sample sizes of only 
culture-confirmed TBM cases is difficult, most studies will include cases of probable 
and possible TBM. In order to improve standardization of clinical diagnosis of TBM 
for research purposes, a uniform research case definition for both adults and children 
was proposed by an international panel of experts. This case definition categorized 
patients as definite, probable, or possible TBM according to a composite score based 
on clinical, CSF, and neuroimaging findings [33]. Individual scoring criteria and score 
weighting were based on an extensive literature review and international expert 
consensus. 
 
Part 2 of this thesis focuses on the diagnostic utility of the uniform research case 
definition criteria for TBM. In chapter 3.1 I aim to retrospectively evaluate the 
diagnostic performance of probable and possible TBM criteria in children with 
culture-confirmed TBM and culture-confirmed bacterial meningitis [34]. The culture-
confirmed TBM cases were prospectively collected in different studies over a 20-year 
period at Tygerberg Children’s Hospital, comprising the largest database of childhood 
Stellenbosch University  https://scholar.sun.ac.za
16				Chapter	1	
	
TBM in the world. Study questions were: The purpose of this retrospective study was 
to determine the diagnostic accuracy of the uniform research case definition for TBM 
when comparing culture-confirmed TBM to culture-confirmed bacterial meningitis. 
Another aim was to determine which of the individual criteria in the uniform research 
case definition could differentiate between culture-confirmed TBM and culture-
confirmed bacterial meningitis?  
 
In chapter 3.2 the uniform research case definition is prospectively applied in a study 
comparing culture-confirmed TBM cases with bacterial and viral meningitis control 
patients. Study questions included the following: What is the diagnostic accuracy of 
the uniform research case definition for differentiating culture-confirmed TBM from a 
control group comprising bacterial and viral meningitis? Which criteria in the cases 
definition most accurately differentiate microbiologically-confirmed TBM from 
bacterial and viral meningitis? 
 
CSF findings are essential for early diagnosis of TBM. Leukocytosis with lymphocyte 
predominance, elevated protein and abnormally decreased CSF glucose are highly 
suggestive of TBM in endemic areas [30,35,36]. A CSF to serum glucose ratio below 
0.4 and an absolute CSF glucose concentration less than 2.2 mmol/L was shown to be 
highly specific for bacterial meningitis [37]. No studies have yet explored CSF glucose 
cut-off values for children with TBM. A CSF protein cut-off of >1g/L (100mg/dL) 
differentiated between cases of TBM and both viral and bacterial meningitis [24,25]. 
Chapter 3.3 aimed to assess the diagnostic utility of CSF glucose levels, CSF to serum 
glucose ratio and CSF protein levels in differentiating TBM from other types of 
meningitis. Study questions were: What is the optimal cut-off value for CSF glucose in 
TBM? What is the optimal cut-off value for CSF protein in TBM? Can decreased CSF 
glucose and raised CSF protein differentiate between TBM and other forms of 
meningitis?  
 
Chest X-ray is available even in resource-limited settings, and often is the first 
investigation that clinically confirms TB in a suspected case. Previous studies showed 










	that 30% to 65% of adults with TBM have chest X-ray findings consistent with active 
pulmonary TB [38-40]. In children the frequency is even higher ranging from 70% to 
84% [41]. Chapter 3.4 aims to describe the frequency of radiological features 
suggestive of pulmonary TB in children with TBM. Study questions were: What is the 
frequency of a chest X-ray suggestive of active pulmonary TB in childhood TBM? How 
many children with TBM have evidence of miliary TB on chest X ray? Does age of the 
patient or severity of TBM disease influence chest X-ray findings?  
 
Microbiological confirmation from CSF remains the gold-standard of diagnosis of 
TBM, but is challenging in young children due to the paucibacillary nature of disease 
and low CSF volumes available for diagnostic analysis [42]. Definite diagnosis of TBM 
requires visualization of acid-fast bacilli and/or a positive M.tuberculosis culture from 
CSF. Direct microscopy for acid-fast bacilli in CSF is fast but has low sensitivity 
(<20%) [43]. M.tuberculosis culture may take up to 42 days and has only slightly 
improved sensitivity (<50%) [30,44,45]. The bacterial yield of M.tuberculosis can be 
improved by obtaining larger volumes of CSF, optimizing centrifugation and 
increasing the amount of time taken with microscopy [46,47].   
 
The introduction of NAA methods, including polymerase chain reaction (PCR) 
techniques, have increased the specific detection and identification of M.tuberculosis. 
Automated amplification assays have simplified PCR within the routine laboratory and 
have also made standardization possible [48]. A decade old meta-analysis of the 
diagnostic value of NAA tests in TBM (studies 1990-2002 comprising both adults and 
children were analysed) showed that heterogeneity affected the accuracy of in-house 
NAA tests while commercial NAA tests were a useful adjunct to clinical findings and 
conventional M.tuberculosis testing but could not confidently exclude a diagnosis of 
TBM [49]. 
 
Since the above study, several new commercially available NAA tests have been 
developed for the rapid diagnosis of TB, but no studies have yet explored the 
diagnostic accuracy of the newer NAA tests in TBM. Chapter 4.1 consists of a 
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systematic review of all studies published since 2003 that evaluated the use of NAA 
tests to diagnose TBM, with particular emphasis on commercial tests, including Xpert 
MTB/RIF® [50]. Study questions included: Is the diagnostic accuracy of newer 
commercial NAA tests improved? What is the diagnostic accuracy of the Xpert 
MTB/RIF® assay on CSF samples? 
 
This last question is especially relevant since the WHO recommended in 2013 that 
Xpert MTB/RIF® be used for rapid diagnosis in preference to conventional 
microscopy and culture as the initial diagnostic test in all adults and children 
suspected of having TBM [51]. Xpert MTB/RIF® also detects susceptibility to 
rifampicin by amplification of the rpoB gene [52,53] The MTBDRplus® assay (Hain 
Lifescience GmbH, Nehren, Germany) version 2 is a line probe assay targeting the 
rpoB, katG and inhA genes, detecting M.tuberculosis, but with the additional 
advantage of detecting both rifampicin and isoniazid susceptibility. Although the 
MTBDRplus® assay version 2 has similar sensitivity and specificity to Xpert 
MTB/RIF® in smear microscopy-negative specimens, Xpert MTB/RIF® detects 
M.tuberculosis more rapidly (under 2 hours vs 5 hours), with easier handling and 
lower contamination rates [54-56]. In order to stop empiric treatment, a diagnostic 
test for TBM requires a negative predictive value >99%. As the negative predictive 
value of Xpert MTB/RIF® is lower than <99%, it is recommended for use in 
conjunction with clinical findings [57]. In chapter 4.2 the utility of MTBDRplus® 
and Xpert MTB/RIF® to diagnose TBM in a clinical setting, alone and/or in 
combination with established diagnostic methods is assessed [58]. Study questions 
were: What is the diagnostic accuracy of Xpert MTB/RIF® on CSF in childhood 
TBM? What is the diagnostic accuracy of MTBDRplus® on CSF in childhood TBM? 
What is the diagnostic accuracy of combined Xpert MTB/RIF® and MTBDRplus® on 
CSF in childhood TBM? 
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ABSTRACT
Tuberculous meningitis (TBM), the most devastating manifestation of tuberculosis, is 
often missed or overlooked due to non-specific symptoms and difficulties in diagno-
sis. It continues to be an important cause of neurological handicap in resource-poor 
countries.
Due to the suboptimal performance of diagnostic tests of TBM, diagnosis relies on 
thorough history, clinical examination and relevant investigations. The development 
of affordable, accurate diagnostic tests for TBM in resource-poor settings remains a 
priority.
Short intensified treatment is safe and effective in both HIV-infected and HIV-unin-
fected children. Treatment of tuberculous hydrocephalus depends on the level of the 
cerebrospinal fluid (CSF) obstruction. Corticosteroids reduce risk of neurodisability 
and death in HIV-uninfected children. Thalidomide should be considered in children 
compromised by TB abscesses and tuberculous-related optochiasmic arachnoiditis. 
In resource-poor countries, home-based TBM treatment after initial in-hospital stabi-
lization is feasible in carefully selected patients. Early diagnosis and treatment of TBM 
is the single most important factor determining outcome.
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Tuberculous meningitis (TBM) is the most devastating manifestation of tuberculosis 
and it continues to be an important cause of neurological handicap in resource-poor 
countries. A recent study in the Western Cape Province of South Africa found TBM 
to be the commonest cause of pediatric meningitis.1 South Africa is one of the 22 
high tuberculosis (TB) burden countries that account for 80% of the world TB cases. 
The estimated incidence of TB in SA is 1000 or more per 100 000 people. One of 
the Millennium Development Goals (MDG) targets are to halt and start to reverse the 
rising incidence of TB and to halve the 1990 prevalence and death rates by 2015.2 
Unfortunately, most African regions, including SA, are not on track to achieve this 
objective due to reasons such as resource constraints, conflict and instability and 
generalized HIV epidemics.
Bacille Calmette-Guerin (BCG) is currently the only available vaccine against TB, and 
is widely administered within the World Health Organization (WHO) Expanded Pro-
gramme for Immunization. It provides protection against disseminated TB and TBM 
(73%; 95% confidence limits 67-79%) but has highly variable and often low efficacy 
against pulmonary TB in adults.3 The impact of BCG vaccination on transmission of 
Mycobacterium tuberculosis (M.tb) is therefore limited. The variable efficacy of BCG 
vaccination together with the not inconsequential threat of multi-drug resistant TB 
highlights the neccessity of new vaccine development, but this is hindered by the lack 
of immune correlates, suboptimal animal models, and limited funding.4
CLINICAL MANIFESTATIONS
TBM may present at any age but is less common at the extremes of life. The peak inci-
dence is in children between 2 to 4 years of age.5 Early clinical diagnosis is notoriously 
difficult and often delayed, with disastrous consequences. Although delayed diagnosis 
of TBM is common, the very young infant, patients with another co-existing illness 
and those from non TB-endemic regions carry the highest risk for missed diagnosis. 
The classical presentation of TBM is as a subacute meningitic illness. The resulting 
dilemma is that the classical sign of meningitis, neck stiffness, is usually absent during 
the early disease stage in children and adults.6 Early diagnosis and treatment of TBM 
has been long recognized as the single most important factor determining outcome.5
Although much effort has gone into improving diagnostic investigations, these may 
not be requested if the possibility of meningitis has not crossed the physician’s 
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mind. This is applicable to health practitioners in resource-poor, as well as resource-
equipped countries, where the increase in migrant populations could potentially lead 
to an increased incidence of TBM. It is therefore important to recognize TBM during 
the early stage, mainly characterized by non-specific symptoms of general ill health 
rather than specific, classical signs of meningitis. In young children these include 
poor weight gain, low-grade fever and listlessness. Most early symptoms relate to un-
derlying pulmonary tuberculosis present in the vast majority of infants who develop 
TBM as a complication of primary infection. The only factor differentiating these 
symptoms of TBM from common illnesses such as influenza is their persistence7; 
however, this is often not recognized because care-givers may not return to the same 
health professional (especially if treatment failed) and often do not inform subsequent 
doctors of previous diagnoses and treatments of the current illness.7 Thus early stage, 
fully curable TBM may progress to the final stages of coma, opisthotonus and death 
following this course of events.
In older children common non-specific symptoms of early TB meningitis are fever, 
headache and vomiting, closely representing a flu-like illness. Recent close contact 
with an infectious pulmonary TB patient is an important diagnostic clue. Once the 
classical neurological signs of advanced TBM (including meningeal irritation, coma, 
seizures, signs of raised intracranial pressure, cranial nerve palsies, hemiparesis, 
movement disorders) appear, the diagnosis is usually apparent but at a considerable 
cost to the patient. It should be noted, however, that the initial presentation of TBM 
may be acute and accompanied by any of the above-mentioned “late” signs and 
without a distinct prodromal period. Neither organism genotype, resistance patterns 
(MDR TB), co-infection with HIV or BCG immunization status consistently modify the 
disease presentation as described above.6
COMPLICATIONS OF TBM
Tuberculous hydrocephalus and raised intracranial pressure
Hydrocephalus occurs in up to 80% of TBM patients.5 In 70% of cases the hydro-
cephalus is of a communicating nature. This occurs when the exudate that fills 
the basal cisterns causes a bottle-neck obstruction of the cerebrospinal fluid (CSF) 
pathways at the level of the tentorium. In 20% of cases, CSF obstruction occurs when 
the basal exudates obstructs the outflow foramina of the 4th ventricle leading to a 
non-communicating hydrocephalus. Other rare causes of non-communicating hydro-
cephalus are obstruction of the foramina of Munro or the aqueduct by strategically 
located tuberculomas.
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Tuberculous hydrocephalus is often complicated by raised intracranial pressure 
(ICP).5 Studies have shown that clinical diagnosis of the presence and degree of raised 
ICP is unreliable, especially in children with closed anterior fontanels.8 The value 
of computed tomography (CT) is limited by the poor correlation that exists between 
the degree of hydrocephalus (ventricular size) and severity of ICP.9 Signs of raised 
ICP may also mimic signs of brainstem dysfunction.10 It is therefore often difficult to 
distinguish between raised ICP and brainstem ischemia in the deeply comatose child 
with stage III TBM.
Tuberculous cerebrovascular disease
Stroke is a common and most devastating complication of TBM. Vessel pathology 
appears to be a consequence of its immersion in the local inflammatory exudate.11 
The terminal segments of internal carotid artery (ICA) and proximal portions of 
middle (M1 portion of MCA) and anterior (ACA) cerebral arteries are most frequently 
involved. Anti-tuberculous chemotherapy is relatively ineffective in preventing the 
vascular complications, suggesting an immune mechanisms. This has led to clinical 
intervention studies aimed at halting the progressive nature of the vasculitis.12
TB-IRIS
Central nervous system TB Immune reconstitution inflammatory syndrome (IRIS) 
often manifests as a life-threatening condition and should be considered when new 
neurological symptoms or signs develop shortly after initiation of antiretroviral ther-
apy (ART) in children.13 Two clinical scenarios may occur; “unmasking” IRIS when 
subclinical, previously unrecognized TB infection flares up after starting ART while 
“paradoxical IRIS” is diagnosed when new or worsening symptoms of TB develop 
despite adherence to appropriate antituberculous treatment in a patient who initiated 
combination antiretroviral ART.13 Neurological manifestations described, include 
neck stiffness, intracranial and spinal tuberculous mass lesions, radiculomyelitis, hy-
drocephalus, visual compromise and seizures.13 Paradoxical TBM-IRIS tends to occur 
within 3 weeks of initiation of ART in children.13
The frequency and mortality of neurological TB-IRIS in children is not well docu-
mented; only 1 case series has been published.14 In adults, TBM-IRIS complicates 
the course of treatment of HIV-associated TBM in 47% of cases, despite the use of 
adjunctive corticosteroid therapy.15 Mortality is high (up to 30%) in those affected.14
As yet, no means exist to predict the syndrome. The optimal time to initiate ART in 
children or adults with HIV-associated TBM is unknown. A recent randomized double-
blind placebo-controlled trial of immediate versus deferred ART in adult Vietnamese 
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patients with TBM showed that HIV-associated TBM in the study population had such 
a poor prognosis that the timing of ART made no appreciable difference regarding 
survival probability.16 Early initiation of ART was not associated with an increased risk 
of IRIS. Corticosteroids are the mainstay of treatment for TBM-IRIS, with interruption 
of ART reserved for life-threatening complications. Other immune-modulatory agents 
that have been used to treat IRIS in a limited number of patients include thalidomide, 
chloroquine, mycophenolate mofetil and cyclosporine.13
TB mass lesions
Tuberculomas of the central nervous system may occur in isolation or in association 
with TBM. Intracranial tuberculomas are often silent and unsuspected, especially if 
no clinical evidence of TB is present. A focal seizure in an otherwise normal child is 
the most common mode of presentation in TB endemic populations. Tuberculomas 
may also manifest with focal neurological signs or raised intracranial pressure due to 
obstruction of cerebrospinal pathways. Diagnosis is dependant on neuroimaging as 
the cerebrospinal findings and culture is negative in most patients. Most tuberculomas 
will resolve uneventfully in response to antituberculous treatment. Corticosteroids 
(prednisone 2mg/kg/day) should be reserved for cases with paradoxically enlarging 
tuberculomas.
TB mass lesions (large tuberculomas or abscesses) are known to develop or enlarge 
despite appropriate anti-TB treatment. This phenomenon, the result of IRIS, is often 
more severe in the setting of HIV co-infection and may be life threatening.13 Clinical 
manifestations depend on the size and location of the lesion(s) and include focal 
neurological signs, ataxia, spastic paraplegia and raised intracranial pressure due 
to obstruction of cerebrospinal fluid pathways. In our experience TB abscesses are 
responsive to thalidomide, a potent tumor necrosis factor alpha (TNF-α) inhibitor.17
DIAGNOSIS
Due to the suboptimal performance of diagnostic tests of TBM, the diagnosis in 
children relies on a thorough assessment of all the evidence derived from a careful 
history, clinical examination and relevant investigations. About 60% of children with 
TBM will have radiological evidence of pulmonary TB.5
There have been efforts to create clinical prediction rules to differentiate TBM from 
other forms of meningitis, especially in resource-poor settings. When comparing TBM 
and bacterial meningitis in adults, using a composite clinical reference standard, 
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sensitivities of 86-97% and specificities of 71-97% were obtained.18,19 When using a 
microbiologically proven M.tb reference standard, sensitivities (86-96%) and speci-
ficities (71-79%) were similar.18,20 However, a prediction rule performed less well in 
an area of high HIV seroprevalence (sensitivity 78% and specificity 43%).21
As CSF in both TBM and viral meningitis is clear and lymphocyte predominant, 
distinguishing between them is more difficult. A recent prediction rule, comprised 
of a diagnostic scoring system, performed well with sensitivity 92% and specificity 
94%.22 Despite numerous reports in the literature describing clinical prediction rules, 
standardized diagnostic criteria are lacking.23
The tuberculin skin test (TST) performed with a sensitivity of 61% in a large retrospec-
tive cohort of children with TBM.5 However sensitivity decreases (34%) when HIV 
co-infection is present due to the high rate of false negative results.24 In the young 
infant population (< 6 months) with BCG vaccination, specificity is decreased due to 
high false-positivity. Furthermore, a positive TST implies probable M.tb infection, but 
cannot delineate active TB disease.25
Although a 2011 meta-analysis of the use of interferon gamma release assays (IGRAs) 
in adults with pulmonary TB showed that there is no value for the diagnosis of active 
TB,26 CSF IGRA showed sensitivity of 59-84% and specificity 73-89%.27-30 However, 
the large CSF volumes needed in order to obtain enough cells to perform IGRA,31 is a 
limiting factor in children where much smaller CSF volumes are obtained.
A 2003 systematic review evaluated the test accuracy of nucleic acid amplification 
tests (NAATs) in the diagnosis of TBM.32 The studies with commercial NAATs revealed 
a pooled sensitivity and specificity of 56% and 98%, respectively. The review con-
cluded that commercial NAATs provided valuable information when positive, but due 
to poor sensitivity a negative test did not exclude TBM.32 The World Health Organiza-
tion has recently endorsed the Xpert MTB/RIF assay (Xpert; Cepheid, Sunnyvale, CA, 
USA) for both smear microscopy-positive and -negative sputum specimens.33 When 
using Xpert for CSF specimens, promising sensitivities of 67-85% and specificities 
94-98% were obtained.34,35
Neuroimaging plays an important role in the diagnosis of TBM especially during 
the early stage of the disease and in cases of diagnostic uncertainty. Computed to-
mography (CT) is most often used in resource-poor countries and a combination of 
hyperdense exudates on pre-contrast CT, basal meningeal enhancement, infarctions 
and hydrocephalus is highly suggestive (Figure 1).36 Bilateral basal ganglia infarcts are 
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particularly characteristic of TBM and this fi nding on CT suggest a high likelihood of 
brainstem involvement. Approximately a third of children with stage 1 TBM disease 
will have a normal CT scan.6
Magnetic resonance imaging (MRI) is superior to CT for diagnosing TBM, by detecting 
basal enhancement and granulomas in more patients, and prognosis, by detecting 
many more infarcts in strategic locations such as the brainstem (Figure 2).37 Gado-
 
 
Figure 1: Contrasted computed tomography showing a combination of hydrocephalus, basal meningeal 
enhancement and infarction. 
Figure 1. Contrasted computed to r y s owing a combination of hydrocephalus, basal meningeal 
enhancement and infarcti .




Figure 2A: Computed tomography of a 13-year old child presenting with disseminated TB and loss of 
consciousness. The initial CT only revealed bilateral periventricular hypodensities and hydrocephalus. Fig 2B-C 
T1-weighted post-gadolinium MRI 2 days later revealed basal meningeal enhancement and multiple ring-
enhancing lesions (miliary nodules) in the cerebellar hemispheres. 
Figure 2A. Computed tomography of a 13-year old child presenting with disseminated TB and loss of 
consciousness. The initial CT only revealed bilateral periventricular hypodensities and hydrocephalus. 
Figure 2B- . T1-weighted post-gadolinium MRI 2 days later revealed basal meningeal enhancement 
and multiple ring-enhancing lesions (miliary nodules) in the cerebellar hemispheres.
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linium enhanced MRI allows detection of miliary leptomeningial tubercles which 
have been reported to be present in 88% of children with TBM.38 MRI is also valuable 
for identification of optochiasmic arachnoiditis, which requires urgent intervention 
to reduce the risk of blindness.39 Magnetic resonance angiography (MRA) is useful 
for assessment of vascular involvement. Vessels most commonly affected include the 
terminal portions of the internal carotid arteries, as well as the proximal parts of the 
middle and anterior cerebral arteries.
TREATMENT
Fluid management
Hyponatremia occurs in up to 85% of children with TBM and is thought to be second-
ary to either syndrome of inappropriate anti-diuretic hormone (SIADH) or cerebral 
salt wasting. Fluid restriction has traditionally been recommended to counter the 
presumed threat of SIADH and reduce the risk of cerebral edema. There is how-
ever no evidence that indicates that fluid restriction is beneficial in children with 
meningitis. It may precipitate hypovolemia, which should be avoided at all costs as 
maintenance of adequate cerebral perfusion is of critical importance in TBM patients. 
TBM is known to induce a hypercoagulable state, which would then increase the risk 
of venous thrombosis and infarction in the setting of inadequate cerebral perfusion.40 
A safer option is to partially correct symptomatic hyponatremia (associated with 
seizures) by slow infusion of 5% hypertonic saline.
Antimicrobial therapy
There is limited evidence regarding the most appropriate treatment regimen for TBM 
or optimal duration of treatment.41 The WHO recommends 12-months treatment 
(2RHZE/10RH) for children with suspected or confirmed TBM. Short, intensified anti-
TBM therapy is advocated by several groups as similar completion and relapse rates 
have been reported when 6-months therapy was compared to 1-year.42 High dose 
intravenous rifampicin may also be associated with a survival benefit in adult patients 
with severe disease.
Local experience is that short, intensified therapy (6RHZEth for HIV-uninfected and 
9RHZEth for HIV-infected children) is safe and effective in children with drug sus-
ceptible TBM.42 This regimen was prospectively evaluated in 184 consecutive TBM 
children and resulted in a good outcome in 80% of cases and mortality of 3.8%.42 
The incidence of antituberculous drug-induced hepatotoxicity in the study was low 
(5%) and in all cases the original regimen was restarted without recurrence.42 The 
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rational for using ethionamide as the 4th drug is that it has good CSF penetration and 
less adverse effects compared to streptomycin and ethambutol. Another advantage is 
that isoniazid mono-resistant TBM may be overcome when ethionamide and pyrazin-
amide are used continuously for a 6-month period.43
In resource-poor countries, lengthy in-hospital treatment of TBM is often not a realis-
tic option. Local experience is that home-based TBM treatment after initial in-hospital 
stabilization is feasible in carefully selected patients under close supervision.44
Multidrug-resistant TBM should be considered in cases where there is deterioration 
despite compliance with adequate antituberculous treatment. In such cases it is vitally 
important to obtain cultures from source contacts. Newer NAAT allows resistance to 
rifampicin and/or isoniazid to be detected. Second-line agents for MDR TBM include 
levofl oxacin, amikacin, terizadone and para-aminosalicylic acid (PAS).
Treatment of tuberculous hydrocephalus
Treatment of tuberculous hydrocephalus depends on the level of CSF obstruction. 
Air-encephalography is the most reliable way of determining the level of CSF obstruc-
tion (Figure 3).45 CT is not a useful tool as panventricular dilatation occurs in both 
communicating and non-communicating types of hydrocephalus.45 Communicating 
hydrocephalus can be successfully treated with medical therapy consisting of acet-
azolamide 50 mg/kg/day and furosemide 1 mg/kg/day in 3 divided daily doses) for a 
   
 
 
Figure 3A: The lateral skull X-ray shows air in the basal cistern and lateral ventricles. This 
indicates communicating hydrocephalus (arrow) due to basal cistern obstruction to the flow of 
cerebrospinal fluid. Figure 3B: The lateral skull X-ray shows only air at the level of the basal 
cistern (arrow). This indicates non-communicating hydrocephalus due to obstruction of the 4th 
ventricle outlet foramen.      
Figure 3A. The lateral skull X-ray shows air in the basal cistern and lateral ventricles. This indicates 
communicating hydrocephalus (arrow) due to basal cistern obstruction to the fl ow of cerebrospinal 
fl uid. 3B. The lateral skull X-ray shows only air at the level of the basal cistern (arrow). This indicates 
non-communicating hydrocephalus due to obstruction of the 4th ventricle outlet foramen.
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period of 4 weeks.9 This drug combination reduces CSF production by blocking car-
bonic anhydrase activity and reduces ICP by decreasing the rate of CSF production. 
It is our experience that normalization of intracranial pressure occurs within days in 
more than 90% of children. Figure 4 illustrates our suggested treatment algorithm for 
children with tuberculous hydrocephalus.
Adjunctive anti-infl ammatory therapy
Corticosteroids
A 2008 Cochrane systematic review of 7 clinical trials involving 1140 participants 
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Furosemide 1 mg/kg/day 
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CT brain (MRI brain preferable if available) 
 
 
Brainstem infarction          Worsening hydrocephalus 




Figure 4. Tygerberg Children’s Hospital treatment algorithm for tuberculous hydrocephalus. 
Comm= communicating, Non-comm= non-communicating,VPS= ventriculo-peritoneal shunt, ICP= 
intracranial pressure 
Figure 4. Tygerberg Children’s Hospital treatment algorithm for tuberculous hydrocephalus.
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disabling neurological deficit (RR 0.82, 95% CI 0.70-0.97) in HIV uninfected TBM 
patients.46 The benefit of corticosteroids in HIV infected patients has not been demon-
strated. There are also no controlled trials comparing corticosteroid regimens. Local 
preference is to prescribe prednisone 2 mg/kg/day (maximum 60 mg/day) for the first 
month of treatment and then to gradually wean over the next 2-weeks.
Aspirin
The value of aspirin’s antithrombotic, anti-ischemic and anti-inflammatory proper-
ties in TBM was explored in two studies. An adult TBM study reported a significant 
reduction in mortality at 3 months (p=0.02).47 In contrast, a childhood TBM study 
found no significant benefit in morbidity (hemiparesis and developmental outcome) 
or mortality at 6 months.40
Thalidomide
TB abscesses are notoriously resistant to therapy and require total surgical excision 
for cure.48 Surgical excision is often not achievable due to the proximity of the 
abscesses to vital brain structures and the lack of neurosurgical care in resource 
poor countries. TB abscesses often teem with tubercle bacilli, which induce a strong 
cytokine response. The most important cytokine implicated is tumour necrosis factor 
alpha (TNF-α). Insufficient TNF-α production delays granuloma formation, which is 
required for control of bacillary growth whilst excessive production leads to extensive 
liquefaction necrosis as is evident in TB abscesses. Thalidomide 3-5 mg/kg/day, given 
orally, is our drug of choice in children who develop life-threatening TB mass lesions 
(IRIS) despite corticosteroids.12 The use of Thalidomide should also be considered in 
children with visual compromise due to tuberculous optochiasmic arachnoiditis.39
Outcome in childhood TBM
Prognosis in TBM largely depends on the stage the disease has reached at the time of 
treatment intervention. Children with stage I TBM disease are likely to have a normal 
outcome, whereas children with stage III disease have a high risk of mortality.42 
Multidrug-resistant TBM in children has a poor clinical outcome and is often associ-
ated with death.43 Inpatient mortality rates are generally similar between HIV-infected 
and uninfected children with TBM.42 However, mortality after hospital discharge 
is substantially worse in HIV-infected TBM children due to HIV-related illnesses. 
Long-term behavioural complications of TBM survivors include general behavioural 
disinhibitions and internalized emotional disorders.49
Stellenbosch University  https://scholar.sun.ac.za








 1. Wolzak NK, Cooke ML, Orth H, et al: The Changing Profile of Pediatric Meningitis at a Refer-
ral Centre in Cape Town, South Africa. J Trop Pediatr 2012; 58(6): 491-5.
 2. World Health Organization. Global Tuberculosis Report. Geneva, Switzerland, 2013.
 3. Rieder HL: Contacts of tuberculosis patients in high-incidence countries: Int J Tuberc Lung Dis 
2003; 7: S333-6.
 4. Hokey DA, Ginsberg A: The current state of tuberculosis vaccines. Hum Vaccin Immunother 
2013; 9(10). [Epub ahead of print]
 5. van Well GT, Paes BF, Terwee CB, et al: Twenty years of pediatric tuberculous meningitis: a 
retrospective cohort study in the western cape of South Africa. Pediatrics 2009; 123: e1-e8.
 6. Thwaites GE, van Toorn R, Schoeman J: Tuberculous meningitis: more questions, still too few 
answers. Lancet Neurol 2013; 12(10): 999-1010.
 7. Smith HV: Tuberculous meningitis. Int J Neurol 1964; 4: 134-57.
 8. Schoeman JF, le Roux D, Bezuidenhout PB, et al: Intracranial pressure monitoring in tubercu-
lous meningitis: clinical and computerized tomographic correlation. Dev Med Child Neurol 
1985; 27(5): 644-54.
 9. Schoeman JF, Van Zyl LE, Laubscher JA, et al: Serial CT scanning in childhood tuberculous 
meningitis: prognostic features in 198 cases. J Child Neurol 1995; 10(4): 320-9.
 10. van Toorn R, Springer P, Laubscher JA, et al: Value of different staging systems for predicting 
neurological outcome in childhood tuberculous meningitis. Int J Tuberc Lung Dis 2012; 16(5): 
628-32.
 11. Lammie GA, Hewlett RH, Schoeman JF, et al: Tuberculous cerebrovascular disease: a review. 
J Infect 2009; 59(3): 156-66.
 12. Schoeman JF, Fieggen G, Seller N, et al: Intractable intracranial tuberculous infection respon-
sive to thalidomide: report of four cases. J Child Neurol 2006; 21(4): 301-8.
 13. van Toorn R, Rabie H, Dramowski A, et al: Neurological manifestations of TB-IRIS: a report of 
4 children. Eur J Paediatr Neurol 2012; 16(6): 676-82.
 14. D.J. Pepper, S. Marais, G. Maartens et al: Neurologic manifestations of paradoxical tubercu-
losis-associated immune reconstitution inflammatory syndrome: a case series. Clin Infect Dis 
2009; 48(11): e96–107.
 15. Marais S, Meintjes G, Pepper DJ, et al: Frequency, Severity, and Prediction of Tuberculous 
Meningitis Immune Reconstitution Inflammatory Syndrome. Clin Infect Dis 2013; 56(3): 
450-60.
 16. Thwaites GE, Nguyen DB, Nguyen HD, et al: Dexamethasone for the treatment of tuberculous 
meningitis in adolescents and adults. N Engl J Med 2004; 351: 1741-51.
 17. Schoeman JF, Fieggen G, Seller N, et al: Intractable intracranial tuberculous infection respon-
sive to thalidomide: report of four cases. J Child Neurol 2006; 21(4): 301-8.
 18. Sunbul M, Atilla A, Esen S, et al: Thwaites’ diagnostic scoring and the prediction of tubercu-
lous meningitis. Med Princ and Prac 2005; 14(3): 151-4.
 19. Thwaites G, Chau T, Stepniewska K, et al: Diagnosis of adult tuberculous meningitis by use of 
clinical and laboratory features. Lancet 2002; 360(9342): 1287-92.
 20. Youssef F, Afifi S, Azab A, et al: Differentiation of tuberculous meningitis from acute bacterial 
meningitis using simple clinical and laboratory parameters. Diagn Microbiol Infect Dis 2006; 
55(4): 275-8.
Stellenbosch University  https://scholar.sun.ac.za
36 Chapter 2
 21. Checkley AM, Njalale Y, Scarborough M, et al: Sensitivity and specificity of an index for the 
diagnosis of TB meningitis in patients in an urban teaching hospital in Malawi. Trop Med Int 
Health 2008; 13(8): 1042-6.
 22. Hristea A, Olaru ID, Baicus C, et al: Clinical prediction rule for differentiating tuberculous 
from viral meningitis. Int J Tuberc Lung Dis 2012; 16(6): 793-8.
 23. Marais S, Thwaites G, Schoeman J, et al: Tuberculous meningitis: a uniform case definition for 
use in clinical research. Lancet Infect Dis 2010; 10(11): 803-12.
 24. Mandalakas AM, van Wyk S, Kirchner HL, et al: Detecting tuberculosis infection in HIV-
infected children: a study of diagnostic accuracy, confounding and interaction. Pediatr Infect 
Dis J 2013; 32(3): e111-8.
 25. McConkey SJ, Youssef FG, Azem E, et al: Evaluation of a rapid-format antibody test and the 
tuberculin skin test for diagnosis of tuberculosis in two contrasting endemic settings. Int J 
Tuberc Lung Dis 2002; 6: 246-52.
 26. Metcalfe JZ, Everett CK, Steingart KR, et al: Interferon-gamma release assays for active pulmo-
nary tuberculosis diagnosis in adults in low- and middle income countries: systematic review 
and meta-analysis. J Infect Dis 2011; 204(S4): S1120-9.
 27. Kim SH, Cho OH, Park SJ, et al: Rapid diagnosis of tuberculous meningitis by T cell-based 
assays on peripheral blood and cerebrospinal fluid mononuclear cells. Clin Infect Dis 2010; 
50: 1349-58.
 28. Patel VB, Singh R, Connolly C, et al: Cerebrospinal T-cell responses aid in the diagnosis of 
tuberculous meningitis in a human immunodeficiency virus- and tuberculosis-endemic popu-
lation. Am J Respir Crit Care Med 2010; 182: 569-77.
 29. Vidhate MR, Singh MK, Garg RK, et al: Diagnostic and prognostic value of Mycobacterium 
tuberculosis complex specific interferon gamma release assay in patients with tuberculous 
meningitis. J Infect 2011; 62: 400-3.
 30. Park KH, Cho OH, Lee EM, et al: T-cell-based assays on cerebrospinal fluid and PBMCs for 
rapid diagnosis of TB meningitis in non-HIV patients. Eur Respir J 2012; 39: 768-70.
 31. Thwaites GE: Advances in the diagnosis and treatment of tuberculous meningitis. Curr Opin 
Neurol 2013; 26(3): 295-300.
 32. Pai M, Flores LL, Pai N, et al: Diagnostic accuracy of nucleic acid amplification tests for 
tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect Dis 2003; 3: 
633-43.
 33. World Health Organization. Molecular line probe assays for rapid screening of patients at risk 
of multi-drug resistant tuberculosis (MDR- TB) Geneva, Switzerland, 2008.
 34. Tortoli E, Russo C, Piersimoni C, et al: Clinical validation of Xpert MTB/RIF for the diagnosis 
of extrapulmonary tuberculosis. Eur Respir J 2012; 40: 442-7.
 35. Patel VB, Theron G, Lenders L, et al: Diagnostic accuracy of quantitative PCR (Xpert MTB/
RIF) for tuberculous meningitis in a high burden setting: a prospective study. PLoS Med 2013; 
10(10): e1001536.
 36. Andronikou S, Smith B, Hatherhill M, et al: Definitive neuroradiological diagnostic features of 
tuberculous meningitis in children. Pediatr Radiol 2004; 34(11): 876-85.
 37. Pienaar M, Andronikou S, van Toorn R: MRI to demonstrate features and complications of 
TBM not seen with CT. Childs Nerv Syst 2009; 25(8): 941-7.
 38. Janse van Rensburg P, Andronikou S, van Toorn R, et al: Magnetic resonance imaging of the 
central nervous system in children with tuberculous meningitis. Pediatr Radiol 2008; 38(12): 
1306-13.
Stellenbosch University  https://scholar.sun.ac.za







 39. Schoeman JF, Andronikou S, Stefan DC, et al: Tuberculous meningitis-related optic neuritis: 
recovery of vision with thalidomide in 4 consecutive cases. J Child Neurol 2010; 25(7): 822-8.
 40. Schoeman JF, Janse van Rensburg A, Laubsher JA, et al: The role of aspirin in childhood tuber-
culous meningitis. J Child Neurol 2011; 26(8): 956-62.
 41. Woodfield J, Argent A: Evidence behind the WHO guidelines: hospital care for children: what 
is the most appropriate treatment for tuberculous meningitis? J Trop Pediatr 2008; 54(4): 220-4.
 42. van Toorn R, Schaaf HS, Laubscher JA, et al: Short intensified treatment in children with drug-
susceptible tuberculous meningitis. Pediatr Infect Dis J 2013; Oct 28 [Epub ahead of print]
 43. Seddon JA, Visser DH, Bartens M, et al: Impact of drug resistance on clinical outcome in 
children with tuberculous meningitis. Pediatr Infect Dis J 2012; 31(7): 711-6.
 44. Schoeman J, Malan G, van Toorn R, et al: Home-based treatment of childhood neurotubercu-
losis. J Trop Pediatr 2009; 55(3): 149-54.
 45. Bruwer GE, van der Westhuizen S, Lombard CJ, et al: Can CT predict the level of CSF block in 
tuberculous hydrocephalus? Childs Nerv Syst 2004; 20(3): 183-7.
 46. Prasad K, Singh MB: Corticosteroids for managing tuberculous meningitis. Cochrane Database 
Syst Rev 2008 Jan 23; (1): CD002244
 47. Misra UK, Kalita J, Nair PP: Role of aspirin in tuberculous meningitis: a randomized open 
label placebo controlled trial. J Neurol Sci 2010; 293(1-2): 12-7.
 48. Patnaik A, Mishra SS, Senapati SB: Surgical management of double giant tuberculomas of 
brain involving both supratentorial and infratentorial compartments. J Pediatr Neurosci 2013; 
8(1): 84-5.
 49. Wait JW, Schoeman JF: Behavioural profiles after tuberculous meningitis. J Trop Pediatr 2010; 
56(3): 166-71.
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
Part II Testing the utility of 
a uniform research case 
definition for tuberculous 
meningitis in children
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
3.1 Uniform research case definition criteria 
differentiate tuberculous 









Clin Infect Dis 2014;59(11):1574-8
Stellenbosch University  https://scholar.sun.ac.za
42 Chapter 3.1
ABSTRACT
BACKGROUND: Tuberculous meningitis (TBM) research is hampered by low num-
bers of microbiologically-confirmed TBM cases and the fact that they may represent 
a select part of the disease spectrum. A uniform TBM research case definition was 
developed to address these limitations, but its ability to differentiate TBM from bacte-
rial meningitis has not been evaluated.
METHODS: We assessed all children treated for TBM from 1985 to 2005 at Tygerberg 
Children’s Hospital, Cape Town, South Africa. For comparative purposes a group 
of children with culture-confirmed bacterial meningitis, diagnosed between 2003 
and 2009, was identified from the National Health Laboratory Service database. The 
performance of the proposed case definition was evaluated in culture-confirmed TBM 
and bacterial meningitis cases.
RESULTS: Of 554 children treated for TBM, 66 (11.9%) were classified as “definite 
TBM”, 408 (73.6%) as “probable TBM” and 72 (13.0%) as “possible TBM”. “Probable 
TBM” criteria identified culture-confirmed TBM with sensitivity 86% and specificity 
100%; sensitivity was increased but specificity reduced when using “possible TBM” 
criteria (sensitivity 100%, specificity 56%).
CONCLUSION: “Probable TBM” criteria accurately differentiated TBM from bacterial 
meningitis and could be considered for use in clinical trials; reduced sensitivity in 
children with early TBM (stage I disease) remains a concern.
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Tuberculosis (TB) continues to pose a major global health challenge with a high mor-
bidity and mortality, despite effective anti-tuberculosis medication, in TB endemic 
areas [1,2]. Tuberculous meningitis (TBM) is the most devastating manifestation of TB 
and is generally associated with poor outcomes. Diagnosis is often delayed due to 
the non-specific nature of early symptoms such as cough, weight loss, fever, vomiting 
and lethargy. With disease progression, a more definitive clinical picture becomes 
manifest [3], however, early treatment initiation is critical to optimize outcome [4,5].
Identification of Mycobacterium tuberculosis (M. tuberculosis) in cerebrospinal 
fluid (CSF) provides bacteriological confirmation of TBM. Unfortunately, due to the 
paucibacillary nature of TBM, CSF microscopy for acid-fast bacilli (AFB) [6] and 
CSF culture for M. tuberculosis has low sensitivity (<20% and <50% respectively) 
[3,7,8] compared to clinical criteria. Although culture provides the accepted “gold 
standard” it has little clinical utility, since it takes up to 42 days to confirm a positive 
result. A meta-analysis of the accuracy of commercial nucleic acid amplification tests 
(NAATs) for the diagnosis of TBM, mostly adult studies, showed a sensitivity of 64% 
and specificity of 98% compared to culture [9]. Thus it may serve as a rapid “rule-in” 
test, but does not provide a reliable ‘rule out’ test.
TBM research is greatly hampered by the absence of reliable diagnostic criteria and 
standardized approaches [10]. A recent review found that existing trials assessing anti-
tuberculosis treatment for TBM had limited power, poor methodology and used varying 
treatment regimens with conflicting results [11]. Answering critical research questions 
will require multi-centre randomized controlled trials using standardized diagnostic and 
staging criteria, with sufficient patient numbers to demonstrate differences in outcome 
[11]. As it is difficult to obtain adequate sample sizes using only culture-confirmed TBM 
cases, inclusion of probable and possible TBM cases require consideration.
A uniform research case definition for TBM in adults and children was developed 
to improve standardization of diagnosis for research purposes [12]. Classification 
as definite, probable or possible TBM is based on a composite score of clinical 
findings and special investigations; summarized in Table 1. Individual criteria and 
their relative weights were assigned based on an extensive literature review together 
with international expert consensus [12-17]. The accuracy of proposed criteria for 
probable and possible TBM has not been assessed. Our study aimed to evaluate 
the diagnostic performance of probable and possible TBM criteria in children with 
culture-confirmed TBM and culture-confirmed bacterial meningitis.
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PATIENTS AND METHODS
We conducted a retrospective review of all children (<13 years of age) treated for 
TBM between January 1985 and April 2005 at Tygerberg Children’s Hospital, Cape 
Town, South Africa. Clinical data were prospectively collected in all TBM patients as 
part of ongoing studies conducted at the time. For comparative purposes we identified 
a group of children (<13years of age) with culture-confirmed bacterial meningitis, 
diagnosed between January 2003 and November 2009. Bacterial meningitis cases 
were identified from the National Health Laboratory Service database at Tygerberg 
Children’s Hospital; relevant clinical data were retrieved from patient files. The study 
was approved by the Human Research Ethics Committee of Stellenbosch University 
(HREC reference number N10/11/367).
CASE DEFINITIONS
Tuberculous meningitis
Patients were classified as “definite TBM” if the CSF culture was positive for M. tuber-
culosis; smear microscopy for acid-fast bacilli and/or commercial NAAT testing was 
not performed at the time.
Identification of probable and possible TBM was based on pre-defined diagnostic 
scoring criteria (Table 1) [12]. Points were allocated in the following categories: 1) 
clinical findings 2) CSF results 3) neuroimaging findings 4) evidence for TB outside 
the central nervous system and 5) additional laboratory criteria. A total score of at 
least 12 was compatible with probable TBM (when neuroimaging was unavailable, 
the total score was reduced to at least 10), while a total score of 6-11 equated to a 
possible TBM diagnosis (when neuroimaging was unavailable the total score required 
was reduced to 6-9), with a minimum number of points coming from CSF or neuro-
imaging criteria.
Potential alternative causes had to be excluded by performing at least 1) CSF Gram 
stain and bacterial culture 2) CSF India ink stain, cryptococcal antigen latex ag-
glutination test and/or cryptococcal culture. These investigations were routinely 
performed. Additional investigations such as 3) viral culture and/or polymerase chain 
reaction (PCR) and tests to exclude 4) neurosyphilis and 5) cerebral malaria should 
be conducted if clinically or epidemiologically indicated; these investigations were 
not routinely performed in our cohort. Due to the retrospective nature of the study, 
the following imaging criteria could not be evaluated: pre-contrast basal hyperdensity 
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Table 1. Diagnostic criteria in the uniform TBM research case definition [12]
Diagnostic score
Clinical criteria (Maximum category score=6)
Symptom duration of more than 5 days 4
Systemic TB symptoms (1 or more of ): weight loss/(poor weight gain in 
children), night sweats or persistent cough > 2 weeks
2
History of recent close contact with an individual with pulmonary TB or a 
positive TST/IGRA in a child <10 years
2
Focal neurological deficit (excluding cranial nerve palsies) 1
Cranial nerve palsy 1
CSF criteria (Maximum category score=4)
Clear appearance 1
Cells: 10–500 per µl 1
Lymphocytic predominance (>50%) 1
Protein concentration greater than 1 g/L 1
CSF to plasma glucose ratio of less than 50% or an absolute CSF glucose 
concentration less than 2.2mmol/L
1
Cerebral imaging criteria (Maximum category score=6)
Hydrocephalus (CT and/or MRI) 1
Basal meningeal enhancement (CT and/or MRI) 2
Tuberculoma (CT and/or MRI) 2
Infarct (CT and/or MRI) 1
Pre-contrast basal hyperdensity (CT) 2
Evidence of tuberculosis elsewhere (Maximum category score=4)
Chest radiograph suggestive of active TB (excludes miliary TB) 2
Chest radiograph suggestive of miliary TB 4
CT/ MRI/ US evidence for TB outside the CNS 2
AFB identified or M. tuberculosis cultured from another source i.e., sputum, 
lymph node, gastric washing, urine, blood culture
4
Exclusion of alternative diagnoses- An alternative diagnosis must be confirmed microbiologically, 
serologically or histopathologically
Definite TBM = AFB seen on CSF microscopy, positive CSF M. tuberculosis culture or CSF M. tuberculosis 
commercial NAAT with symptoms/signs suggestive of meningitis; or AFB seen in the context of histology 
consistent with TB brain or spinal cord together with suggestive symptoms/signs and CSF changes, or 
visible meningitis (on autopsy).
Probable TBM = total score of ≥12 when neuroimaging available
 = total score of ≥10 when neuroimaging unavailable
Possible TBM = total score of 6-11 when neuroimaging available
 = total score of 6-9 when neuroimaging unavailable
TBM=tuberculous meningitis, TB=tuberculosis, TST=tuberculin skin test, IGRA=interferon gamma-re-
lease assay, CSF=cerebrospinal fluid, CT=computed tomography, MRI=magnetic resonance imaging, 
US=ultrasound, AFB=acid-fast bacilli, NAAT=nucleic acid amplification test
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on computed tomography (CT), imaging of TB outside the CNS (apart from standard 
postero-anterior and lateral chest radiographs). TBM disease staging was determined 
as follows: Stage I) Glasgow Coma Scale (GCS) of 15 and no focal neurological signs, 
Stage IIa) GCS of 15 plus focal neurological signs, Stage IIb) GCS of 11-14 with focal 
neurological signs and Stage III) GCS <11 [17,18].
Bacterial meningitis
A diagnosis of definite bacterial meningitis was made if bacterial pathogens were 
identified by Gram stain and/or culture from CSF, and patients were treated for bacte-
rial meningitis.
Statistical analysis
Statistical analysis was done using SPSS version 20 (SPSS Inc, Chicago, IL, USA) and 
SAS version 9.1 (SAS Institute Inc., Cary, North Carolina, USA). The Fishers-exact test 
and odds ratios were used in univariable analyses comparing “definite TBM” and 
“definite bacterial meningitis”; using a two-tailed test for statistical significance.
RESULTS
In total, 554 children were treated for TBM during the study period; 66 (11.9%) were 
classified as definite TBM, 408 (73.6%) as probable TBM, 72 (13.0%) as possible TBM 
and 8 had insufficient information for reliable classification [12]. Table 2 provides an 
overview of TBM cases, including staging and diagnostic criteria. Diagnostic criteria 
are also reflected for the 32 cases with definite bacterial meningitis identified. When 
applying the uniform research case definition for TBM to bacterial meningitis cases, 
14 scored as possible TBM and 18 as ‘no TBM’. None of the bacterial meningitis 
cases tested positive for human immunodeficiency virus (HIV). Among TBM patients, 
8 were HIV-infected, 205 HIV-uninfected and the HIV status was unknown in 341 
patients. HIV prevalence was low during the earlier part of the 20-year study period 
when HIV testing was not routinely done. In the possible TBM group, 25% of patients 
had stage III disease, compared to 42% and 41% in the probable and definite TBM 
groups respectively.
When scoring children with definite TBM independent of their M. tuberculosis cul-
ture results, 57/66 (86%) scored as probable TBM and 9/66 (14%) as possible TBM. 
Of the nine culture-confirmed TBM cases that scored as ‘possible’ TBM, three had 
limited clinical symptoms (one TBM stage I and IIa) and six had minimal signs on 
neuroimaging. Seven culture-confirmed TBM cases were within 2 points of the cut-off 
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for a ‘probable’ TBM score; the remaining 2 patients had low scores for both clinical 
and neuroimaging criteria.










Total number 66 408 72 32
Stage I 2 (3) 5 (1) 4 (6) n/a
Stage IIa 35 (53) 214 (52) 47 (65) n/a
Stage IIb 2 (3) 16 (4) 1 (1) n/a
Stage III 27 (41) 172 (42) 18 (25) n/a
Unknown stage 0 1 2 n/a
Symptom duration > 5 days 47/66 (71) 366/408 (90) 40/72 (56) 6/32 (19)
≥1 of: weight loss/poor weight gain, night 
sweats or persistent cough >2 weeks
31/66 (47) 204/408 (50) 25/72 (35) 1/32 (3)
History of recent TB contact or positive TST 
or IGRA
33/65 (52) 291/374 (78) 36/66 (55) 2/32 (6)
Focal neurological deficit 33/66 (50) 286/408 (70) 27/72 (38) 2/32 (6)
Cranial nerve palsy 18/66 (27) 110/408 (27) 17/72 (24) 2/32 (6)
Altered consciousness 46/66 (70) 398/408 (98) 65/72 (90) 19/32 (59)
CSF clear 66/66 (100) 408/408 (100) 72/72 (100) 18/32 (56)
CSF cells: 10–500 per µl 55/63 (87) 361/396 (91) 53/54 (98) 20/32 (63)
CSF lymphocyte predominance (>50%) 51/63 (81) 326/396 (82) 53/54 (98) 19/32 (59)
CSF protein concentration >1 g/L 49/61 (80) 292/387 (72) 42/52 (81) 15/32 (47)
CSF:serum gluc ratio <50% and/or CSF gluc 
concentration <2.2mmol/L
47/59 (80) 263/361 (73) 34/48 (71) 17/32 (53)
Hydrocephalus (CT and/or MRI) 60/62 (97) 353/391 (90) 51/62 (82) 9/21 (43)
Basal meningeal enhancement (CT and/or 
MRI)
48/62 (77) 318/391 (81) 19/62 (31) 1/21 (5)
Tuberculoma (CT and/or MRI) 5/62 (8) 55/391 (14) 5/62 (8) 1/21 (5)
Infarct (CT and/or MRI) 15/62 (24) 142/391 (36) 3/62 (5) 3/21 (14)
Pre-contrast basal hyperdensity (CT) No data No data No data 0
CXR suggestive of active TB 26/66 (39) 206/398 (52) 17/66 (26) 3/32 (9)
CXR suggestive miliary TB 11/66 (17) 53/398 (13) 1/66 (2) 0
Extraneural radiological TB 0 0 0 0
Extraneural M. tuberculosis confirmation 19/66 (29) 100/408 (25) 2 (3) 0
TBM=tuberculous meningitis, BM=bacterial meningitis, TB=tuberculosis, TST=tuberculin skin test, 
IGRA=interferon gamma-release assay, CSF=cerebrospinal fluid, gluc=glucose, CT=computed tomog-
raphy, MRI=magnetic resonance imaging, CXR=chest radiograph
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Among the definite bacterial meningitis group, 18/32 (56%) scored as unlikely TBM 
and 14/32 (44%) as possible TBM. Comparing patients with definite TBM and definite 
bacterial meningitis, a probable TBM score provided good diagnostic accuracy; sen-
sitivity 86% and specificity 100%. A possible TBM score was more sensitive but very 
non-specific; sensitivity 100% and specificity 56%.
Table 3 summarizes findings for specific criteria on univariate analysis. Comparing 
definite TBM to definite bacterial meningitis the most informative clinical criteria 
were either weight loss or persistent cough longer than 2 weeks (OR 27.5; 95% 
Confidence interval (CI) 3.5-213.1), recent close TB contact or positive tuberculin 
skin test (OR 15.0; 95% CI 3.3-67.9), and focal neurological deficit (OR 15.0; 95% 
CI 3.3-67.9). Macroscopically clear CSF was highly indicative (OR 50.6; 95% CI 
6.2-410.7) as were hydrocephalus (OR 53.7; 95% CI 13.4-215.7) and basal menin-
govascular enhancement (OR 82.7; 95% CI 10.5-651.0) on CT scan.
Table 3. Findings on univariate analysis comparing definite TBM to definite bacterial meningitis
OR (95% CI) p value
Symptom duration > 5 days 10.7 (3.8-30.2) <0.01
Weight loss or persistent cough > 2 weeks 27.5 (3.5-213.1) <0.01
Recent close TB contact or positive TST/IGRA 15.0 (3.3-67.9) <0.01
Focal neurological deficit 15.0 (3.3-67.9) <0.01
Cranial nerve palsy 5.6 (1.2-26.0) 0.03
Altered level of consciousness 1.6 (0.7-3.8) 0.31
CSF clear 50.6 (6.2-410.7) <0.01
CSF cells 10-500/µl 3.0 (1.1-7.9) 0.26
CSF lymphocyte predominance >50% 1.6 (0.6-4.0) 0.37
CSF raised protein >1g/L 3.3 (1.4-7.9) <0.01
CSF:serum glucose ratio <50% 2.2 (0.9-5.2) 0.08
Hydrocephalus (CT and/or MRI) 53.7 (13.4-215.7) <0.01
Basal meningovascular enhancement (CT and/or MRI) 82.7 (10.5-651.0) <0.01
Tuberculoma (CT and/or MRI) 2.5 (0.3-22.7) 0.40
Infarct (CT and/or MRI) 2.8 (0.8-10.7) 0.12
CXR suggestive of active TB 6.3 (1.7-22.8) <0.01
CXR suggestive miliary TB 6.2 (0.8-50.3) 0.09
Extraneural M. tuberculosis confirmation 12.5 (1.6-98.5) 0.02
OR= odds ratio, CI= confidence interval, TB= tuberculosis, TST=tuberculin skin test, IGRA=interferon 
gamma-release assay, CSF= cerebrospinal fluid, CT= computed tomography, MRI= magnetic resonance 
imaging, CXR= chest radiograph
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In this retrospective assessment, the proposed uniform research case definition [12], 
provided excellent diagnostic accuracy compared to culture-confirmation of TBM, if 
a ‘probable’ TBM score was used. With a ‘possible’ TBM score not a single TBM case 
would have been missed, but clinical utility was minimal given the low specificity 
achieved. It is important to try and strike an optimal balance between improved 
sensitivity and adequate specificity given the need to initiate anti-tuberculous therapy 
as early as possible in all TBM cases.
TBM often presents with non-specific symptoms in stage I disease, which compli-
cates early diagnosis. Morbidity and mortality increases exponentially with disease 
progression. Therefore rapid diagnosis is needed to initiate treatment at the earliest 
opportunity. Unfortunately it is difficult to achieve a bacteriologically confirmed 
diagnosis at this early stage.
Maintaining a high index of suspicion and using a combination of clinical, laboratory 
and neuroimaging criteria for early identification of TBM suspects, remains essential 
for early treatment initiation. In two previous studies (one comprising both adults 
and children and the other comprising only adult patients) comparing TBM and bac-
terial meningitis features suggestive of TBM included: young age, sub-acute onset, 
headache, peripheral white blood cell count, clear CSF appearance, total CSF white 
cell count, low CSF neutrophil proportion, and elevated CSF protein [13,16]. Good 
sensitivities and specificities were obtained using both a composite clinical reference 
standard, and when applied to a microbiologically proven M. tuberculosis reference 
standard [14].
Our study was limited by absence of data regarding pre-contrast basal hyperdensity, 
suggestive CT, MRI or ultrasound imaging of TB outside the CNS and positive PCR 
evidence of extra neural TB. Pre-contrast basal hyperdensity was described only in 
2004 and was therefore not available [19]. Univariate analysis showed that the ma-
jority of criteria were associated with a diagnosis of TBM, which warrants inclusion 
in the proposed research algorithm [12]. The uniform research TBM case definition 
needs to be tested robustly in future prospective studies including bacterial meningi-
tis, viral meningitis and normal CSF control groups, and in both adult and pediatric 
populations. It should be noted that while some of the TBM data were collected 
prospectively, all bacterial meningitis data were collected retrospectively.
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It is important to appreciate that the proposed research case definition criteria were 
not designed for use in clinical practice. The normal clinical examination findings 
in stage I TBM are a limitation of the diagnostic criteria. It would therefore be less 
likely to score as probable TBM at an earlier stage of disease. The uniform case 
definition holds promise for research purposes, also in resource-constrained settings 
with limited availability of more sophisticated diagnostic methods until better rapid 
diagnostic testing becomes available. Larger prospective studies are required where 
the uniform case definition is robustly tested.
CONCLUSION
The proposed uniform TBM research case definition performed well when using a 
‘probable’ TBM score to differentiate childhood TBM and bacterial meningitis. Rigor-
ous data collection is essential to obtain the necessary information in all criterion 
categories and should assist comparability of future prospective studies. However, 
caution is needed when applying the uniform research case definition to clinical 
diagnosis of children with early TBM.
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ABSTRACT
BACKGROUND: Bacteriological confirmation of tuberculous meningitis (TBM) is 
problematic and rarely guides clinical management. A uniform TBM case-definition 
has been proposed for research purposes, but its diagnostic accuracy in a clinical 
setting has not been evaluated.
METHODS: We prospectively enrolled patients with meningitis confirmed by cere-
brospinal fluid analysis aged 3 months to 13 years at Tygerberg Children’s Hospital, 
Cape Town, South Africa. Participants were investigated for TBM, bacterial and viral 
meningitis. Criteria that differentiated TBM from other causes were explored and the 
accuracy of a probable TBM score assessed by comparing bacteriologically-confirmed 
cases to “non-TBM” controls.
RESULTS: Of 139 meningitis suspects, 79 were diagnosed with TBM (35 bacteriolog-
ically-confirmed), 10 with bacterial meningitis and 50 with viral meningitis. Among 
bacteriologically-confirmed TBM, 15 were M. tuberculosis culture positive, 20 were 
culture negative but positive on GenoType MTBDRplus® and Xpert MTB/RIF®, 18 
were positive on only a single commercial nucleic acid amplification test. A prob-
able TBM score provided good diagnostic accuracy; sensitivity 74% (95% confidence 
interval (57-88%) and specificity 97% (95% confidence interval 86-99%) compared 
to bacteriologically-confirmed TBM.
CONCLUSION: A probable TBM score demonstrated excellent specificity compared 
to bacteriological confirmation, justifying consideration as a “rule-in” test. However, 
accurate diagnosis of early TBM remains a challenge.
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In 2013, there was an estimated 9.0 million new tuberculosis (TB) cases world-wide.1 
Central nervous system involvement, mostly tuberculous meningitis (TBM), is con-
sidered to account for approximately 1% of all cases.2 Although TB is predominantly 
a pulmonary disease, extrapulmonary involvement is particularly common in young 
children and immune-compromised individuals.3 In TB endemic areas with access 
to routine Haemophilus influenza type-B and pneumococcal vaccination, such as 
Cape Town (South Africa), TBM has surpassed other causes of bacterial meningitis.4 
In clinical practice, diagnosis is based on a combination of clinical, laboratory, and 
neuroimaging findings.
The early clinical presentation of TBM is often non-specific. With delayed treatment 
initiation TBM outcome is often poor, emphasizing the importance of early and accu-
rate diagnosis.5,6 TBM is a paucibacillary disease and the sensitivity of cerebrospinal 
fluid (CSF) microscopy is low.7 The sensitivity of CSF culture is increased compared 
to microscopy, but remains low and the result rarely influences clinical management 
due to delays of up to 6 weeks.8-10 Nucleic-acid amplification tests (NAATs) offer the 
prospect of rapid and specific diagnosis, but sensitivity remains suboptimal. A recent 
meta-analysis assessing the accuracy of commercial NAATs for the diagnosis of TBM 
showed a sensitivity of 64% and specificity of 98%, compared to CSF culture.11
In clinical practice, TBM is diagnosed based on a combination of clinical, labora-
tory, and neuroimaging findings. Previous studies identified key characteristics 
suggestive of TBM. Initial symptoms and signs are non-specific but persistent, and 
include poor weight gain or weight loss, fever, and lethargy. More specific signs have 
a sub-acute onset and include meningeal irritation, reduced consciousness, focal 
neurological deficits, raised intracranial pressure, brainstem dysfunction, and cranial 
nerve palsies.6 Typical CSF features include a moderately increased white cell count 
with lymphocyte predominance, increased protein, and decreased glucose. Apart 
from hyponatremia,12 no peripheral blood test result has consistently been associated 
with TBM. On neuroimaging, hydrocephalus, basal ganglia infarctions, and basal 
meningeal enhancement are common features.6
Clinical prediction rules that differentiate TBM from other forms of meningitis in adults 
include five parameters: young age (<36 yrs), sub-acute presentation (symptom dura-
tion >5 days), normal peripheral white blood cell count, moderately raised CSF white 
cell count (<500 cells/ml), and lymphocyte predominance (CSF neutrophil proportion 
<50%).13 Good diagnostic accuracy was obtained using both a composite clinical 
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case-definition and bacteriologically-confirmed TBM as reference standards,14 but 
was reduced in human immunodeficiency virus (HIV)-infected patients.15 Although 
macroscopically clear CSF with lymphocyte predominance may differentiate TBM 
from bacterial meningitis,16 many additional characteristics (sub-acute onset, focal 
neurological deficit, low CSF/serum glucose ratio, and elevated CSF protein) were 
required to differentiate TBM from viral meningitis in adult patients.17 Data that com-
pare TBM to other causes of meningitis in children are limited.
The absence of standardized TBM diagnostic criteria hampers progress, since diag-
nostic accuracy measures are often reported against variable composite clinical refer-
ence standards. For this reason a uniform research case definition was proposed by an 
international panel of experts, categorizing patients as definite, probable, or possible 
TBM according to clinical, CSF, and neuroimaging findings (Table 1).18 The diagnostic 
accuracy and potential clinical utility of the proposed case definition has not been 
prospectively evaluated. We aimed to describe the clinical features of children with 
suspected meningitis, identify criteria that differentiate bacteriologically-confirmed 
TBM from other forms of meningitis, and assess the diagnostic accuracy of the pro-
posed TBM research case definition in clinical practice.
METHODOLOGY
This prospective study was conducted at Tygerberg Children’s Hospital, a tertiary 
referral centre in Cape Town, South Africa. All children with meningitis confirmed by 
CSF analysis aged 3 months to 13 years were prospectively enrolled between January 
2010 and June 2013.
Signs and symptoms
Patients underwent comprehensive clinical evaluation by a pediatric neurologist. A 
TB contact was determined as household contact within the previous 12 months with 
an adult receiving treatment for pulmonary TB. The following signs and symptoms 
were collected; fever (axillary temperature >38.5°C); seizures (generalized or partial); 
recent weight loss, or poor weight gain (documented in the Road to Health booklet); 
meningeal irritation; focal motor deficit (monoparesis, hemiparesis, quadriparesis); 
cranial nerve palsy (deficit in any of the cranial nerves, especially III and VI); ex-
trapyramidal signs (dystonia and/or chorea, athetosis, ballismus); raised intracranial 
pressure (bulging fontanelle, setting sun sign, acute onset strabismus in infancy, pap-
illedema in the older child).
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Table 1. Diagnostic criteria in the uniform TBM research case definition18
Diagnostic score
Clinical criteria (Maximum category score=6)
Symptom duration of more than 5 days 4
Systemic symptoms suggestive of TB (1 or more of): weight loss/
(poor weight gain in children), night sweats or persistent cough > 
2 weeks
2
History of recent close contact with an individual with pulmonary 
TB or a positive TST/IGRA in a child <10 years
2
Focal neurological deficit (excluding cranial nerve palsies) 1
Cranial nerve palsy 1
CSF criteria (Maximum category score=4)
Clear appearance 1
Cells: 10–500 per µl 1
Lymphocytic predominance (>50%) 1
Protein concentration greater than 1 g/L 1
CSF to plasma glucose ratio of less than 50% or an absolute CSF 
glucose concentration less than 2.2mmol/L
1
Cerebral imaging criteria (Maximum category score=6)
Hydrocephalus 1
Basal meningeal enhancement 2
Tuberculoma 2
Infarct 1
Pre-contrast basal hyperdensity 2
Evidence of tuberculosis elsewhere (Maximum category score=4)
Chest X-ray suggestive of active TB (excluding miliary TB) 2
Chest X-ray suggestive of miliary TB 4
CT/ MRI/ US evidence for TB outside the central nervous system 2
AFB identified or M.tuberculosis cultured from another source i.e. 
lymph node, gastric washing, urine, blood culture
4
Exclusion of alternative diagnoses- An alternative diagnosis must be confirmed microbiologically, 
serologically or histopathologically
Definite TBM = AFB seen on CSF microscopy, positive CSF M.tuberculosis culture, or positive CSF 
M.tuberculosis commercial NAAT in the setting of symptoms/signs suggestive of meningitis; or AFB seen 
in the context of histological changes consistent with TB brain or spinal cord together with suggestive 
symptoms/signs and CSF changes, or visible meningitis (on autopsy).
Probable TBM = total score of ≥12 when neuroimaging available
 = total score of ≥10 when neuroimaging unavailable
Possible TBM = total score of 6-11 when neuroimaging available
 = total score of 6-9 when neuroimaging unavailable
TBM- tuberculous meningitis, TB- tuberculosis, TST- tuberculin skin test, IGRA- interferon gamma-re-
lease assay, CSF- cerebrospinal fluid, CT- computed tomography, MRI- magnetic resonance imaging, 
US- ultrasound, AFB- acid-fast bacilli, NAAT- nucleic acid amplification test
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Clinical procedures
Routine special investigations included peripheral blood for full blood count and 
differential, renal function tests, liver transaminases, tuberculin skin testing, spu-
tum or gastric washing microscopy and culture for Mycobacterium tuberculosis 
(M.tuberculosis), blood culture, and chest radiography. HIV screening included HIV 
enzyme-linked immunosorbent assay in children >18 months and <18 months with-
out maternal HIV exposure (ARCHITECT® HIV Ag/Ab Combo; Abbott Laboratories, 
Abbott Park, IL, USA). HIV DNA polymerase chain reaction (PCR) was performed in 
children <18 months exposed to maternal HIV or where the HIV enzyme-linked im-
munosorbent assay screening test was positive (Roche CAP/CTM HIV-1 assay; Roche 
Molecular Systems, Branchburg, NJ, USA). Neuroimaging, including brain computed 
tomography (CT), and magnetic resonance imaging, was performed if clinically 
indicated (routine in TBM, but not in uncomplicated viral and bacterial meningitis).
CSF, by lumbar puncture, was evaluated in all patients including macroscopic ap-
pearance, total and differential cell count, protein, glucose, chloride, Gram stain, 
India ink examination, auramine “O” fluorescence microscopy, culture for pyogenic 
bacteria, culture for M.tuberculosis, GenoType MTBDRplus® and GeneXpert MTB/
RIF® assays. When viral meningitis was suspected, a CSF PCR panel for cytomegalo-
virus, Epstein-Barr virus, enteroviruses, human herpesvirus-6, herpes simplex 1 & 2 
and varicella zoster was performed.
For M.tuberculosis culture, 0.5 ml of CSF was directly inoculated into a Mycobateria 
Growth Indicator Tube (MGIT; Becton Dickinson, Sparks, MD, USA) and incubated 
at 37°C. The presence of acid-fast bacilli was verified by Ziehl-Neelsen staining and 
microscopy. The Genotype MTBDRplus® assay analyzed a CSF volume of 0.5ml, with 
a 160 colony forming unit/ml limit of detection. Improvements in the DNA extraction 
from sonication and heat (version 1) to a chemical method (version 2), enabled its 
usage on smear microscopy-positive and -negative samples. For the Xpert MTB/RIF® 
assay, an aliquot of 1 ml CSF was mixed with 2 ml Xpert Sample Reagent (Cepheid) and 
incubated at 37°C. All further processing happened automatically (GeneXpert Dx 4.0, 
Cepheid). Bacterial load was semi-quantitatively reported, with rifampicin resistance 
indicated separately. The limit of detection was 100 colony forming units/ml.
Descriptive case definitions
For descriptive purposes children were categorized as TBM and non-TBM. TBM was 
clinically diagnosed when CSF changes were suggestive of TBM (clear appearance 
and pleocytosis 10-500/µl and/or increased protein >1g/dl, and/or decreased glucose 
defined as <2.2mmol/l or CSF to serum ratio of <50%) and at least two of the follow-
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ing criteria were met: 1) recent contact with an infectious TB source case or a positive 
tuberculin skin test, 2) a chest x-ray suggestive of TB, 3) CT or magnetic resonance 
imaging demonstrating features of TBM (hydrocephalus, meningovascular enhance-
ment, infarction, and/or granuloma/s).19 TBM was staged according to revised British 
Medical Research Council criteria as: Stage I) Glasgow Coma Scale (GCS) of 15 and 
no focal neurology, Stage IIa) GCS of 15 plus focal neurology, Stage IIb) GCS of 11-14 
with focal neurology and Stage III) GCS <11.20,21
Non-TBM included bacterial and viral meningitis. Bacterial meningitis was identi-
fied by either 1) microscopy and/or culture confirmation of a bacterial pathogen on 
CSF or 2) culture confirmation of a bacterial pathogen on blood and purulent CSF.22 
Viral meningitis was diagnosed when a viral pathogen was identified by CSF PCR, or 
the clinical outcome was favourable with only supportive care and other causes of 
meningitis excluded.17
Comparative case definitions
For comparative purposes, children with bacteriologically-confirmed (definite) TBM 
were used as the reference standard. “Definite TBM” included meningitis suspects 
with acid-fast bacilli seen on CSF microscopy, positive CSF M.tuberculosis culture 
and/or detection by commercial NAAT. “Definite TBM” cases were differentiated into 
probable and possible TBM cases (not taking into account bacteriological confirma-
tion) in order to evaluate the proposed research case definition criteria,18 with points 
allocated for 1) clinical presentation, 2) CSF findings, 3) neuroimaging, 4) evidence 
of extraneural TB and 5) additional laboratory criteria (Table 1). “Probable TBM” 
required a score >9 if neuroimaging was not performed and >11 if neuroimaging 
was performed, while “possible TBM” required a score 6-9 if neuroimaging was not 
performed and 6-11 if neuroimaging was performed.
STATISTICAL ANALYSIS
Data analysis was performed using Statistical Package for the Social Sciences version 
21 (SPSS Inc, Chicago, IL, USA). For descriptive purposes, frequencies were deter-
mined for categorical variables, with median and interquartile range reflected for 
continuous variables. The X2 and Fisher’s exact tests were used to assess differences 
between continuous and categorical variables respectively. The level of significance 
was set at p <0.05 (2-sided). For diagnostic accuracy assessment a multivariable 
logistic regression model was constructed to identify criteria that were independently 
associated with bacteriologically-confirmed TBM, compared to “non-TBM”. Three 
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criteria that were identified by both forward and backward stepwise selection at the 
15% level were then used to construct a receiver operating characteristic curve. The 
diagnostic accuracy between the multivariable model and a probable TBM score 
using criteria from the proposed uniform research case definition was compared.
The study was approved by the Human Research Ethics Committee of Stellenbosch 
University, South Africa (study nr. N11/01/006).
RESULTS
We identified 139 children with suspected meningitis: 79 were bacteriologically 
or clinically diagnosed with TBM, 10 with bacterial meningitis and 50 with viral 
meningitis.
Table 2 reflects the relevant demographic and clinical characteristics. Few TBM patients 
presented with early (stage I) disease; 85% had stage II or III disease. Four bacterial 
meningitis cases had positive CSF cultures; 2 Streptococcus pneumoniae and 2 Neisse-
ria meningitides. Twenty children with viral meningitis had viral pathogens detected by 
PCR in their CSF, including cytomegalovirus (3), Epstein-Barr virus (2), herpes simplex 
type-2 virus (1), human herpes virus-6 (2) and human enterovirus (12). Among those 
clinically diagnosed with TBM, 35/79 (44%) had bacteriological confirmation; 3/35 
(9%) by microscopy, 15/35 (43%) by culture, and 29/35 (83%) by commercial NAAT.
Table 3 shows the bacteriological yield achieved with various methods. Among 
commercial NAATs, the sensitivity of GenoType MTBDRplus® was (20/35; 57%) 
and Xpert MTB/RIF® (14/35; 40%). With one exception, all cases with a positive 
Table 2. Demographics, symptoms and signs in children with TB, bacterial and viral meningitis
TB meningitis* Bacterial meningitis Viral meningitis
DEMOGRAPHICS
Median (IQR)
Age (in months) 31 (21-54) 29 (20-81) 62 (22-92)
Monthly income (US $) 150 (50-250) 120 (28-200) 173 (73-300)
n (%)
Gender (male) 41 (52) 5 (50) 38 (76)
Informal housing 29 (37) 3 (30) 13 (26)
Clinic visits 2 (2-3) 2 (2-3) 2 (2-3)
TB contact 30 (38) 4 (40) 23 (46)
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NAAT test on CSF had clinical and radiological signs suggestive of TBM. A single 
case diagnosed as stage I TBM on account of a positive GenoType MTBDR, presented 
with non-specific symptoms and CSF pleocytosis but had no other clinical, CSF, or 
imaging findings typical of TBM. Of the 29 cases diagnosed by NAAT, 21 only tested 
Table 2 (continued)
TB meningitis* Bacterial meningitis Viral meningitis
SYMPTOMS
Fever 62 (79) 9 (90) 44 (88)
Vomiting 51 (65) 7 (70) 35 (70)
Seizures 24 (30) 2 (20) 7 (14)
Weight loss 20 (25) 1 (10) 10 (20)
Coughing 26 (33) 4 (40) 14 (28)
Poor feeding 49 (62) 5 (50) 27 (54)
Headache 27 (34) 3 (30) 32 (64)
>5 days duration 45 (57) 3 (30) 10 (20)
SIGNS
GCS <11 27 (34) 4 (40) 4 (8)
  11-14 31 (39) 3 (30) 1 (2)
  Normal 21 (27) 3 (30) 45 (90)
Meningism 22 (28) 4 (40) 19 (38)
Focal motor deficit 28 (35) 3 (30) 0 (0)
Cranial nerve palsy 25 (32) 1 (10) 0 (0)
Extrapyramidal signs 6 (8) 0 (0) 0 (0)
Raised ICP 11 (14) 3 (30) 3 (6)
Brainstem dysfunction 9 (11) 2 (20) 2 (4)
TOTAL 79 10 50
*As per descriptive case definition defined in methods; 15% TBM stage I, 15% stage IIa, 35% stage IIb, 
35% stage III
TB – tuberculosis; GCS – Glasgow Coma Scale; ICP – intracranial pressure








Xpert MTB/RIF® GenoType 
MTBDRplus®
Smear microscopy 3 (0)* 2 0 1
MGIT® culture 2 15 (1)* 5 7
Xpert MTB/RIF® 0 5 14 (4)* 5
GenoType MTBDRplus® 1 7 5 20 (7)*
CSF- cerebrospinal fluid
*The number in brackets reflects the patients who tested positive with a particular method only
Stellenbosch University  https://scholar.sun.ac.za
62 Chapter 3.2
positive for one of the two NAAT tests used in this study. CSF volume recorded in 52 
patients (42 TBM and 10 non-TBM) was relatively small (mean 2.1ml: range 0.5 ml to 
5.0 ml), with no clear correlation between CSF volume and diagnostic yield.
Table 4 summarizes laboratory and radiological features of children diagnosed with 
TBM compared to those diagnosed with bacterial and viral meningitis. Overall the 











HIV-infected 3 (9) 3 (7) 2 (20) 2 (4)
TST ≥10mm 7 (20) 14 (32) 0 (0) 3 (6)
Hyponatremia* 12 (34) 12 (27) 1 (10) 4 (8)
CSF
n (%)
Clear 33 (94) 38 (86) 6 (60) 45 (90)
Leucocytes 10-500 cells/L 28 (80) 32 (73) 8 (80) 42 (84)
Lymphocytes > 50% 31 (89) 37 (84) 6 (60) 34 (68)
Protein >1g/L 24 (69) 24 (55) 5 (50) 7 (14)
Glucose <2.2mmol/L 16 (46) 19 (43) 6 (60) 5 (10)
Median (IQR)
Leucocytes (cells/uL) 129 (63-268) 36 (11-133) 279 (72-558) 70 (36-174)
Neutrophils (cells/uL) 12 (4-31) 1 (0-7) 46 (6-369) 11 (0-54)
Lymphocytes (cells/uL) 122 (50-215) 35 (9-114) 127 (28-401) 40 (23-134)




hyperdensity 5 (14) 10 (23) 1 (10) 0 (0)
Hydrocephalus 24 (69) 38 (86) 4 (40) 1 (2)
Infarctions 4 (11) 18 (41) 1 (10) 1 (2)
Basal meningeal 
enhancement
24 (69) 35 (80) 3 (30) 2 (4)
Tuberculoma(s) 5 (14) 9 (20) 0 (0) 0 (0)
Extraneural TB
CXR suggestive of TB 14 (40) 19 (43) 1 (10) 7 (14)
M.tuberculosis isolated 11 (31) 11 (25) 0 (0) 1 (2)
TOTAL 35 44 10 50
* Serum sodium <130mmol/L
TBM – tuberculous meningitis; TST- tuberculin skin test; CSF- cerebrospinal fluid; CT- computed to-
mography
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proportion of HIV-infected children was low (9%) and not increased among TBM 
cases. The vast majority of TBM patients had neuroimaging abnormalities with hydro-
cephalus and basal meningeal enhancement the most common findings.
Table 5 includes uni- and multivariate analyses assessing the diagnostic value of vari-
ous clinical, laboratory and CT criteria in TBM and non-TBM cases; the multivariable 
Table 5. Analysis of clinical, laboratory and radiological criteria in children with bacteriologically-
confirmed TB meningitis compared to “non-TB meningitis”
Criteria OR (95% CI) p value
HIV-infected 1.08 (0.27-5.15) 0.93
Sub-acute onset 3.10 (1.27-7.58) 0.01
Seizures 2.27 (0.82-6.29) 0.11
Weight loss 1.54 (0.57-4.20) 0.40
TB contact 0.82 (0.35-1.90) 0.64
GCS <15 6.77 (2.66-17.21) <0.01
Focal deficit 6.58 (1.64-26.31) <0.01
Cranial nerve palsy 23.60 (2.87-194.30) <0.01
Raised ICP 1.50 (0.42-5.33) 0.53
TST ≥10mm 4.75 (1.14-19.77) 0.02
Serum Na <130mmol/L 4.66 (1.41-15.41) <0.01
CSF clear 2.91 (0.59-14.33) 0.17
CSF 10-500 cells/uL 0.80 (0.27-2.34) 0.68
CSF lymphocytes >50% 3.88 (1.20-12.50) 0.02
CSF protein >1g/L 10.22 (3.78-27.66) <0.01
CSF glucose <2.2mmol/L 4.99 (1.89-13.18) <0.01
CT hydrocephalus 7.86 (2.32-26.63) <0.01
CT infarctions 1.36 (0.23-8.08) 0.74
CT basal meningeal enhancement 7.86 (2.32-26.63) <0.01
CT tuberculoma(s) *0 non-TBM pts 0.06
Chest X-ray suggestive of TB 2.33 (0.81-6.75) 0.11
M.tuberculosis from extraneural source 9.43 (1.06-84.04) 0.02
Criteria that differentiated TBM from non-TBM on multivariable analysis*
Cranial nerve palsy 9.94 (0.89-110.86) 0.06
CSF protein >1g/L 11.55 (3.72-35.87) <0.01
TST ≥10mm 3.89 (0.65-23.33) 0.14
OR - odds ratio, CI - confidence interval; TST - tuberculin skin test; GCS - Glasgow Coma Scale; ICP 
- intracranial pressure, CSF - cerebrospinal fluid; CT – computed tomography; TB – tuberculosis; OR- 
odds ratio; CI - confidence interval
*Neuro-imaging criteria had to be excluded since these were performed on a minority of non-TBM 
patients
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logistic regression analysis excluded neuroimaging findings, since this was performed 
in a minority (62/157; 39%) of non-TBM cases. Three variables were significantly 
associated with TBM on multivariable analysis; cranial nerve palsy, TST ≥10mm and 
CSF protein >1g/L. However these three criteria had sensitivity of only 0.50, 95% 
confidence interval (CI) 0.12-0.88, in stage I disease compared to 0.88 (95% CI 0.70-
0.98) in stage II and II disease. A receiver operating characteristic curve using the 
three-variable predictive model delivered an area under the curve of 0.82 (95% CI 
0.73-0.92); sensitivity 0.79 (95% CI 0.61-0.91) and specificity 0.78 (95% CI 0.65-
0.88) (Figure 1).
Of 79 children clinically diagnosed with TBM, 66 scored as “probable TBM”, 12 as 
“possible TBM”, and one as “not TBM” using the proposed research case definitions. 
Using clinically diagnosed TBM cases as the reference standard, a probable TBM 
score had sensitivity of 0.84 (95% CI 0.74-0.91) and specificity of 0.95 (95% CI 0.86-
0.99). The ability to detect stage I TBM was sub-optimal with a sensitivity of only 42% 
(5/12). Among 35 bacteriologically-confirmed TBM cases (“definite TBM”), 26 had a 
probable TBM score; sensitivity 0.74 (95% CI 0.57-0.88) and specificity 0.95 (95% 
CI 0.86-0.99). A possible TBM score had greater sensitivity 0.97 (95% CI 0.85-1.00), 
but reduced specificity 0.48 (95% CI 0.35-0.62).
Figure 1. ROC curves of a) a “probable TBM” score and b) the three criteria identified on multivariable 
analysis*; using bacteriologically-confirmed TBM” as the reference standard
*Cranial nerve palsy, elevated CSF protein and a TST ≥10mm (Table 5)
Stellenbosch University  https://scholar.sun.ac.za









This study represents the first prospective evaluation of the diagnostic accuracy 
of the recently proposed uniform TBM research case definition. A probable TBM 
score demonstrated reasonable sensitivity, 84% in clinically diagnosed and 74% 
in bacteriologically-confirmed TBM cases, with excellent specificity. The clinical 
importance of a reliable clinical case definition for TBM is emphasized by the fact 
that bacteriological confirmation was achieved in less than half (44%) of the children 
clinically diagnosed with TBM, despite exhaustive evaluation. The high specificity of 
a probable TBM score justifies its use as an alternative reference standard to bacterio-
logical confirmation in future studies, although the diagnosis and study inclusion of 
early stage 1 disease remains problematic.
The low incidence of stage I TBM in our study is consistent with other studies from 
TB endemic areas and underlines the difficulty in diagnosing TBM early.6,23 The poor 
sensitivity of a probable TBM score to diagnose stage I TBM versus stage II and II 
TBM was disappointing but not unexpected, since scoring is based on clinical, CSF 
and radiological findings which all tend to become more pronounced as the disease 
progresses. The diagnosis of early stage I TBM remains a major clinical dilemma. 
Since the early presentation of TBM is so non-specific, diagnosis is essentially reliant 
on a very high clinical index of suspicion in vulnerable young children with recent 
TB exposure and persistent non-specific signs despite treatment for other possible 
causes. Early diagnosis and treatment of TBM is vital to ensure an optimal outcome 
and this poses a major clinical dilemma.6,23
The majority of CSF specimens tested positive by means of a single bacteriological-
confirmation method, highlighting the need for multiple diagnostic tests in children 
suspected with TBM and optimizing bacteriological confirmation in paucibacillary 
CSF specimens; especially with the collection of low CSF volumes. It has been sug-
gested that high volumes of CSF should be collected and concentrated to improve 
diagnostic yields, as well as provide complete drug susceptibility information.24,25 The 
relatively low CSF volumes collected in this study prevented specimen concentration, 
however, the volumes obtained are consistent with what is achieved in routine pedi-
atric practice. The GenoType MTBDRplus® assay was found to be the most sensitive 
single test. There are concerns about the possibility of cross-contamination with the 
GenoType MTBDRplus® assay, but this was not a major concern in the current study; 
19/20 patients had multiple clinical-radiological signs consistent with TBM and a 
single one had CSF pleocytosis only.
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A reliable clinical reference standard should be more representative of the disease 
spectrum seen in clinical practice and be more feasible than bacteriological confir-
mation in TB endemic areas. The overall performance of a probable TBM score was 
better than the three-variable predictive model, but the use of three simple criteria 
(cranial nerve palsy, TST ≥10mm and elevated CSF protein) may offer better clinical 
utility in areas with limited access to neuro-imaging. However, its diagnostic ac-
curacy is likely to have been over-estimated, given that the analysis was optimized 
for the study cohort and the non-TBM arm included relatively few children with 
bacterial, fungal or complicated viral meningitis.
A number of clinical prediction rules to differentiate TBM from bacterial meningitis in 
adults from resource-poor settings have been proposed.13,14,16 However, most of these 
were based on case-control studies and failed to include all meningitis suspects. 
Our study focused on a pediatric population and is strengthened by the inclusion 
of bacterial and viral meningitis, as encountered in every-day clinical practice. We 
were unable to determine the role of HIV co-infection, because of the relatively low 
prevalence of HIV co-infection among TBM patients in our cohort (8%). Karande et 
al. also found that only 6.5% of 123 children with clinically diagnosed TBM had HIV 
co-infection.26 TBM seems to be proportionally less common than other TB mani-
festations among HIV-infected children; an intriguing finding which may reflect the 
contribution of an appropriate immune response to TBM pathology.27 Immune recon-
stitution inflammatory syndrome, a well-recognized complication in HIV-infected 
patients with TBM who are initiated on antiretroviral therapy provides further support 
for the role of immunity in the pathogenesis of TBM.28-30
Our study is limited by the fact that the study cohort included few cases of bacte-
rial meningitis. Haemophilus influenza type-B and pneumococcal vaccination are 
provided free of cost to all children in South Africa. Neuroimaging was performed 
in a minority of non-TBM cases, which prevented its inclusion in multivariable 
analysis. However, neuroimaging is not routinely performed in non-TBM suspects 
and ethical justification would have been problematic. The relatively low proportion 
of bacteriologically-confirmed TBM cases reflects the paucibacillary nature of the 
disease, sub-optimal sensitivity of available diagnostic tests, and low CSF volumes 
obtained.5,8-11 The study was performed at a single hospital which may limit general-
ization of the study findings to other settings, but Tygerberg Children’s Hospital serves 
a population that share a similar disease burden and health challenges experienced 
in other TB endemic areas.
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In conclusion, a probable TBM score demonstrated good diagnostic accuracy in this 
prospective study,18 both in children with clinically diagnosed and bacteriologically-
confirmed TBM. The excellent specificity achieved support its use as an alternative 
reference standard in research studies, at least in settings with a similar disease 
spectrum among non-TBM patients, although its clinical utility is limited in resource-
limited settings.
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ABSTRACT
BACKGROUND: Tuberculous meningitis (TBM) is diagnosed based on a combina-
tion of clinical, laboratory, and radiological findings, including signs suggestive of 
tuberculosis (TB) on a standard chest radiograph.
METHODS: We describe the radiological features suggestive of intra-thoracic TB in 
children diagnosed with TBM during a prospective evaluation of meningitis suspects 
seen at Tygerberg Children’s Hospital, Cape Town, South Africa.
RESULTS: Of 84 children treated for TBM, 31 (37%) had ‘definite’ TBM, 45 (55%) 
‘probable’ TBM and 8 (9%) ‘possible’ TBM. In total, 37 (44%) TBM patients had 
chest radiograph findings suggestive of TB; 9 (11%) with disseminated (miliary) TB. 
Only 1 in 4.39 children ≤3 years of age with TBM had suggestive chest radiograph 
findings. The presence of complicated intra-thoracic lymph node disease was signifi-
cantly higher in children ≤3 years of age, odds ratio 21.69 (95% confidence interval 
2.73-172.67); p <0.01. Among 6 HIV-infected children, 3 (50%) had intrathoracic 
lymphadenopathy.
CONCLUSION: The majority of children with TBM, including the very young, did not 
have signs suggestive of TB on chest radiograph.
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Globally there were an estimated 8.6 million new cases and 1.3 million deaths 
from tuberculosis (TB) in 20121. TB is predominantly a pulmonary disease, but 
extrapulmonary involvement is particularly common in young children and in im-
munocompromised individuals2. Central nervous system (CNS) involvement, mostly 
tuberculous meningitis (TBM), accounts for approximately 1% of all TB cases3. TBM 
is the most devastating manifestation of TB and early treatment initiation is critical 
to achieve optimal outcomes4. In clinical practice, diagnosis is hampered by non-
specific clinical features and sub-optimal accuracy of existing diagnostic methods5-9, 
therefore TBM is mainly diagnosed based on a combination of clinical, laboratory, 
and radiological findings.
A uniform research case definition was proposed by an international panel of experts, 
categorizing patients as definite, probable, or possible TBM (Table 1)10. Chest radio-
graph findings are included within the scoring criteria. Previous observations suggest 
that chest radiograph findings consistent with active pulmonary TB are observed in 
30% to 65% of adults with central nervous system TB11-13. Chest radiograph evidence 
of TB in children with TBM is usually considered to be more frequent, ranging from 
70% of HIV-uninfected to 84% of HIV-infected children diagnosed with TBM14. In the 
group of children with TBM and HIV co-infection, hilar lymphadenopathy, pleural ef-
fusion and cavity formation was significantly increased compared to HIV uninfected 
children14.
We aimed to describe the radiological features and frequency of chest radiograph 
signs suggestive of TB in children with TBM.
METHODOLOGY
This prospective descriptive cross-sectional study was conducted at Tygerberg Chil-
dren’s Hospital, South Africa, a major referral centre for Cape Town and surrounding 
areas. Children were enrolled between January 2010 and January 2014. Inclusion 
criteria were 1) age 3 months to 13 years 2) clinical suspicion of TBM 3) CSF evalua-
tion 4) chest radiograph performed at admission 5) written consent from the caregiver 
and assent if the child was older than 7 years and competent to do so. The study was 
approved by the Human Research Ethics Committee of Stellenbosch University, South 
Africa (study nr. N11/01/006).
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Clinical procedures
All patients underwent a comprehensive clinical evaluation. Routine investigations 
included full blood count, basic biochemistry, human immunodeficiency virus (HIV) 
screening, tuberculin skin test (TST), microbiological analysis of sputum or gastric 
washings, bacterial blood culture, chest radiography and neuroimaging (if clinically 
indicated). Chest radiographs were independently interpreted by a pediatrician and 
an experienced pediatric pulmonologist, using a standard reporting form. Findings 
were categorized as certain TB, uncertain TB or not TB. Intra-thoracic lymph node 
disease was classified as either uncomplicated or complicated, accordingly to a 
radiological classification of childhood intrathoracic tuberculosis, using a structured 
approach to interpretation and recording chest radiograph findings15. Airway com-
pression was defined as either compression of the trachea, left main bronchus or 
bronchus intermedius. Parenchymal changes were defined as either consolidation 
(including expansile pneumonia) or miliary.
Case definition of tuberculous meningitis
A diagnosis of TBM was based on the proposed uniform research case definition 
(Table 1)10. TBM was classified as ‘definite’ when CSF demonstrated acid-fast bacilli, 
positive M. tuberculosis culture and/or positive M. tuberculosis commercial nucleic 
acid amplification test (NAAT). TBM was classified as ‘probable’ when patients scored 
≥ 12 when neuroimaging was available and ≥10 when neuroimaging was unavail-
able. TBM was classified as ‘possible’ when a patient had a diagnostic score of 6–11 
when neuroimaging was available and 6–9 when neuroimaging was unavailable10. 
TBM was staged according to revised British MRC criteria as: Stage I) Glasgow Coma 
Scale (GCS) of 15 and no focal neurology, Stage IIa) GCS of 15 plus focal neurology, 
Stage IIb) GCS of 11-14 with focal neurology and Stage III) GCS <1116,17. All patients 
diagnosed with TBM were treated with a standard short-course regimen18.
Statistical analysis
Data analysis was performed using SAS (Statistical analysis system) version 9.1 (SAS 
Institute Inc., Cary, North Carolina, USA). Frequencies were obtained for chest radio-
graph findings, stratified for TBM stage. An unweighted kappa statistic was used to 
assess inter-observer agreement. Comparison was made, using the X2 test with a p-
value <0.05 considered statistically significant. Chest radiograph criteria were further 
compared between children ≤3 years and age >3 years and odds ratios determined. A 
need to treat calculation was used to reflect the number of TBM patients ≤3 years of 
age with “certain TB” on chest radiograph evaluation.
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Table 1. Diagnostic criteria in the uniform TBM research case definition10
Diagnostic score
Clinical criteria (Maximum category score=6)
Symptom duration of more than 5 days 4
Systemic symptoms suggestive of TB (1 or more of ): weight loss/(poor weight gain in 
children), night sweats or persistent cough > 2 weeks
2
History of recent close contact with an individual with pulmonary TB or a positive 
TST/IGRA in a child <10 years
2
Focal neurological deficit (excluding cranial nerve palsies) 1
Cranial nerve palsy 1
CSF criteria (Maximum category score=4)
Clear appearance 1
Cells: 10–500 per µl 1
Lymphocytic predominance (>50%) 1
Protein concentration greater than 1 g/L 1
CSF to plasma glucose ratio of less than 50% or an absolute CSF glucose 
concentration less than 2·2mmol/L
1
Cerebral imaging criteria (Maximum category score=6)
Hydrocephalus 1
Basal meningeal enhancement 2
Tuberculoma 2
Infarct 1
Pre-contrast basal hyperdensity 2
Evidence of tuberculosis elsewhere (Maximum category score=4)
Chest X-ray suggestive of active TB (excluding miliary TB) 2
Chest X-ray suggestive of miliary TB 4
CT/ MRI/ US evidence for TB outside the CNS 2
AFB identified or M.tuberculosis cultured from another source i.e. lymph node, 
gastric washing, urine, blood culture
4
Exclusion of alternative diagnoses- An alternative diagnosis must be confirmed microbiologically, 
serologically or histopathologically
Definite TBM = AFB seen on CSF microscopy, positive CSF M.tuberculosis culture, or positive CSF 
M.tuberculosis commercial NAAT in the setting of symptoms/signs suggestive of meningitis; or AFB seen 
in the context of histological changes consistent with TB brain or spinal cord together with suggestive 
symptoms/signs and CSF changes, or visible meningitis (on autopsy).
Probable TBM = total score of ≥12 when neuroimaging available
 = total score of ≥10 when neuroimaging unavailable
Possible TBM = total score of 6-11 when neuroimaging available
 = total score of 6-9 when neuroimaging unavailable
TBM- tuberculous meningitis, TB- tuberculosis, TST- tuberculin skin test, IGRA- interferon gamma-re-
lease assay, CSF- cerebrospinal fluid, CT- computed tomography, MRI- magnetic resonance imaging, 
US- ultrasound, AFB- acid-fast bacilli, NAAT- nucleic acid amplification test
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RESULTS
In total 84 children met the inclusion criteria; 31 (37%) had ‘definite/microbiological-
ly-confirmed’ TBM, 45 (55%) had ‘probable’ TBM and 8 (9%) had ‘possible’ TBM10. 
According to revised British MRC TBM staging criteria, 12 (14.3%) had stage I, 13 
(15.5%) stage IIa, 30 (35.7%) stage IIb and 29 (34.5%) stage III disease. Tuberculin 
skin testing was positive in 24 (28.6%) TBM patients, of whom 11/37 (29.7%) had 
certain pulmonary TB on chest radiograph, 10/39 (25.6%) had no visible abnormality, 
and 3 had inconclusive signs. HIV co-infection was identified in 6 patients. Of these, 
3 had no radiographic evidence of pulmonary TB. Of the three HIV-infected patients 
with abnormal chest radiograph, one had isolated lymph node involvement, one 
lymph node involvement plus lobar pneumonia and the third lymph node involve-
ment plus a miliary picture.
A summary of chest radiograph findings is reflected in table 2. Inter-reviewer 
variability between the pediatrician and pediatric pulmonologist was minimal (un-
weighted kappa statistic 0.62 95% confidence interval (CI) 0.46-0.79); differences 
were resolved by consensus. The proportion of ‘certain TB’ and miliary TB on chest 




 ≤3 years 46/84 (55)
 >3 years 38/84 (45)
Chest radiograph findings
Normal CXR 39/84 (46)
Abnormal CXR (not TB) 5/84 (6)
Abnormal CXR (Uncertain TB) 3/84 (4)
Abnormal CXR (certain TB) 37/84 (44)
 Miliary TB 9/84 (11)
 Parenchymal consolidation 15/84 (18)
 Intrathoracic lymphadenopathy 32/84 (38)
  Paratracheal 16/84 (19)
  Hilar 24/84 (29)
 Complicated lymph node disease 18/84 (21)
 Airway compression 16/84 (19)
  Bronchus intermedius 8/84 (10)
  Left main bronchus 8/84 (10)
TBM= tuberculous meningitis, CXR= chest radiograph, TB= tuberculosis
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radiograph was 44% (37/84) and 11% (9/84) when including all TBM categories; 
39% (12/31) and 13% (4/31) respectively in those with microbiologically-confirmed 
TBM. Among those with microbiological TBM confirmation, 1/31 (3%) had acid-fast 
bacilli on microscopy, 13/31 (42%) were M. tuberculosis culture positive, and 27/31 
(87%) confirmed by commercial NAAT (Either GenoType MTBDRplus® assay and/or 
GeneXpert MTB/RIF® assay). M. tuberculosis was cultured in gastric washings from 
27 patients; 10 with microbiologically-confirmed and 17 with ‘probable’ TBM. No 
significant differences were observed when comparing chest radiograph findings in 
children with different stages of TBM.
Chest radiographs were more frequently indicative of TB in very young children (≤3 
years of age) compared to older children (>3 yrs); 25/46 (54%) versus 12/38 (32%) 
(odds ratio (OR) 2.58 (95 % CI 1.05-6.33; p=0.04 (Table 3). Chest radiograph findings 
in children ≤3 years of age were more likely to include complicated intra-thoracic 
lymph node disease (OR 21.69; 95% CI 2.73-172.67), and the presence of airway 
compression (OR 17.90; 95% CI 2.24-143.27) than in older children Despite the 
fact that chest radiographs were most informative in young children, only 1 in 4.39 
children ≤3 years of age had “certain TB” on chest radiograph evaluation.






Odds ratio (95% CI) p-value
Normal CXR 17 22 0.43 (0.18-1.03) 0.06
Abnormal CXR (not TB) 3 2
Abnormal CXR (Uncertain TB) 1 2
Abnormal CXR (certain TB) 25 12 2.58 (1.05-6.33) 0.04
 Miliary TB 5 4 1.04 (0.26-4.17) 0.96
 Parenchymal consolidation 12 4 3.00 (0.88-10.24) 0.07
 Intra-thoracic lymphadenopathy 23 9 3.22 (1.25-8.29) 0.02
 Complicated lymph node disease 17 1 21.69 (2.73-172.67) <0.01
 Airway compression (any) 15 1 17.90 (2.24-143.27) <0.01
TBM= tuberculous meningitis, CI= confidence interval, CXR= chest radiograph, TB= tuberculosis, 
LAD= lymphadenopathy
DISCUSSION
The main finding in this study is the lower percentage of chest radiograph findings 
suggestive of certain pulmonary TB in children with TBM, compared to the study by 
van Weert et al (44% vs 70%)14, with a need to treat calculation showing that only 
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1 in 4.39 of children ≤3 years of age with TBM are likely to have certain TB on chest 
radiograph. The lower proportion of certain pulmonary TB in our study compared to 
van Weert et al could potentially be explained by our 2 reviewers reaching consensus 
on chest radiograph findings thereby minimizing the possibility of over-reporting of 
chest radiograph findings.14 Another possible reason could be the difference in the 
study cohort, with 28% of our TBM group having positive tuberculin skin testing 
compared to 62% in the HIV-uninfected TBM group of the study by van Weert et 
al.14 A normal chest radiograph was found in almost half (46%) of children clinically 
diagnosed with TBM, and in 52% of cases with microbiologically-confirmed TBM. 
This less than expected diagnostic sensitivity of the chest radiograph in TBM may 
impact the scoring of future diagnostic algorithms for the disease.
The most common radiological findings in young children (<5 years) with pulmo-
nary TB is hilar or paratracheal lymph nodes19. This age group also has a higher 
risk for developing lympho-bronchial TB due to small airway size15. Our findings 
on chest radiograph of visible lymph nodes, complicated lymph node disease and 
airway compression were significant in children ≤3 years, confirming that this is the 
predominant radiological finding in young children. TBM stage did not affect the 
radiographic picture.
Sixteen of eight-four (19%) patients had radiological evidence of airway compression 
highlighting the need for pulmonary assessment, including flexible bronchoscopy20. 
The smaller percentage of patients with airway compression, compared to a reported 
figure of 41-63%20, could possibly be explained by differences in the immune re-
sponse between pulmonary TB in isolation versus pulmonary TB in the setting of CNS 
involvement. A better understanding of immunology in CNS TB is warranted3.
Inter-observer variability is a well-recognized problem in the interpretation of chest 
radiographs in children with pulmonary TB. Swingler et al have reported difficulty in 
distinguishing lymphadenopathy from a normal thymus and were not able to distin-
guish normal from pathological nodes21. The areas most reliable for lymphadenopathy 
were the right hilum and the sites around the carina22.
The uniform research case definition for TBM by Marais et al. uses chest radiograph 
findings as part of the scoring criteria10. The score weighting of a miliary pattern is 
higher than that of active TB on chest radiograph (excluding miliary TB). Our find-
ing that hilar lympadenopathy is the more common finding of certain TB on chest 
radiograph, in both suspected and definite TBM, suggests that its weighting may have 
to be reconsidered.
Stellenbosch University  https://scholar.sun.ac.za








A limitation of our study was the small number of HIV co-infected patients (7%), 
which did not allow separate statistical analysis of this group. This low percentage is 
consistent with a previous study that found that only 7% of 123 children with clini-
cally diagnosed TBM had HIV co-infection23. The low number of microbiologically-
confirmed TBM cases, (31/84), is another limitation but not unexpected in a cohort 
of this age group5-9. CSF NAATs offer improved sensitivity (27/84; 32.1%), compared 
to CSF culture (13/84; 15.5%), and a potential for same day diagnosis. A further 
limitation is that all the chest radiographs were from patients with TBM. A sample that 
includes other forms of meningitis could allow improved analysis of disseminated TB 
(miliary pattern on chest radiograph).
The main finding of this study is that about half of children with suspected and proven 
TBM have a normal chest radiograph. Significant chest radiograph findings in children 
≤3 years of age were the presence of certain TB, complicated lymph node disease and 
the presence of airway compression. However, only 1 in 4.39 of children ≤3 years of 
age with TBM were likely to have certain TB on chest radiograph. Apart from a lower 
proportion of airway compression, the radiological findings of pulmonary TB in the 
setting of TBM, irrespective of stage of disease, did not differ from those reported for 
pulmonary TB in isolation. Definite evidence of TB on a chest radiograph remains 
valuable supportive evidence for TBM in a patient suspected of having the disease. 
However, in cases with a normal chest radiograph, diagnosis of TBM depends even 
more on microbiological confirmation of the disease.
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ABSTRACT
PURPOSE: Cerebrospinal fluid (CSF) hypoglycorrhachia and elevated protein is well-
described in bacterial meningitis, but evidence for its differential diagnostic value in 
tuberculous meningitis (TBM) is lacking. We aimed to assess the diagnostic utility of 
CSF glucose, CSF to serum glucose ratio and CSF protein in children with suspected 
TBM.
METHODS: We describe CSF glucose and protein values, as well as CSF to serum 
glucose ratios in a prospective evaluation of TBM suspects seen at Tygerberg Chil-
dren’s Hospital, Cape Town, South Africa from January 1985 to January 2014.
RESULTS: Of 615 TBM suspects, 88 (14%) had microbiologically-confirmed TBM, 
381 (62%) ‘probable’ TBM and 146 (24%) ‘no-TBM’. Mean absolute CSF glucose 
concentration was significantly lower in the microbiologically-confirmed (1.87 
+/-1.15 mmol/L, and ‘probable’ TBM (1.82 +/-1.19 mmol/L) groups compared to 
non-TBM (3.66 +/-0.88 mmol/L). A CSF glucose concentration of <2.2 mmol/L diag-
nosed TBM with sensitivity 0.68 and specificity 0.96. Sensitivity using a CSF:serum 
glucose ratio of <0.5 was 0.90. Mean CSF protein was significantly elevated in the 
microbiologically-confirmed TBM (1.91 +/-1.44 g/L), and ‘probable’ TBM (2.01 +/-
1.49 g/L) groups compared to the non-TBM (0.31 +/-0.31 g/L). A CSF protein >1g/L 
diagnosed TBM with sensitivity 0.78 and specificity 0.94.
CONCLUSION: Absolute CSF glucose values of <2.2 mmol/L and protein values of 
>1g/L differentiated between TBM and non-bacterial meningitis with good specificity, 
although sensitivity was poor. A CSF:serum glucose ratio is more informative than the 
absolute value.
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In 2012 there were an estimated 8.6 million new cases and 1.3 million deaths from 
tuberculosis (TB), worldwide [1]. Although progress has been made, Africa as well 
as Europe are not on track in achieving the reduced prevalence and mortality targets 
suggested by the World Health Organization [1]. TB affects predominantly the respi-
ratory system, and central nervous system (CNS) involvement, mostly tuberculous 
meningitis (TBM), accounts for approximately 1% of all TB cases [2]; none the less 
TBM is a major cause of TB mortality and morbidity amongst children. Diagnosis of 
TBM is often delayed by the non-specific clinical presentation and poor diagnostic 
accuracy of available investigative methods [3-6]. TBM is therefore frequently diag-
nosed based on a combination of clinical, laboratory, and radiological findings.
Cerebrospinal fluid (CSF) findings are integral to the diagnosis of TBM. Typical CSF 
findings consist of leukocytosis with lymphocyte predominance, elevated protein, ab-
normally decreased CSF glucose (hypoglycorrhachia) [7,8]. These findings are highly 
suggestive of TBM in TB endemic areas [9]. Hypoglycorrhachia is reflected as either CSF 
to plasma glucose ratio [7-9] or decreased CSF glucose [7,10], and is not affected by HIV 
co-infection [11]. Despite the determination of CSF glucose being one of the commoner 
investigations undertaken in pediatric practice, the diagnostic cut-off values for the diag-
nosis of bacterial meningitis vary considerably in different reference textbooks [12-15].
As a result of the interplay between serum and CSF glucose, exact determination of 
a cut-off value for CSF glucose is difficult to elucidate [16]. Other studies on menin-
gitis suggest lower limits of absolute CSF glucose concentrations from 2.20 to 2.78 
mmol/L (40-50 mg/dl) and that of CSF to serum glucose ratios range from 0.40 to 0.66 
[12-15,17]. For bacterial meningitis, a CSF to serum glucose ratio below 0.4 and an 
absolute CSF glucose concentration less than 2.2 mmol/L was shown to be highly 
specific [17]. Similar evidence for values of hypoglycorrhachia in TBM is lacking. 
A CSF protein cut-off of >1g/L (100mg/dL) differentiated between cases of TBM and 
bacterial meningitis [10], as well as viral meningitis [18].
A uniform research case definition, categorizing patients as definite, probable or pos-
sible TBM, was proposed by an international panel of experts [19]. Scoring criteria 
to aid in the diagnosis of TBM include cerebrospinal fluid (CSF) to serum glucose 
ratio less than 0.5 or an absolute CSF glucose concentration less than 2.2 mmol/L 
and elevated CSF protein >1g/L. We aimed to describe CSF glucose, CSF to serum 
glucose ratio and CSF protein in children with suspected meningitis, and assess their 
diagnostic utility in the diagnosis of TBM.
Stellenbosch University  https://scholar.sun.ac.za
86 Chapter 3.4
METHODOLOGY
This study was conducted at Tygerberg Children’s Hospital, Cape Town, a major 
referral centre for Cape Town and surrounding areas. Between January 1985 and 
April 2005 and between January 2010 and January 2014 children were prospectively 
enrolled in several TBM research studies and CSF and serum glucose prospectively 
determined. Inclusion criteria were 1) age 3 months to 13 years 2) clinical suspicion 
of TBM 3) CSF glucose and/or CSF glucose:serum glucose ratio 4) written consent 
from the caregiver and assent if the child was older than 7 years and competent to do 
so. Patients with bacterial meningitis were excluded.
Clinical procedures
All patients had comprehensive clinical assessment. Routine investigations, includ-
ing full blood count, basic biochemistry, tuberculin skin test (TST), mycobacterial 
analysis of sputum, gastric washings and CSF, bacterial blood culture, HIV screening, 
chest radiography and neuroimaging, when clinically indicated. CSF was evaluated 
in all patients including macroscopic appearance, total and differential cell count, 
protein, glucose, chloride, Gram stain, India ink examination, auramine “O” fluores-
cence microscopy and culture for M. tuberculosis. CSF glucose was determined by 
the glucose oxidase method and CSF protein by the biuret method (currently both 
Beckman Synchron CX7 Clinical Systems, Beckman, Miami, FL, USA). CSF lactate 
was not routinely performed in meningitis suspects.
Descriptive case definitions
A diagnosis of TBM was based on the uniform research case definition by Marais et al 
[19]. TBM was classified as ‘definite’ when CSF demonstrated acid-fast bacilli and/or 
positive M. tuberculosis culture and/or positive commercial nucleic-acid amplifica-
tion test for M. tuberculosis in a patient with symptoms or signs suggestive of the 
disease. Probable and possible TBM cases were identified according to the uniform 
research case definition criteria, with points allocated for 1) clinical presentation, 
2) CSF findings, 3) neuroimaging, 4) evidence of extraneural TB and 5) additional 
laboratory criteria. For this study, only ‘definite’ and ‘probable’ TBM were included, 
as ‘possible’ TBM criteria had low sensitivity in the identification of TBM [20]. TBM 
was staged according to revised British MRC criteria as: Stage I) Glasgow Coma Scale 
(GCS) of 15 and no focal neurology, Stage IIa) GCS of 15 plus focal neurology, Stage 
IIb) GCS of 11-14 with focal neurology and Stage III) GCS <11 [21,22]. All patients 
diagnosed with TBM were treated with a standard short-course regimen [23].
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Non-TBM included viral or no meningitis. Viral meningitis was diagnosed when a 
viral pathogen was identified by CSF PCR, or the clinical outcome was favourable 
with only supportive care and other causes of meningitis were excluded [18]. A diag-
nosis of “no meningitis” was made when an alternative cause could be identified that 
explained the clinical findings. Cases of proven bacterial meningitis were excluded, 
since the study focused on the value of CSF chemistry to differentiate TBM from 
non-bacterial meningitis.
STATISTICAL ANALYSIS
Data analysis was performed using Statistical Package for the Social Sciences ver-
sion 21 (SPSS Inc, Chicago, IL, USA). For descriptive purposes, frequencies were 
determined for categorical variables. For continuous variables, mean and standard 
deviation were reflected with a normal distribution; median and interquartile range 
reflected for a skewed distribution. Logistic regression was used to determine odds 
ratios for categorical variables. The level of significance was set at p <0.05. Using 
receiver operating characteristic (ROC) curves, optimal sensitivities and specifici-
ties were determined for different cut-off values of CSF glucose and CSF protein by 
comparing area under the curve (AUC). AUC of 0.7-0.8 is deemed adequate, 0.8-0.9 
good and >0.9 excellent. Box plots were used to illustrate absolute CSF glucose 
concentration and mean CSF protein in both TBM and non-TBM.
The study was approved by the Human Research Ethics Committee of Stellenbosch 
University, South Africa (study nr. N11/01/006).
RESULTS
In total 615 children with suspected TBM were included; 469 TBM and 146 non-TBM. 
Of the TBM group, 88 patients had ‘definite’ TBM and 381 patients had ‘probable’ 
TBM [19]. Among non-TBM patients, there were 50 viral meningitis and 96 did not 
have meningitis. Twenty children with viral meningitis had viral pathogens detected 
by PCR in their CSF.
TBM stage, age, gender, HIV status and CSF findings are shown in table 1, 15 (3%) 
patients were stage I, 245 (52%) patients stage IIa, 137 (29%) patients stage IIb and 
71 (15%) patients stage III. Besides CSF volume, all CSF criteria differed significantly 
between non-TBM and TBM groups. The most distinctive findings in the TBM group 
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were high CSF protein and low CSF glucose. Human immunodeficiency virus (HIV) 
co-infection was identified in 24 patients; 9 TBM and 15 non-TBM. There was no sig-
nificant difference in mean CSF glucose concentration (p=0.37) or mean CSF protein 
(p=0.56) between HIV-infected and -uninfected TBM patients.
The mean CSF glucose in microbiologically-confirmed TBM was 1.87 (standard de-
viation +/-1.15 mmol/L), that in the TBM group (comprising ‘definite’ and ‘probable’ 
TBM), 1.85 +/-1.18 mmol/L and 3.66 +/-0.88 mmol/L in the non-TBM group. In both 
microbiologically-confirmed and case-defined TBM groups, the mean CSF glucose 
differed significantly from the non-TBM group (both p<0.01). Mean CSF glucose 
did not differ between microbiologically-defined and case-defined TBM (p=0.88). 
Serum glucose was measured in only 4 out of 146 non-TBM patients, and in 152 out 
of 469 TBM patients. This precluded comparison. In the microbiologically-defined 
TBM group the mean serum glucose was 6.31 +/-1.27 mmol/L and the CSF:serum 
glucose ratio was 0.27 +/-0.14, and in the case-defined TBM group the mean serum 
Table 1. Clinical and CSF findings of children with suspected meningitis
Clinical characteristics Non-TBM* (n=146) TBM** (n=469) p-value
TBM stage  Stage I (n/N/%) n/a 15/468 (3)
(1 unknown)  Stage IIa (n/N/%) n/a 245/468 (52)
    Stage IIb (n/N/%) n/a 137/468 (29)
    Stage III (n/N/%) n/a 71/468 (15)
Age in months- mean (SD) /N 47.70 (40.33) /146 36.063 (29.11) /463 <0.01
Male gender (n/N/%) 97/146 (66) 244/468 (52) <0.01
Positive HIV (n/N/%) 15/146 (10) 9/469 (2) <0.01
Macroscopically clear CSF (n/N/%) 136/145 (94) 462/467 (99) <0.01
CSF volume - mean (SD) /N 2.23 (1.03) /11 2.20 (1.32) /33 0.94
CSF leucocytes (cells/µL) - median (IQR) /N 2.00 (0-43.00) /144 123.00 (54.00-243.00) /458 <0.01
CSF neutrophils (cells/µL) - median (IQR) /N 0 (0-3.75) /144 10.00 (2.00-38.75) /458 <0.01
CSF lymphocytes (cells/µL) - median (IQR) /N 1.50 (0-29.75) /144 94.50 (40.0-180.75) /458 <0.01
CSF protein (g/L) - mean (SD) /N 0.33 (0.31) /140 1.98 (1.48) /442 <0.01
CSF glucose (mmol/L) - mean (SD) /N 3.66 (0.88) /146 1.85 (1.18) /469 <0.01
Serum glucose (mmol/L) - mean (SD) /N 4.50 (1.29) /4 6.71 (2.21) /152 ***
CSF:serum glucose ratio - mean (SD) /N 0.86 (0.62) /4 0.28 (0.17) /152 ***
TBM= tuberculous meningitis, n/a= not applicable, IQR= interquartile range, HIV= Human Immunode-
ficiency Virus, CSF= cerebrospinal fluid
*Non-TBM: 50 viral meningitis and 96 No meningitis. Cases of bacterial meningitis were excluded
**TBM: Micobiologically-confirmed (definite) and probable TBM according to the uniform research 
case definition [19]
***Due to only 4 patients in the non-TBM group with recorded serum glucose, p-values were not de-
termine
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glucose was 6.71 +/-2.21 mmol/L and the CSF:serum glucose ratio was 0.28 +/-0.17. 
Again, mean serum glucose did not differ between microbiologically-defined and 
case-defined TBM (p=0.37).
The mean CSF protein in the microbiologically-confirmed TBM group was 1.91 +/-
1.44 g/L), that in the TBM group (comprising ‘definite’ and ‘probable’ TBM), 1.98 
+/-1.48 g/L) and 0.33 +/-0.31 g/L) in the non-TBM group. In both microbiologically-
confirmed and case-defined TBM groups, the mean CSF protein differed significantly 
from the non-TBM group (both p<0.01). Mean CSF protein did not differ between 
microbiologically-defined and case-defined TBM (p=0.68).
Box plots illustrate absolute CSF glucose concentration and mean CSF protein in TBM 
and non-TBM groups (figure 1). TBM outliers with increased CSF glucose concentra-
tion numbered 14/469 patients. Age range was 6-180 months. Mean CSF lymphocyte 
and neutrophil counts were 162 cells/µL and 20 cells/µL; protein concentration was 
2.78 g/L. Mean serum glucose was increased in these patients, 12.42 mmol/L. There 
were no TBM outliers with low CSF protein. Non-TBM outliers with decreased CSF 
glucose concentration numbered 5/146 patients. Four patients had a diagnosis of 
viral meningitis, 2/4 had CSF PCR confirmation of a viral pathogen, both cytomega-
lovirus; 1 patient did not have meningitis. Age range was 4-142 months. Mean CSF 
lymphocyte and neutrophil counts were 127 cells/µL and 10 cells/µL. Mean serum 
glucose was decreased in these patients, 2.24 mmol/L. Non-TBM outliers with raised 
CSF protein numbered 10/146 patients; age range 4-165 months. Mean CSF lym-
phocyte and neutrophil counts were 97 cells/µL and 10 cells/µL. Mean CSF glucose 
concentration was decreased; 1.25 mmol/L. Seven patients had a diagnosis of viral 
meningitis, 2/7 had CSF PCR confirmation of a viral pathogen, 1 cytomegalovirus and 
1 Epstein- Barr virus; 3 patients did not have meningitis.
As CSF glucose concentration and mean CSF protein did not differ between 
microbiologically-confirmed and case-defined TBM, for comparative purposes only 
case-defined TBM was used. A CSF glucose concentration cut-off of <1.0 mmol/L 
had 100% specificity, but resulted in sensitivity of only 0.22. The best combination of 
good (0.8-0.9) AUC (indicating optimal sensitivity and specificity) and highest odds 
ratio was achieved with a CSF glucose cut-off of <2.2 mmol/L (table 2). This cut-off 
point resulted in an odds ratio of 48.9 (95% confidence interval (CI) 21.18-112.77); 
p<0.01 when comparing non-TBM to TBM. Although specificity could not be deter-
mined for CSF:serum glucose ratio, the sensitivity in clinically-defined TBM for a ratio 
<0.4 was 0.80 and for a ratio of <0.5 was 0.90. For an CSF glucose cut-off of <2.2 
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mmol/L 32% of clinically-defined TBM would have been missed compared to 10% 
for a CSF:serum glucose ratio of <0.50.
For mean CSF protein level, the best combination of excellent (>0.9) AUC (indicating 
optimal sensitivity and specificity) and highest odds ratio was achieved with a CSF 
protein cut-off of >0.6 g/L (table 2). This cut-off point resulted in an odds ratio of 




Figure 1. Box plots illustrating absolute CSF glucose concentration and mean CSF protein in non-TBM 
and TBM groups.
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The optimal lower limit of CSF glucose concentration as a diagnostic aid for TBM, 
2.2 mmol/L (40 mg/dl), is similar to that of bacterial meningitis [17]. This is prob-
lematic, but illustrates the importance of considering the macroscopic appearance 
and cell count in combination with CSF chemistry. The finding that less patients with 
TBM would have been missed using a CSF:glucose ratio <0.5 (10%) compared to 
an absolute CSF glucose concentration of <2.2 mmol/L (32%), highlights the value 
of determining both a serum and CSF glucose at the same time. Unfortunately, this 
is rarely done in clinical practice. Use of an absolute CSF glucose <2.2 mmol/L 
or CSF:serum glucose ratio <0.50, as suggested by expert consensus opinion when 
criteria for a uniform TBM research case definition was devised [19], is confirmed by 
this study.
The optimal CSF protein cut-off to differentiate TBM from bacterial meningitis [10], 
and viral meningitis [18], is >1g/L (100mg/dL). Our finding of an optimal CSF protein 
cut-off of >0.6 g/L only considered viral meningitis and non-meningitis as alternative 
diagnoses. Consideration of a higher CSF protein cut-off (>1g/L), as suggested by 
the uniform TBM research case definition [19], as well as cell counts are required to 
assist the distinction between TBM and bacterial meningitis. A macroscopically clear 
Table 2. Sensitivities and specificities of different cut-off points for CSF levels of absolute glucose con-
centration and mean protein in clinically-defined TBM**
CSF glucose (mmol/L) Sensitivity Specificity Area under 
ROC curve
OR 95% CI
<1.8 0.54 0.97 0.75 32.45 13.10-80.39
<2.0 0.60 0.97 0.78 42.87 17.29-106.29
<2.2 0.68 0.96 0.82 48.87 21.18-112.77
<2.4 0.72 0.93 0.82 30.99 16.32-58.87
<2.6 0.76 0.92 0.84 35.91 18.75-64.99
<2.8 0.80 0.90 0.85 38.31 21.26-69.06
CSF protein (g/L)
>0.4 0.97 0.81 0.89 118.12 62.89-221.84
>0.6 0.95 0.91 0.93 167.42 84.6-331.33
>0.8 0.85 0.93 0.89 75.81 38.13-150.70
>1.0 0.76 0.95 0.86 60.32 27.49-132.37
>1.2 0.70 0.97 0.82 68.78 25.03-188.99
TBM= tuberculous meningitis, CSF= cerebrospinal fluid, ROC= receiver operating characteristic, OR= 
odds ratio, CI= confidence interval
**TBM: Micobiologically-confirmed (definite) and probable TBM according to the uniform research 
case definition [19]
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CSF and total CSF cell count 10-500 cells/µL with >50% lymphocyte predominance 
points to a diagnosis of TBM [19].
Although CSF lactate levels were not measured in our cohort, there is potential for 
its use in children with TBM. CSF lactate has been shown to be a good biomarker to 
distinguish bacterial from aseptic meningitis [24]. CSF lactate remains unaffected by 
serum lactate concentration, reflecting the severity of cerebral hypoxia, and therefore 
the overall prognosis [25]. In a study by Thwaites et al., CSF lactate levels were sig-
nificantly higher in adult TBM patients that subsequently demised [25].
Many other CSF biomarkers have been considered in TBM cases, but diagnostic util-
ity is rarely described [26]. A 2011 meta-analysis on the use of interferon gamma 
release assays (IGRAs) in adult pulmonary TB showed limited value for active TB 
diagnosis [27]. Studies evaluating CSF IGRA showed good sensitivity and specificity 
[28-31], but low CSF volumes are a limitation in children when requiring sufficient 
cells to perform IGRA (typically 5-10ml CSF is required) [32, 33]. A study of the 
host immune response to M. tuberculosis showed the potential value of CSF inter-
leukin-13, vascular endothelial growth factor and cathelicidin LL-37 as biomarkers 
when differentiating TBM from other forms of meningitis [34]. HIV-infected patients 
with TBM immune reconstitution inflammatory syndrome (IRIS) compared to TBM 
non-IRIS showed a marked neutrophil driven immune response [35]. Understanding 
the host immune response is key to a better understanding of the pathophysiology, 
clinical presentation of TBM and treatment of TBM.
The study was limited by the small number of patients with serum glucose concentra-
tions, and HIV co-infection (4%). Our incidence of HIV co-infection in TBM is in 
agreement with the study of Karande et al. who reported an incidence of only 7% in 
a similar cohort of 123 children [36]. There was no difference in absolute CSF glucose 
concentration or CSF protein between TBM with and without HIV co-infection, but 
the small numbers precluded statistical comparison.
In conclusion, a 2.2 mmol/L cut-off point for absolute CSF glucose differentiated 
“non-bacterial non-TBM “from TBM cases with reasonable specificity. Poor sensitivity 
(0.68) indicates that an absolute CSF glucose concentration cannot be used as a 
‘rule-out’ test. A CSF:serum glucose ratio as an adjunct to CSF glucose concentra-
tion provides additional information. Although CSF protein >0.6g/L distinguished 
TBM from non-TBM with sensitivity 0.95 and specificity 0.91, the non-TBM group 
excluded bacterial meningitis cases. According to the literature a CSF protein cut-
off of >1g/L improves specificity when bacterial meningitis cases are included, but 
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sensitivity in our study dropped significantly (to 0.76). Using cut-offs of <2.2 mmol/L 
for CSF glucose and >1g/L for CSF protein seems justified as optimal CSF chemistry 
criteria in the uniform TBM research case definition.
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ABSTRACT
INTRODUCTION: Although nucleic acid amplification tests (NAATs) promise a rapid, 
definitive diagnosis of tuberculous meningitis, the performance of first-generation 
NAATs were sub-optimal and variable.
METHODS: We conducted a meta-analysis of studies published between 2003 and 
2013, using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) 
tool to evaluate methodological quality. The diagnostic accuracy of newer commer-
cial NAATs was assessed.
RESULTS: Pooled estimates of diagnostic accuracy for commercial NAATs measured 
against a cerebrospinal fluid Mycobacterium tuberculosis culture positive gold 
standard were; sensitivity 0.64, specificity 0.98 and diagostic odds ratio 64.0. Het-
erogeneity was limited; p value=0·147 and I2 =33·85%. The Xpert MTB/RIF® test 
was evaluated in one retrospective study and four prospective studies, with pooled 
sensitivity 0.70 and specificity 0.97. The QUADAS-2 tool revealed low risk of bias, as 
well as low concerns regarding applicability. Heterogeneity was pronounced among 
studies of in-house tests.
CONCLUSIONS: Commercial NAATs proved to be highly specific with greatly re-
duced heterogeneity compared to in-house tests. Sub-optimal sensitivity remains a 
limitation.
Keywords: central nervous system; tuberculosis; nucleic acid amplification tests; 
diagnostic accuracy
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In 1993, the World Health Organization (WHO) declared tuberculosis (TB) a global 
public health emergency, with an estimated 7-8 million cases and 1.3-1.6 million 
TB deaths per year. By 2012, the situation has improved in many areas, but absolute 
numbers remain virtually unchanged with an estimated 8.7 million new cases and 1.4 
million TB deaths.1 Central nervous system (CNS) involvement, mostly tuberculous 
meningitis (TBM), accounted for approximately 1% of all TB cases.2 In fact, TBM has 
been reported as the most common form of meningitis diagnosed in children from 
TB endemic areas with access to expanded program of vaccination (EPI) vaccines, 
including Haemophilus influenza type-B and pneumococcal vaccination.3 Delayed 
diagnosis of TBM is universally associated with poor treatment outcome.4
The early clinical presentation of TBM is often non-specific with symptoms such as 
cough, loss of weight, fever, vomiting and malaise. As the disease progresses, more 
specific features such as meningism, focal neurological signs, convulsions and de-
pressed level of consciousness occur.5 TBM outcome is often poor despite adequate 
anti-mycobacterial therapy, due to irreversible damage preceding delayed diagnosis 
and ongoing immune-mediated pathology on treatment. Early treatment initiation is 
critical to reduce TBM-associated morbidity, mortality and healthcare costs, empha-
sizing the importance of early and accurate diagnosis.6,7
Culture of Mycobacterium tuberculosis (M.tb) from cerebrospinal fluid (CSF) is re-
garded as the most definitive diagnosis, although this is rarely attained. TBM is a 
paucibacillary disease. This could explain that direct microscopy for acid-fast bacilli 
in CSF is rarely positive,8 while mycobacterial culture may take up to 42 days and has 
limited sensitivity (<50%) compared to clinical criteria.5,9,10 In clinical practice the 
diagnosis of TBM is usually based on a combination of clinical, laboratory and radio-
logical findings. The use of uniform case definition categories has been proposed for 
research purposes11 with “definite TBM” defined as a positive CSF M.tb culture and/
or commercial nucleic acid amplification test (NAAT).
NAATs have been introduced to provide rapid TB diagnosis and enhanced sensitivity 
compared to smear microscopy.4,12-15 Although primarily developed for the analysis 
of respiratory specimens, these methods are often used in non-respiratory specimens 
as well.13,14,16-18 They are presumed to be highly specific,11,19 since they detect M.tb-
specific DNA sequences such as the IS6110 insertion element, MBP64, 65 kDa 
antigen, and the rpoB region.20,21
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In 2003 a systematic review evaluated the test accuracy of NAATs in the diagnosis 
of TBM.18 The authors included 49 studies published between 1990 and 2002; both 
commercial and in-house NAATs were evaluated. The 14 studies with commercial 
NAATs revealed a pooled sensitivity and specificity of 56% and 98%, respectively. 
Summary accuracy measures of 35 studies with in-house NAATs could not be 
determined due to heterogeneity of the tests. Reasons for heterogeneity included: 
1) inadequate standardization of laboratory techniques, 2) use of highly variable 
reference standards, 3) and small patient numbers with limited statistical power.4 
The review concluded that commercial NAATs provided valuable information when 
positive, but due to poor sensitivity a negative test did not exclude TBM.18 This finding 
motivated the inclusion of a positive commercial NAAT as a marker of “definite TBM” 
in a proposed uniform TBM case definition for use in clinical research.11
Since then, many additional studies evaluated the use of commercial NAATs in the 
diagnosis of TBM, but no updated meta-analysis has been performed. We performed 
a systematic review of all recent studies (published since 2003) that evaluated the use 
of NAATs to diagnose TBM, with particular emphasis on commercial tests including 
the Xpert MTB/RIF® test.
METHODS
We identified all studies published between January 2003 and April 2013 from the 
following online databases: PubMed (MedLine), Web of Knowledge, Scopus and 
LILACS. Search terms used were: “Tuberculosis, Central Nervous System”, “Tubercu-
loma, Intracranial”, “Tuberculosis”, “Mycobacterium tuberculosis”, “Extrapulmonary 
tuberculosis”, “Tuberculous meningitis”, “Tuberculous pachymeningitis”, “Central 
nervous system” and/or “Kochs disease” and “Polymerase Chain Reaction”, “Ligase 
chain reaction”, “GeneXpert” and/or “ Nucleic acid amplification testing”. Only 
articles written in English were included. Case reports and review articles were ex-
cluded. Studies with less than 10 subjects were also excluded. References of selected 
articles were reviewed to identify additional eligible studies. Three reviewers (RS, 
SLvE and AMvF) independently evaluated study inclusion; differences were resolved 
by consensus.
Data extraction
Two reviewers (RS and SLvE) independently extracted data including number of 
cases, number of controls, reference standard used, type of NAAT evaluated. Diag-
nostic odds ratios were extracted or calculated from the data provided. Differences 
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were resolved by consensus. Methodological quality was assessed using the Quality 
Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool.23-25
Statistical analysis
Data analysis was performed using Statistical Package for the Social Sciences version 
19 (SPSS Inc, Chicago, IL, USA), Comprehensive Meta Analysis version 2 (Biostat, 
Eaglewood, NJ, USA) and Meta-DiSc (Unit of Clinical Biostatistics, Ramón y Cajal 
Hospital, Madrid, Spain). Sensitivity, specificity and diagnostic odds ratio (DOR) 
were computed for each of the included studies. Pooled summary effect estimates 
were calculated, using a random effects model. Where both CSF culture and clinical 
criteria were analyzed separately as reference standards, only the studies with CSF 
culture as the reference standard were included. When articles evaluated more than 
one NAAT, or more than one quality measure, these were analyzed separately.
Receiver operating characteristic (ROC) curves based on either the regression of 
logit sensitivity on specificity, the regression of logit specificity on sensitivity, or an 
orthogonal regression line by minimizing the perpendicular distances were derived. 
These lines were transformed back to the original ROC scale to obtain a summary 
ROC (SROC) curve. Derived logit estimates of sensitivity, specificity and respective 
variances were used to construct a hierarchical SROC curve with these summary 
estimates. The area under the curve serves as a global measure of test performance; a 
value of 1 indicates perfect accuracy.26 Heterogeneity was assessed by applying the 
X2 homogeneity test to calculated odds ratios (as a single measure) and determining 
I2, with values of more than 50% indicating heterogeneity.26-28 Statistical significance 
was set at 0.05 for heterogeneity testing.
RESULTS
The study selection process is summarized in Figure 1. The literature search revealed 
1125 potential articles, which was narrowed down to 69 articles after title screening. 
This was narrowed down further to 62 articles after abstract screening. Thirty-six ar-
ticles were excluded after screening the text, and 4 articles added after cross referenc-
ing. Ten studies in 8 articles, describing commercial tests were selected; 40 studies 
in 22 articles describing in-house NAATs were tabulated seperately4,8,14,15,19,21,28-48-53 
(Supplementary table 1). Reference standards used in the ten studies evaluating 
commercial NAATs included a positive CSF M.tb culture in nine (90%) and clinical 
criteria in one (10%). To avoid misleading results, only the 9 commercial studies 
with positive CSF M.tb culture as the reference standard were analyzed. A variety of 
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DNA extraction techniques and target sequences were used. Table 1 summarizes key 
characteristics of the commercial NAAT studies. Figure 2 reflects formal assessment 
of the four study domains evaluated by the QUADAS-2 tool; inter-reviewer variability 
using the tool was 10.6%.24
Summary test accuracy estimates for the nine commercial NAATS evaluated were; 
sensitivity 0.64 (95% CI 0.56-0.72), specificity 0.98 (95% CI 0.96-0.99), positive 
likelihood ratio 20.36 (95% CI 11.29-36.73), negative likelihood ratio 0.39 (95% 
CI 0.30-0.53) and DOR 64.0 (95% CI 26.9-152.1). Heterogeneity was limited; p 
value=0.147 and I2 =33.85%. Table 2 shows heterogeneity testing after stratifica-
tion of the commercial NAATs based on study design, prospective nature and Xpert 
MTB/RIF testing. Figure 3 provides an overview of sensitivities and specificities of 
commercial NAATs in forest plot format. Figure 4 presents the SROC curve for the 
commercial NAAT studies combined, with the respective studies presented as circles. 
The area under the curve (AUC) for all commercial tests combined was 0.92.
Figure 1. Flow diagram of all studies identified and those selected for meta-analysis
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Figure 2. Bar graphs representing quality assessment by the QUADAS-2 tool24
The numbers in the bars represent the individual commercial NAATs
Table 1. Characteristics of commercial nucleic acid amplification test studies included in the meta-
analysis






Johnsson9 Retrospective case-control Clinical criteria Cobas 
Amplicor
0·56(0·21-0·86) 0·97(0·93-0·99)
Johansen29 Prospective cross-sectional CSF culture standard BD 
ProbeTec ET
0·62(0·32-0·86) 0·99(0·94-1·00)
Johansen29 Prospective cross-sectional CSF culture modified BD 
ProbeTec ET
0·77(0·46-0·95) 0·99(0·94-1·00)
Thwaites4 Retrospective case-control CSF culture enhanced 
MTD
0·50(0·34-0·66) 0·95(0·88-0·99)
Causse50 Prospective cross-sectional CSF culture Xpert MTB/Rif 0·83(0·36-1·00) 1.00(0·92-1·00)
Causse50 Prospective cross-sectional CSF culture Cobas Taqman 
MTB
0·67(0·22-0·96) 0·98(0·88-1·00)
Malbruny51 Prospective cross-sectional CSF culture Xpert MTB/Rif 1·00(0·03-1·00) 1·00(0·77-1·00)
Vadwai52 Prospective cross-sectional CSF culture Xpert MTB/Rif 0·33(0·01-0·91) 0·95(0·74-1·00)
Tortoli47 Retrospective case-control CSF culture Xpert MTB/Rif 0.85(0·55-0·98) 0.98(0·94-1·00)
Patel53 Prospective cross-sectional CSF culture Xpert MTB/Rif 0·67(0·53-0·79) 0·94(0·85-0·98)
CI= confidence interval, CSF= cerebrospinal fluid
*NAAT used: Cobas amplicor (Roche Molecular Systems, Branchburg, NJ, USA), BD ProbeTec ET assay 
(Becton, Dickinson and Company, Sparks, MD, USA), MTD (Gen-Probe Inc, San Diego, Ca, USA), Ge-
nei Amplification kit (Bangalore Genei, Banglore, India), Xpert MTB/RIF (Xpert) (Cepheid, Sunnyvale, 
CA, USA)
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Summary test accuracy estimates for the 40 in-house tests revealed sensitivity of 0.73 
(95% CI 0.71-0.75), specificity of 0.92 (95% CI 0.90-0.93), positive likelihood ratio 
of 9.56 (95% CI 6.61-13.84), negative likelihood ratio of 0.27 (95% CI 0.20-0.35) and 
DOR of 40.6 (95% CI 26.6-61.9). Heterogeneity was pronounced; p-value=0.001 and 
I2 = 58·86%. Supplementary table 2 shows heterogeneity testing after stratification 
of the in-house NAATs based on study design, prospective nature, randomization, 
blinding, reference standard and type of PCR used. Forest plots of sensitivities and 
specificities of in-house NAATs and the relevant SROC plot are included in Supple-
mentary figure 1. The AUC for all in-house tests combined was 0.94.
Figure 3. Forest plots of A) sensitivity and B) specificity of commercial NAATs
Each circle shows the point estimate of sensitivity and specificity from each included study. Error bars 
represent 95% confidence intervals.






Test for heterogeneity 
p-value I2 (%)
Study design
Case-control 2 68.5 4.3-1106.8 0.018 82.06
Cross-sectional 7 59.8 26.2-136.2 0.416 1.08
Prospective data collection
Yes 7 59.8 26.2-136.2 0.416 1.08
No 2 68.5 4.3-1106.8 0.018 82.06
PCR type
Xpert MTB/Rif 5 70.7 17.4-287.1 0.157 39.65
DOR= diagnostic odds ratio, CI= confidence interval, I2 is a measure of heterogeneity (>50%= hetero-
geneity)
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The need for a test that can diagnose TBM rapidly and accurately, especially during 
its early phases, is self-evident.54 Our systematic review and meta-analysis of com-
mercial NAATs with a CSF M.tb culture-positive gold standard found a summary 
sensitivity estimate of 0.64. Unfortunately this remains suboptimal and is unlikely to 
greatly enhance early accurate diagnosis, since most study specimens were collected 
from patients with advanced TBM disease. In contrast, commercial NAATs exhibited 
excellent specificity of 0·98 and in the correct clinical context it may be regarded as 
a definitive test.11 Similar to findings from the previous systematic review performed 
in 2003,18 we found significant heterogeneity among in-house NAATs and consistent 
performance in the commercial group. When comparing our summary estimates to 
the previous meta-analysis, the sensitivity of more recent commercial NAATs shows 
improvement (0.64 vs 0.56) with a similar specificity (0.98). Our summary estimate 
of negative likelihood ratio is lower (0.39 vs 0.44), but still far from ideal when 
considering its use as a “rule-out” test.
Figure 4. SROC curve for commercial NAATs
Each study is represented by a circle (the size of the circle reflecting study size) and the dark line shows 
the summary diagnostic accuracy.
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Despite suboptimal sensitivity, the rapid turnaround time of NAATs compared to 
culture enhances its role in the early accurate diagnosis of TBM. However, most 
commercial NAATs are validated for pulmonary samples and are still not advised 
for routine diagnostic use.47 The Xpert MTB/RIF assay (Cepheid, CA, USA) has been 
endorsed by the WHO for use on both smear positive and negative respiratory 
specimens. The findings of the Xpert MTB/RIF assay demonstrated rapid diagnosis 
in a large retrospective study of extrapulmonary specimens, including an encourag-
ing sensitivity of 0.85 and specificity 0.98 for CSF samples.47 When combined with 
the 4 prospective studies testing the Xpert MTB/RIF assay in CSF samples, a pooled 
sensitivity and specificity of 0.70 and 0.97 was obtained.47,50-53 Provided that similar 
measures of sensitivity and specificity can be maintained in future studies using the 
Xpert MTB/RIF assay in CSF specimens, the goal of Xpert MTB/RIF assay as a “stand 
alone” test for diagnosis of TBM can be achieved.
The use of microscopy, culture and NAATs together with clinical features and neuro-
imaging in a pragmatic algorithm seems preferable to improve diagnostic accuracy. 
This updated meta-analysis supports the conclusion that a positive commercial NAAT 
result provides a definite TBM diagnosis in the right clinical context, as suggested 
in the proposed uniform research case definition for TBM in adults and children.11 
The rest of the components of the proposed uniform research case definition can 
compensate for commercial NAATs when excluding a diagnosis of TBM.
The ‘gold standard’ for the diagnosis of TBM is the identification of M.tb on CSF 
culture or identification of acid-fast bacilli on CSF microscopy. The low sensitivity 
of both these methods has prompted leading researchers to use alternate clinical 
reference standards. In our meta-analysis we attempted to avoid overestimating sum-
mary estimates of diagnostic accuracy by only analyzing commercial NAATs using 
an M.tb culture positive reference standard. The low heterogeneity observed when 
studies were prospective or cross-sectional was also encouraging (Table 2). Similar to 
previous findings, in-house NAAT studies demonstrated excessive heterogeneity with 
wide variability in methodological quality (Supplementary table 2).18
The quality and reporting of diagnostic accuracy studies on commercial tests for 
TB, malaria and HIV are problematic.25 To minimize these concerns, screening and 
selection of articles were assessed by three independent reviewers followed by rigor-
ous quality assessment using the QUADAS-2 tool.24 This resulted in multiple study 
exclusions, but careful assessment of study accuracy and reliability strengthens the 
findings of our meta-analysis. Overall, the studies revealed a low risk of bias in the 
Stellenbosch University  https://scholar.sun.ac.za








categories of flow and timing, reference standard, index test and patient selection. 
There was little concern regarding the applicability of study findings.
In conclusion, commercial NAATs revealed good specificity and postive predictive 
values for the diagnosis of TBM on CSF samples in areas of high TB prevalence. 
However, sensitivity and negative predictive values remain suboptimal, hampering 
the ability to direct treatment, especially early in the disease process when the best 
treatment outcomes can be achieved.
ACKNOWLEDGEMENTS
We would like to acknowledge Dr Justin Harvey from the department of statistics at 
Stellenbosch University for assistance with the statistical analaysis of this manuscript.
CONFLICT OF INTERESTS
None of the authors have any conflict of interests.
Stellenbosch University  https://scholar.sun.ac.za
110 Chapter 4.1
REFERENCES
 1. World Health Organization. Global Tuberculosis Report. WHO report 2012. Geneva, Switzer-
land.
 2. Rock RB, Olin M, Baker CA, et al. Central nervous system tuberculosis: pathogenesis and 
clinical aspects. Clin Microbiol Rev 2008; 21(2): 243-61.
 3. Wolzak NK, Cooke ML, Orth H, et al. The Changing Profile of Pediatric Meningitis at a Refer-
ral Centre in Cape Town, South Africa. J Trop Pediatr 2012; 58(6): 491-5.
 4. Thwaites GE, Caws M, Chau TTH, et al. Comparison of conventional bacteriology with 
nucleic acid amplification (amplified mycobacterium direct test) for diagnosis of tuberculous 
meningitis before and after inception of antituberculosis chemotherapy. J Clin Microbiol 
2004; 42: 996-1002.
 5. van Well GT, Paes BF, Terwee CB, et al. Twenty years of pediatric tuberculous meningitis: a 
retrospective cohort study in the Western Cape of South Africa. Pediatrics 2009; 123(1): 1-8.
 6. Schoeman JF, Wait J, Burger M, et al. Long-term follow-up of childhood tuberculous meningi-
tis. Dev Med Child Neurol 2002; 44: 522-6.
 7. Garg RK. Tuberculosis of the central nervous system. Postgrad Med J 1999; 75: 133-140.
 8. Thwaites G, Chau TTH, Mai NTH, et al. Tuberculous meningitis. J Neurol Neurosurg Psychia-
try 2000; 68: 289-299.
 9. Jönsson B, Ridell M. The Cobas Amplicor MTB Test for Detection of Mycobacterium tubercu-
losis Complex from Respiratory and Non-respiratory Clinical Specimens. Scand J Infect Dis 
2003; 35(6-7): 372-7.
 10. Hosoglu S, Geyik MF, Balik I, et al. Predictors of outcome in patients with tuberculous men-
ingitis. Int J Tuberc Lung Dis 2002; 6(1): 64-70.
 11. Marais S, Thwaites GE, Schoeman JF, et al. Tuberculous meningitis: a uniform case definition 
for use in clinical research. Lancet Infect Dis 2010; 10(11): 803-12.
 12. Reischl U, Lehn, N, Wolf H, et al. Clinical evaluation of the automated Cobas Amplicor MTB 
assay for testing respiratory and nonrespiratory specimens. J Clin Microbiol 1998; 36: 2853-60.
 13. Caws M, Wilson SM, Clough C, et al. Role of IS6110-targeted PCR, culture, biochemical, 
clinical, and immunological criteria for diagnosis of tuberculous meningitis. J Clin Microbiol 
2000; 38: 3150-5.
 14. Pfyffer G, Kissling P, Jahn E, et al. Diagnostic performance of amplified Mycobacterium tuber-
culosis direct test with cerebrospinal fluid, other nonrespiratory, and respiratory specimens. J 
Clin Microbiol 1996; 34: 834-41.
 15. Rafi A, Naghily B. Efficiency of polymerase chain reaction for the diagnosis of tuberculous 
meningitis. Southeast Asian J of Trop Med Public Health 2003; 34(2): 357-360.
 16. Bonington A, Strang JI, Klapper PE, et al. Use of Roche AMPLICOR Mycobacterium tubercu-
losis PCR in early diagnosis of tuberculous meningitis. J Clin Microbiol 1998; 36: 1251-4.
 17. Chedore P, Jamieson FB.Rapid molecular diagnosis of tuberculous meningitis using the Gen-
probe Amplified Mycobacterium Tuberculosis direct test in a large Canadian public health 
laboratory. Int J Tuberc Lung Dis 2002; 6: 913-9.
 18. Pai M, Flores LL, Pai N, et al. Diagnostic accuracy of nucleic acid amplification tests for 
tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect Dis 2003; 3: 
633-43.
 19. Brisson NA, Aznar C. Diagnosis of tuberculosis by DNA amplification in clinical practice 
evaluation. Lancet 1991; 338: 364-6.
Stellenbosch University  https://scholar.sun.ac.za








 20. Rafi W, Venkataswamy MM, Ravi V, et al. Rapid diagnosis of tuberculous meningitis: A com-
parative evaluation of in-house PCR assays involving three mycobacterial DNA sequences, 
IS6110, MPB-64 and 65 kDa antigen. J Neurol Sci 2006; 252: 163-8.
 21. Blakemore R, Story E, Helb D, et al. Evaluation of the analytical performance of the Xpert 
MTB/RIF assay. J Clin Microbiol 2010; 48(7): 2495-501.
 22. Kusum S, Aman S, Pallab R, et al. Multiplex PCR for rapid diagnosis of tuberculous meningitis. 
J Neurol 2011; 258(10): 1781-7.
 23. Whiting P, Rutjes AWS, Reitsma JB, et al. The development of QUADAS: a tool for the quality 
assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res 
Methodol 2003; 3: 25.
 24. Whiting PF, Rutjes AWS, Westwood ME, et al. QUADAS-2: A revised tool for the quality 
assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155(8): 529-36.
 25. Fontela PS, Pant Pai N, Schiller I, et al. Quality and reporting of diagnostic accuracy studies in 
TB, HIV and malaria: evaluation using QUADAS and STARD standards. PLoS One 2009; 4(11): 
e7753.
 26. Dwamena B. MIDAS: Stata module for meta-analytical integration of diagnostic test accuracy 
studies. Statistical Software Components S456880, Boston College Department of Economics, 
2007.
 27. Greco S, Girardi E, Masciangelo R, et al. Adenosine deaminase and interferon gamma mea-
surements for the diagnosis of tuberculous pleurisy: a meta-analysis. Int J Tuberc Lung Dis 
2003; 7(8): 777-86.
 28. Abroug F, Ouanes-Besbes L, Dachraoui F, et al. An updated study-level meta-analysis of 
randomized controlled trials on proning in ARDS and acute lung injury. Crit Care 2011; 15(1): 
R6.
 29. Johansen IS, Lundgren B, Tabak,F, et al. Improved sensitivity of nucleic acid amplification for 
rapid diagnosis of tuberculous meningitis. J Clin Microbiol 2004; 42(7): 3036-40.
 30. Kulkarni SP, Jaleel MA, Kadival GV. Evaluation of an in-house-developed PCR for the diagnosis 
of tuberculous meningitis in Indian children. J Med Microbiol 2005; 54(4): 369-73.
 31. Desai D, Nataraj G, Kulkarni S, et al. Utility of the polymerase chain reaction in the diagnosis 
of tuberculous meningitis. Res Microbiol 2006; 157(10): 967-70.
 32. Juan RS, Sánchez-Suárez C, Rebollo MJ, et al. Interferon gamma quantification in cerebro-
spinal fluid compared with PCR for the diagnosis of tuberculous meningitis. J Neurol 2006; 
253(10): 1323-30.
 33. Quan C, Lu CZ, Qiao J, et al. Comparative Evaluation of Early Diagnosis of Tuberculous 
Meningitis by Different Assays. J Clin Microbiol 2006; 44(9): 3160-6.
 34. Bhigjee AI, Padayachee R, Paruk H, et al. Diagnosis of tuberculous meningitis: clinical and 
laboratory parameters. Int J of Infect Dis 2007; 11: 348-354.
 35. Deshpande PS, Kashyap RS, Ramteke SS, et al. Evaluation of the IS6110 PCR assay for the 
rapid diagnosis of tuberculous meningitis. Cerebrospinal Fluid Res 2007; 4: 10.
 36. Rafi W, Venkataswamy MM, Nagarathna S, et al. Role of IS6110 uniplex PCR in the diagnosis 
of tuberculous meningitis: experience at a tertiary neurocentre. Int J Tuberc Lung Dis 2007; 
11(2): 209-14.
 37. Dora JM, Geib G, Chakr R, et al. Polymerase chain reaction as a useful and simple tool for 
rapid diagnosis of tuberculous meningitis in a Brazilian tertiary care hospital. Braz J Infect Dis 
2008; 12(3): 245-7.
Stellenbosch University  https://scholar.sun.ac.za
112 Chapter 4.1
 38. Takahashi T, Tamura M, Asami Y, et al. Novel wide-range quantitative nested real-time PCR 
assay for Mycobacterium tuberculosis DNA: clinical application for diagnosis of tuberculous 
meningitis. J Clin Microbiol 2008; 46(5): 1698-1707.
 39. Haldar S, Sharma N, Gupta,VK, et al. Efficient diagnosis of tuberculous meningitis by detec-
tion of Mycobacterium tuberculosis DNA in cerebrospinal fluid filtrates using PCR. J Med 
Microbiol 2009; 58: 616-24.
 40. Huang HJ, Xiang DR, Sheng JF, et al. rpoB nested PCR and sequencing for the early diagnosis 
of tuberculous meningitis and rifampicin resistance. Int J Tuberc Lung Dis 2009; 13(6): 749-54.
 41. Rana SV, Chacko F, Lal V, et al. To compare CSF adenosine deaminase levels and CSF-PCR for 
tuberculous meningitis. Clin Neurol Neurosurg 2010; 112(5): 424-30.
 42. Nagdev KJ, Kashyap RS, Deshpande PS, et al. Determination of polymerase chain reaction 
efficiency for diagnosis of tuberculous meningitis in Chelex-100 extracted DNA samples. Int J 
Tuberc Lung Dis 2010; 14(8): 1032-8.
 43. Nagdev KJ, Kashyap RS, Deshpande PS, et al. Comparative evaluation of a PCR assay with an 
in-house ELISA method for diagnosis of Tuberculous meningitis. Med Sci Monit 2010; 16(6): 
CR289–95.
 44. Sharma K, Sharma A, Singh M, et al. Evaluation of polymerase chain reaction using protein b 
primers for rapid diagnosis of tuberculous meningitis. Neurol India 2010; 58(5): 727-31.
 45. Nagdev KJ, Kashyap RS, Parida MM, et al. Loop-mediated isothermal amplification for rapid 
and reliable diagnosis of tuberculous meningitis. J Clin Microbiol 2011; 49(5): 1861-5.
 46. Iacob SA, Banica D. The usefulness of IS6110 nested polymerase chain reaction in neuro-
tuberculosis diagnosis before and after empirical treatment starting. Romanian review of 
laboratory medicine 2009; 16(3): 29-40.
 47. Tortoli E, Russo C, Piersimoni C, et al. Clinical validation of Xpert MTB/RIF for the diagnosis 
of extrapulmonary tuberculosis. Eur Respir J 2012; 40: 442-7.
 48. Sastry AS, Bhat KS, Kumudavathi. The diagnostic utility of Bact/ALERT and nested PCR in the 
diagnosis of tuberculous meningitis. J Clin Diagn Res 2013; 7(1): 74-8.
 49. Chaidir L, Ganiem AR, vander Zanden A, et al. Comparison of real time IS6110-PCR, mi-
croscopy, and culture for diagnosis of tuberculous meningitis in a cohort of adult patients in 
Indonesia. PLoS One 2012; 7(12): e52001.
 50. Causse M, Ruiz P, Gutiérrez-Aroca JB, et al. Comparison of two molecular methods for rapid 
diagnosis of extrapulmonary tuberculosis. J Clin Microbiol. 2011; 49(8): 3065-7.
 51. Malbruny B, Le Marrec G, Courageux K, et al. Rapid and efficient detection of Mycobacterium 
tuberculosis in respiratory and non-respiratory samples. Int J Tuberc Lung Dis. 2011; 15(4): 
553-5.
 52. Vadwai V, Boehme C, Nabeta P, et al. Xpert MTB/RIF: a new pillar in diagnosis of extrapulmo-
nary tuberculosis? J Clin Microbiol. 2011; 49(7): 2540-5.
 53. Patel VB, Theron G, Lenders L, et al. Diagnostic accuracy of quantitative PCR (Xpert MTB/RIF) 
for tuberculous meningitis in a high burden setting: a prospective study. PLoS Med. 2013; 
10(10): e1001536.
 54. Ho J, Marais BJ, Gilbert GL, et al. Diagnosing tuberculous meningitis - have we made any 
progress? Trop Med Int Health 2013; 18(6): 783-93.
Stellenbosch University  https://scholar.sun.ac.za








Supplementary table 1. Characteristics of in-house studies included in the meta-analysis
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Chaidir49 Prospective cohort 
study














CI= confidence interval, CSF= cerebrospinal fluid, OR-QNRT= original quantitative nested real-time, 
WR-QNRT= wide-range quantitative nested real-time.
Supplementary table 2. Heterogeneity testing of in-house NAATs in stratified sub-groups








Case-control 29 44.7 27.1-73.8 0.000 63.43
Cross-sectional 7 19.3 8.7-42.8 0.479 0.00
Prospective data collection
Yes 9 49.7 17.0-145.4 0.068 45.05
No 31 39.7 24.7-63.7 0.000 62.60
Randomization
No 36 40.6 26.2-63.0 0.000 62.25
Blinding
Single-blinded 10 106.4 27.1-417.6 0.002 66.34
Non-blinded 28 30.2 19.8-46.2 0.000 54.15
Reference standard
Culture 7 72.2 21.3-245.5 0.000 78.65
Clinical criteria 13 57.7 26.9-123.5 0.743 0.00
CSF microscopy 
and/or culture and 
clinical criteria
20 31.0 18.1-53.2 0.000 64.39
PCR type
IS6110 19 36.5 20.3-65.7 0.001 58.89
Other 21 46.2 24.6-86.7 0.000 60.19
Presence of nesting 7 42.0 16.8-104.8 0.648 0.00
DOR= Diagnostic odds ratio, CI= confidence interval, I2 is a measure of heterogeneity (>50%= hetero-
geneity)
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Supplementary Figure 1. Forest plots of A) sensitivity B) specificity and c) SROC curve of in-house 
NAATs
Each circle shows the point estimate of sensitivity and specificity from each included study.
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ABSTRACT
BACKGROUND: Early treatment is critical to reduce tuberculous meningitis (TBM)-
related morbidity and mortality. Diagnosis based on cerebrospinal fluid (CSF) culture 
is impractical due to slow turn-around times, while microscopy has poor sensitivity. 
Enhanced detection methods are essential to guide early treatment initiation, espe-
cially in vulnerable young children.
METHODS: We assessed the diagnostic accuracy of Genotype MTBDRplus® and Xpert 
MTB/RIF® assays on CSF collected from pediatric meningitis suspects prospectively 
enrolled at Tygerberg Hospital, Cape Town, South Africa. Fluorescent auramine-O 
microscopy, liquid culture for Mycobacterium tuberculosis, MTBDRplus® and Xpert 
MTB/RIF® assays were performed on all CSF samples.
RESULTS: Of 101 meningitis suspects, 55 were diagnosed with TBM and 46 served 
as non-TBM controls. Using a pre-defined TBM case-definition as reference standard, 
sensitivities and specificities were 4% and 100% for fluorescent microscopy, 22% 
and 100% for culture, 33% and 98% for MTBDRplus®, 26% and 100% for Xpert 
MTB/RIF®, 22% and 100% for microscopy and/or culture combined and 49% and 
98% for MTBDRplus® and Xpert MTB/RIF® combined. Culture, MTBDRplus® and 
Xpert MTB/RIF® combined performed best with 56% sensitivity and 98% specificity.
CONCLUSION: Commercial nucleic-acid amplification tests performed on CSF re-
vealed incrementally-improved diagnostic accuracy, providing rapid microbiological 
confirmation but cannot serve as a rule-out test.
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In 1993, the World Health Organization declared tuberculosis (TB) a global public 
health emergency1. Although some progress has been made, patient numbers in 2012 
are essentially unchanged with an estimated 8.6 million new cases and 1.3 million 
deaths from TB worldwide2. In South Africa, the TB incidence has risen to 1000 new 
cases/100,000 population in 20122, while large numbers of retreatment cases with a 
second or third episode of TB are not included in this figure2,3.
Tuberculous meningitis (TBM) is the most devastating manifestation of TB and early 
treatment initiation is critical to optimize outcomes4. Confirmation of TBM diagnosis 
is challenging in young children due to the paucibacillary nature of disease and low 
cerebrospinal fluid (CSF) volumes available for diagnostic analysis5. Currently TBM 
confirmation requires visualization of acid-fast bacilli and/or a positive Mycobacte-
rium tuberculosis (M.tuberculosis) culture from CSF. Direct microscopy for acid-fast 
bacilli in CSF is fast but has very low sensitivity (<20%)6 whereas mycobacterial 
culture may take up to 42 days and has only slightly improved sensitivity7-9.
Several commercially available nucleic acid amplification tests (NAATs) have been 
developed for the rapid diagnosis of TB. The World Health Organization has en-
dorsed the Xpert MTB/RIF® assay (Cepheid, Sunnyvale, CA, USA) for both smear 
microscopy-positive and -negative sputum specimens. Xpert simultaneously detects 
M.tuberculosis and susceptibility to rifampicin by amplification of the rpoB gene10,11. 
It is usable for a variety of liquid clinical samples12,13. However, lower sensitivities 
attributed to low numbers of bacilli (59-62%), were obtained for CSF specimens14,15.
The MTBDRplus® assay (Hain Lifescience GmbH, Nehren, Germany) version 1 is 
recommended for smear microscopy-positive specimens only16,17, while version 2 
of the assay can also be applied to smear microscopy-negative specimens, having 
similar sensitivity compared to Xpert MTB/RIF®18,19. The MTBDRplus® is a line probe 
assay targeting the rpoB, katG and inhA genes, detecting M.tuberculosis, as well 
as rifampicin and isoniazid susceptibility. Although the MTBDRplus® assay version 
2 has similar sensitivity and specificity to Xpert MTB/RIF® in smear microscopy-
negative specimens, Xpert MTB/RIF® detects M.tuberculosis quicker (under 2 hours 
vs 5 hours) and is a closed-tube system, with easier handling and decreasing con-
tamination rates20.
In order to assess the utility of MTBDRplus® and Xpert MTB/RIF® to diagnose TBM in 
a clinical setting, alone and/or in combination with established diagnostic methods, 
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we collected CSF samples from children with suspected meningitis in a setting where 
TBM is common.
METHODS
We conducted a prospective hospital-based study of all children clinically suspected 
of having meningitis.
Study Population and Setting
This study was conducted at Tygerberg Hospital, Cape Town, a major tertiary referral 
centre for Cape Town and surrounding areas. TBM is a common diagnosis among 
children diagnosed with meningitis21. Children were enrolled between January 2010 
and March 2013. Inclusion criteria were 1) age 3 months to 13 years 2) clinical sus-
picion of meningitis 3) CSF sample collected for fluorescent auramine-O microscopy, 
M.tuberculosis culture, MTBDRplus® and Xpert MTB/RIF® assays and 4) written 
consent from the caregiver and assent if the child was older than 7 years and compe-
tent to do so. The study was approved by the Human Research Ethics Committee of 
Stellenbosch University, Cape Town, Western Cape, South Africa.
Clinical procedures
All patients underwent a comprehensive clinical evaluation. Routine investigations, 
including full blood count, basic biochemistry, HIV-screening, tuberculin skin test 
(TST), microbiological analysis of sputum or gastric washing (fluorescence micros-
copy for acid-fast bacilli and M.tuberculosis culture), bacterial blood culture, chest 




A diagnosis of TBM was based on a uniform research case definition (Table 1)22. TBM 
was classified as ‘definite’ when CSF demonstrated acid-fast bacilli and/or positive 
M.tuberculosis culture in a patient with symptoms or signs suggestive of the disease. 
As MTBDRplus® and Xpert MTB/RIF® were tested, M.tuberculosis detected by com-
mercial NAATs in CSF was not used as a criteria for ‘definite’ TBM. TBM was classified 
as ‘probable’ or ‘possible’ based on a scoring system22. All patients diagnosed with 
TBM were treated with a standard short-course regimen23.
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Table 1. Diagnostic criteria in the uniform TBM research case definition22
Diagnostic score
Clinical criteria (Maximum category score=6)
Symptom duration of more than 5 days 4
Systemic symptoms suggestive of TB (1 or more of ): weight loss/(poor 
weight gain in children), night sweats or persistent cough > 2 weeks
2
History of recent close contact with an individual with pulmonary TB or 
a positive TST/IGRA in a child <10 years
2
Focal neurological deficit (excluding cranial nerve palsies) 1
Cranial nerve palsy 1
CSF criteria (Maximum category score=4)
Clear appearance 1
Cells: 10–500 per µl 1
Lymphocytic predominance (>50%) 1
Protein concentration greater than 1 g/L 1
CSF to plasma glucose ratio of less than 50% or an absolute CSF 
glucose concentration less than 2·2mmol/L
1
Cerebral imaging criteria (Maximum category score=6)
Hydrocephalus 1
Basal meningeal enhancement 2
Tuberculoma 2
Infarct 1
Pre-contrast basal hyperdensity 2
Evidence of tuberculosis elsewhere (Maximum category score=4)
Chest X-ray suggestive of active TB (excluding miliary TB) 2
Chest X-ray suggestive of miliary TB 4
CT/ MRI/ US evidence for TB outside the CNS 2
AFB identified or M.tuberculosis cultured from another source i.e. 
lymph node, gastric washing, urine, blood culture
4
Exclusion of alternative diagnoses- An alternative diagnosis must be confirmed microbiologically, 
serologically or histopathologically
Definite TBM = AFB seen on CSF microscopy, positive CSF M.tuberculosis culture, or positive CSF 
M.tuberculosis commercial NAAT in the setting of symptoms/signs suggestive of meningitis; or AFB seen 
in the context of histological changes consistent with TB brain or spinal cord together with suggestive 
symptoms/signs and CSF changes, or visible meningitis (on autopsy).
Probable TBM = total score of ≥12 when neuroimaging available
    = total score of ≥10 when neuroimaging unavailable
Possible TBM = total score of 6-11 when neuroimaging available
    = total score of 6-9 when neuroimaging unavailable
TBM- tuberculous meningitis, TB- tuberculosis, TST- tuberculin skin test, IGRA- interferon gamma-re-
lease assay, CSF- cerebrospinal fluid, CT- computed tomography, MRI- magnetic resonance imaging, 
US- ultrasound, AFB- acid-fast bacilli, NAAT- nucleic acid amplification test
Stellenbosch University  https://scholar.sun.ac.za
122 Chapter 4.2
Non-TBM
This included viral, fungal or bacterial meningitis (other than TBM) and cases without 
meningitis (normal CSF and/or confirmation of an alternative diagnosis). Viral menin-
gitis was confirmed when a viral pathogen was identified in the CSF by polymerase 
chain reaction (PCR). Viral meningitis was considered probable with clinical evidence 
of acute meningitis and absence of any micro-organism on Gram stain of CSF and 
negative routine bacterial culture of CSF if antibiotics were not administered prior 
to the first lumbar puncture24. Bacterial or fungal meningitis was determined by the 
identification of a bacterial pathogen in the CSF using microscopy, culture or antigen 
detection methods. Probable bacterial meningitis was defined as clinical evidence of 
meningitis in addition to a suggestive CSF examination25.
CSF COLLECTION AND TESTING
CSF was obtained by lumbar puncture from all children included and the following 
investigations performed: appearance and color determination, differential cell count 
determination by standard methods, protein, glucose and chloride determination by 
standard methods, centrifugation with Gram stain and India ink examination on the 
deposit and culture of the centrifuged deposit on blood agar plates for pyogenic bac-
teria. When viral meningitis was suspected, PCR for cytomegalovirus, Epstein-Barr 
virus, enteroviruses, human herpesvirus-6, herpes simplex 1 & 2 and varicella zoster, 
was performed on CSF. Fluorescence microscopy was conducted using standardized 
auramine-O staining methods26.
M.tuberculosis culture
A volume of 0.5 ml of CSF was directly inoculated into a Mycobateria Growth Indica-
tor Tube (MGIT; Becton Dickinson, Sparks, MD, USA) supplemented with 0.8 ml 
OADC (oleic acid, albumin, dextrose, catalase) containing PANTA (polymyxin B, 
amphotericin B, nalidixic acid, trimethoprim, azlocillin). The MGIT was placed into 
a BACTEC MGIT 960 instrument, incubated at 37°C. Flagged cultures were removed 
and the presence of acid-fast bacilli verified by Ziehl-Neelsen staining and micros-
copy. Bacterial contamination was excluded by placing one drop of culture on a 
blood agar plate with no growth after 48 hours incubation at 37°C. Specimens were 
determined negative if not flagged after 42 days of incubation.
GenoType MTBDRplus®
CSF samples were processed by the National Health Laboratory Service (NHLS) TB 
laboratory at Tygerberg Hospital. Samples were mixed by pipetting. The Genotype 
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MTBDRplus® assays were used according to the manufacturer’s instructions. The 
CSF volume analyzed was 0.5ml, with a 160 colony forming unit (CFU)/ml limit of 
detection. Quality control included a negative and positive control. Improvements 
in the DNA extraction from sonication and heat (version 1) to a chemical method 
(version 2), enabled its usage on smear microscopy-positive and -negative samples; 
the laboratory adopted version 2 in July 2012.
Xpert MTB/RIF®
An aliquot of 1 ml specimen was mixed with 2 ml of Xpert Sample Reagent (Cepheid), 
inverted 10 times, and incubated at room temperature. The inversion was repeated 
after 8 minutes and the incubation continued until a total duration of 15 minutes. 
After this, the mixture was completely transferred into an Xpert MTB/RIF cartridge, 
which was loaded into the GeneXpert instrument. All further processing, measuring 
and analysis steps happened automatically (GeneXpert Dx 4.0, Cepheid). Bacterial 
load was semi-quantitatively reported as very low, low, medium or high positive, with 
the presence or absence of resistance against rifampicin indicated separately27. The 
limit of detection is 100 CFU/ml28. Invalid results were repeated or excluded.
Statistical analysis
The study reporting conforms to the STARD guidelines for diagnostic accuracy 
reporting (www.stard-statement.org). Data analysis was performed using Statistical 
Package for the Social Sciences version 20 (SPSS Inc, Chicago, IL, USA). Frequencies 
were obtained for categorical clinical variables. Median and interquartile range was 
determined for continuous variables. Sensitivity, specificity, positive predictive value, 
negative predictive value and diagnostic odds ratio (DOR) was calculated compar-
ing non-TBM to TBM. Categorical variables were compared using Fisher’s exact test 
and continuous variables were compared using the Mann-Whitney U test. A p-value 
<0.05 was considered statistically significant.
RESULTS
In total 101 children with suspected meningitis met the inclusion criteria; 55 TBM and 
46 “non-TBM”. Of the TBM group, 13 patients had ‘definite’ TBM, 32 patients had 
‘probable’ TBM and 10 patients had ‘possible’ TBM22. Among “non-TBM” patients, 
30 did not have meningitis. Non-TBM patients with meningitis included three cases 
of bacterial meningitis (1 with pneumococcal meningitis) and 13 cases of viral men-
ingitis. Confirmed viral meningitis cases included human enterovirus (5), Epstein-Barr 
virus (2) and Herpes simplex type-2 virus (1). CSF volume was recorded in 45 patients 
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(36 TBM and 9 non-TBM) with a mean of 2.19 ml (95% confidence interval 1.83-
2.55ml). The odds ratio for CSF volume vs positive Genotype MTBDRplus® assay 
was 2.28 (95% confidence interval 1.20-4.36 p=0.012). There was no correlation 
between CSF volume and positive fluorescent microscopy, culture or Xpert MTB/RIF® 
assay. Clinical characteristics are summarized in Table 2.
Human immunodeficiency virus (HIV) co-infection was identified in 8 patients; 6 
had neuroimaging suggestive of TBM. Of these, 5 had a positive TB contact within 
the last 12 months, 3 had a chest radiograph suggestive of pulmonary TB, 3 had 
bacteriologically-confirmed TBM and 1 had bacteriological confirmation of extra-
neural TB. Of the 2 non-TBM patients with HIV, 1 had confirmed pneumococcal 
meningitis and 1 patient did not have meningitis.
Table 2. Clinical and investigation findings of children enrolled with suspected meningitis
Clinical characteristics TBM Non-TBM p-value
Age in months- median (IQR) 36.0 (21.0-54.0) 34.0 (17.0-56.3) 0.800
Male gender (n/N/%) 26/55 (47) 30/46 (65) 0.107
Positive HIV (n/N/%) 6/55 (11) 2/45 (4) 0.289
Positive TB contact* (n/N/%) 26/55 (47) 12/46 (26) 0.039
Poor weight gain** (n/N/%) 21/55 (38) 4/46 (9) 0.001
Hemiplegia (n/N/%) 17/55 (31) 2/46 (4) 0.001
Positive gastric washing culture (n/N/%) 25/39 (64) 11/33 (33) 0.017
Clear CSF macroscopic appearance (n/N/%) 51/55 (93) 45/45 (100) 0.125
CSF lymphocytes (cells/uL) - median (IQR) 54.0 (17.8-170.0) 1.0 (0.0-49.8) 0.515
CSF protein (g/L) - median (IQR) 1.49 (0.78-2.00) 0.25 (0.18-0.38) 0.000
CSF glucose (mmol/L) - median (IQR) 2.40 (1.10-3.40) 3.70 (3.00-4.20) 0.000
Positive AFB on CSF microscopy (n/N,%) 2/55 (4) 0/46 (0) 0.125
Positive CSF culture (n/N,%) 12/55 (22) 0/46 (0) 0.000
Positive Genotype MTBDRplus version 1 (n/N,%) 9/38 (24) 0/27 (0) 0.008
Positive Genotype MTBDRplus version 2 (n/N,%) 9/16 (56) 1/20 (5) 0.002
Positive Xpert (n/N,%) 14/55 (26) 0/46 (0) 0.000
CXR- suggestive PTB (n/N,%) 26/55 (47) 7/46 (15) 0.001
CT brain- suggestive TBM (n/N,%) 43/55 (78) 3/28 (11) 0.000
IQR= interquartile range, HIV= Human Immunodeficiency Virus, TB= tuberculosis, GCS= Glasgow 
coma score, CSF= cerebrospinal fluid, AFB= acid-fast bacilli, CXR= Chest X-ray, PTB= pulmonary tu-
berculosis, CT= computed tomography, TBM- tuberculous meningitis
*TB contact is defined as a history of recent close contact with a person with infectious tuberculosis 
within the past 1 year
**Poor weight gain is defined as weight loss, or slower weight gain compared to age and gender-
matched controls on the WHO weight for age charts
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The diagnostic accuracy of the CSF tests against a TBM case definition and culture-
confirmed TBM is reflected in Table 3 and 4, respectively. When using a TBM case 
definition as the reference standard, both NAATs performed better than liquid 
culture and demonstrated some incremental value, although sensitivity remained 
sub-optimal. When using ‘definite’ TBM as the reference standard, the MTBDRplus® 
assay performed with 92% sensitivity and 98% specificity and Xpert MTB/RIF® as-
say performed with 39% sensitivity and 100% specificity in a small (n=13) group of 
children.
One “non-TBM” case tested positive with the Genotype MTBDRplus® assay version 
2, but was negative on microscopy, culture and Xpert. The patient had a CSF picture 
suggestive of viral meningitis, and CSF PCR confirmation of Epstein-Barr virus, as 
well as normal brain computed tomography (CT). The patient improved clinically 
without any TB treatment and likely represented a false-positive test. Laboratory 
cross-contamination could not be ruled out with certainty, but no other cases of 
potential cross-contamination were detected.










PPV NPV Diagnostic odds 
ratio (95% CI)
Total no of subjects 55 46
Fluorescence 
microscopy
2 0 0.04 (0.00-0.13) 1.00 (0.92-
1.00)
1.00 0.46 4.35 (0.20-
92.84)
MGIT 12 0 0.22 (0.12-0.35) 1.00 (0.92-
1.00)




12 0 0.22 (0.12-0.35) 1.00 (0.92-
1.00)
1.00 0.52 26.72 (1.54-
465.15)
MTBDRplus 18 1 0.33 (0.21-0.47) 0.98 (0.89-
1.00)
0.95 0.55 21.89 (2.79-
171.78)
Xpert 14 0 0.26 (0.15-0.39) 1.00 (0.92-
1.00)




25 1 0.46 (0.32-0.59) 0.98 (0.89-
1.00)
0.96 0.60 37.50 (4.82-
291.73)
MGIT/Xpert 21 0 0.38 (0.25-0.52) 1.00 (0.92-
1.00)




27 1 0.49 (0.35-0.63) 0.98 (0.89-
1.00)




31 1 0.56 (0.42-0.70) 0.98 (0.89-
1.00)
0.97 0.65 58.13 (7.47-
452.43)
TBM= tuberculous meningitis, MGIT= Mycobateria Growth Indicator Tube, PPV= positive predictive 
value, NPV= negative predictive value, CI= confidence interval
*** Uniform research case definition of Marais et al22.
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An inhA mutation was detected in one patient, using the Genotype MTBDRplus® 
assay version 2, which is usually associated with low-level isoniazid resistance. This 
specific patient’s treatment regimen included high dose isoniazid (20mg/kg), along 
with high dose rifampicin (20mg/kg), ethionamide (20mg/kg) and pyrazinamide 
(40mg/kg). As this patient defaulted treatment for 1 month, the total treatment period 
was 12 months. The patient was clinically followed up at 1-monthly intervals, with 
consistent weight-gain throughout. After 12 months of therapy the patient was con-
sidered cured, and discharged.
DISCUSSION
The main finding of this study is the incremental increase in diagnostic accuracy that 
can be achieved with commercial NAATs performed on CSF. Although both NAATs 
were superior to liquid culture, sensitivity remained low compared to a rigorous pre-
defined clinical case definition. Combining any positive NAAT provided a sensitivity 
of 49%, which is insufficient to serve as a rule-out test and provides limited clinical 
guidance. However, a positive test provides useful microbiological confirmation with 
rapid turn-around times. When compared to culture-confirmed TBM, both NAATs 
Table 4. Sensitivity, specificity, predictive values and diagnostic odd ratios against A) a bacteriologically-









PPV NPV Diagnostic odds 
ratio (95% CI)
A
Total no of subjects 13 46




0.92 0.98 540.00 (31.42-
9279.80)












0.92 0.98 540.00 (31.42-
9279.80)
B
Total no of subjects 45 46




0.93 0.59 20.32 (2.54-
162.62)












0.96 0.67 47.05 (5.96-
371.35)
TBM= tuberculous meningitis, MGIT= Mycobateria Growth Indicator Tube, PPV= positive predictive 
value, NPV= negative predictive value, CI= confidence interval
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performed with better sensitivities (especially MTBDRplus® assay with sensitivity 
92%), however patient numbers in this group were small.
A recent meta-analysis of the accuracy of commercial NAATs for the diagnosis of 
TBM revealed a pooled sensitivity and specificity of 64% and 98%. These studies 
used culture-confirmed TBM as the reference standard29, a group where higher sen-
sitivities would have been expected. A uniform research case definition proposed 
for adults and children state that a TBM diagnosis can be regarded as “definite” 
when M.tuberculosis is cultured from CSF and/or a commercial NAAT is positive for 
M.tuberculosis22. Our findings support this position, since only a single NAAT test 
was considered to be a false positive test; likely the result of laboratory contamina-
tion. This emphasizes the importance of ensuring optimal laboratory infection and 
contamination control standards.
The relatively poor correlation between NAATs and liquid culture may reflect the fact 
that NAATs detect DNA from viable and non-viable bacteria. Although every attempt 
was made to collect the CSF sample prior to the initiation of empiric therapy, some 
children were referred from outside centers and received initial treatment prior to CSF 
collection. This could explain the relatively low culture yields achieved, but it cannot 
explain why only a minority of cases with positive NAAT were both MTBDRplus® 
and Xpert MTB/RIF® positive. NAAT discrepancy may be due to random sampling 
variation in a pauci-bacillary CSF specimen. It has been suggested that at least 6 ml 
of CSF should be collected and concentrated to improve the diagnostic yield30. From 
our paediatric population we could only obtain a mean of 2.19 ml of CSF, and split-
ting these low volumes for four different tests could have resulted in false negative 
tests in instances where the bacterial load was below detection threshold. However, 
low CSF volumes are an unfortunate clinical reality in young children and in clinical 
practice all these tests will not have to be performed in parallel. Even with the low 
CSF volume obtained, the yield for the MTBDRplus® assay increased significantly 
with increased CSF volume.
The sensitivity of fluorescence microscopy (4%) was lower than that reported in the 
literature (10-20%)6 and that of MGIT liquid culture was comparable (26% vs 22%)31. 
There are no studies describing the use of the MTBDRplus® assay in CSF samples 
of either adults or children. The sensitivity of 33% (98% specificity) against a TBM 
case definition and sensitivity of 98% (98% specificity) against microbiologically-
confirmed TBM, is encouraging and compares favorably with the performance on 
smear microscopy-negative sputa (19%)32. Xpert was 26% sensitive (100% speci-
ficity) against a TBM case definition and 39% sensitive (100% specificity) against 
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microbiologically-confirmed TBM, but the use of this assay on CSF is not yet that 
well described. A pooled sensitivity of 70%; specificity of 97% for Xpert MTB/RIF® 
compared to liquid culture as a reference standard, was obtained in five studies in a 
recent meta-analysis13,14,30,33-35. Concentration steps could have helped to reach the 
Xpert MTB/RIF® assay’s detection threshold of approximately 100 bacteria/ml13.
Our clinical practice is to start anti-tuberculosis treatment on clinical suspicion prior 
to bacteriological confirmation. In settings with low TB incidence where experience 
with TBM is limited, treatment can be delayed with potentially dire consequences. 
In such settings NAATs offer improved CSF sensitivity, with good specificity, and a 
potential for same day diagnosis. The cost of the NAAT assays needs to be put into 
perspective to potential cost-savings by shorter hospital stay and better outcomes due 
to earlier initiation of treatment.
CONCLUSION
Commercial NAATs performed on CSF revealed incremental improvement in sensitiv-
ity, with specificity maintained. The best sensitivity was obtained with the combina-
tion of liquid culture and both NAATs, but there is not a massive gain when compared 
to both NAATs only. However, NAATs alone or in combination, cannot serve as a rule 
out test but can provide rapid microbiological confirmation. Cost-analysis needs to 
be performed comparing the expense of NAATs to the potential cost saving of early 
initiation of treatment and shorter hospital stay.
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It is important to recognize TBM in the early stage of disease, as it is fully treatable. 
However, early stage TBM is characterized by non-specific symptoms of general ill 
health rather than features of meningitis. The only factor differentiating these symptoms 
of TBM from other common illnesses is their persistence, often >5 days duration [1]. 
Failure to recognize the threat of TBM by both caregivers and healthcare professionals 
can lead to neurological deterioration and death. Due to the suboptimal performance 
of definite diagnostic tests, the early identification of paediatric TBM relies on a 
thorough assessment of all the evidence derived from a careful history, clinical 
examination and relevant investigations. All the criteria for definite diagnosis of TBM 
depend on demonstrating the organism in the CSF. This fact underlines the difficulty in 
diagnosing stage 1 TBM which is defined by absence of neurological signs, including 
meningism. As a rule, lumbar puncture will only be done once meningitis is clinically 
suspected. This means that current criteria for definite diagnosis of TBM mainly apply 
to stage 2 and 3 TBM. 
 
Previous studies (one comprising both adults and children and the other comprising 
only adult patients) have identified young age, sub-acute onset, headache, normal 
peripheral white blood cell count, clear cerebrospinal fluid (CSF) appearance, 
moderately raised total CSF white cell count (<900 cells/µL), low CSF neutrophil 
proportion, and elevated CSF protein as differentiating features between TBM and 
bacterial meningitis [2-4].  
 
UNIFORM RESEARCH CASE DEFINITION FOR TBM 
 
RETROSPECTIVE CLINICAL EVALUATION OF THE RESEARCH CASE DEFINITION 
 
The uniform case definition for TBM was devised as an instrument to improve accuracy 
of clinical diagnosis in future interventional studies on TBM. It was compounded by a 
group of experts and based on existing knowledge of TBM as portrayed in the literature 
[5]. It has never before been tested clinically. Our existing database of hundreds of 
childhood TBM cases enabled us to test this proposed diagnostic tool retrospectively. I 
showed that the proposed clinical case definition had excellent diagnostic performance 
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in differentiating culture-confirmed TBM from culture-confirmed bacterial meningitis if 
the suggested ‘probable’ TBM score was used [6]. When the ‘possible’ TBM score was 
used not a single TBM case would have been missed, however clinical utility was 
minimal given the low specificity achieved. Univariable analysis showed that the 
majority of criteria were associated with a diagnosis of TBM, warranting inclusion in 
the uniform research algorithm [5]. 
 
Because it was performed retrospectively, the study was limited by absence of data 
required by the uniform case definition. This included pre-contrast basal hyperdensity 
as shown by computed tomography (CT), magnetic resonance imaging (MRI) or 
ultrasound imaging of TB outside the CNS and PCR evidence of extra neural TB. Pre-
contrast basal hyperdensity on CT was described only in 2004 and was therefore not 
available retrospectively [7]. Another limitation of the clinical application of the 
uniform case definition, shown by the above study, was its inability to identify TBM in 
the early stage [8,9]. This can be explained by the absence of abnormal neurological 
findings as well as CSF and radiological features typical of TBM in stage 1 disease 
resulting in a low score when applying the uniform case definition. Consequently many 
of these cases will be diagnosed as ‘possible’ rather than ‘probable’ TBM. This is a 
significant limitation since both mortality as well as morbidity significantly increases 
when TBM progresses from stage 1 to stage 2. The diagnosis of early stage I TBM, 
therefore remains problematic and emphasizes the importance of a very high clinical 
index of suspicion in young children with recent TB exposure and persistent non-
specific signs. 
 
PROSPECTIVE CLINICAL EVALUATION OF THE RESEARCH CASE DEFINITION 
 
My prospective evaluation of the uniform TBM research case definition was a first 
attempt to determine the diagnostic value of this research tool in clinical practice. The 
findings of this study confirmed those of the retrospective study in that excellent 
diagnostic accuracy was obtained for a diagnosis of TBM when compared to bacterial 
and viral meningitis controls. In this study a ‘probable’ TBM score demonstrated 
sensitivity of 84% and excellent specificity of 95% in clinically-diagnosed TBM, while 
in microbiologically-confirmed TBM cases a sensitivity of 74% and specificity of 95% 
was obtained. The high specificity of a ‘probable’ TBM score justifies its use as an 
alternative reference standard to microbiological confirmation in future studies. 
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However, univariable analysis showed that only half of criteria in the uniform case 
definition was associated with a diagnosis of microbiologically-confirmed TBM, 
warranting a re-look at inclusion criteria which were based on consensus opinion. The 
overall performance of a probable TBM score was better than a three-variable 
predictive model determined by multivariable analysis, but the use of three simple 
criteria (cranial nerve palsy, TST ≥10mm and elevated CSF protein) may offer better 
clinical utility in areas with limited access to neuro-imaging, taking into consideration 
that the analysis was optimized for my study cohort. 
 
This study was limited by the small number of cases of bacterial meningitis. This can 
be explained by the fact that both Haemophilus influenza type-B and pneumococcal 
vaccination are part of the expanded national immunization program which is 
provided free of charge to all children. A further limitation is the low rate of 
neuroimaging in non-TBM cases, which is due to the fact that neuroimaging is not 
routinely performed in non-TBM suspects in the local setting. The relatively low 
proportion of microbiologically-confirmed TBM cases reflects the paucibacillary nature 
of the disease, sub-optimal sensitivity of available diagnostic tests, and low CSF 
volumes obtained [10-14]. The fact that the study was performed at a single site may 
theoretically limit generalization of the study findings to other settings. However, this is 
unlikely because our population shares a similar disease burden, health challenges and 
resource constraints with other TB endemic areas. 
 
CEREBROSPINAL FLUID CHEMISTRY FINDINGS IN CHILDHOOD TBM 
 
The clinical diagnosis of TBM relies on the triad of history, clinical examination and 
special investigtaions. The diagnosis of meningitis, including TBM, relies on a pattern 
of CSF findings, which also forms the basis for inclusion of CSF criteria in the uniform 
research case definition. My study on the diagnostic value of CSF chemistry in the 
diagnosis of childhood TBM found that the optimal lower limit of CSF glucose 
concentration as a diagnostic aid for TBM was 2.2 mmol/L (40 mg/dl). This is 
problematic, as it is similar to that proposed for bacterial meningitis [15]. This 
highlights the value of including other aspects of CSF chemistry such as macroscopic 
appearance, cell count and protein level in the final analysis. Absolute CSF glucose 
differentiated non-TBM from TBM cases with sensitivity of 68% and specificity of 96%, 
excluding its use as a ‘rule-out’ test. This sudy emphasized that fewer patients with 
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TBM would have been missed using a CSF:glucose ratio <0.5 (10%) compared to an 
absolute CSF glucose concentration of <2.2 mmol/L (32%). Unfortunately, this is rarely 
done in clinical practice as confirmed by the lack of retrospective data in this regard. 
 
The optimal CSF protein cut-off differentiating TBM from bacterial meningitis and viral 
meningitis is >1g/L (100mg/dL) [2,16]. I found that an optimal CSF protein cut-off of 
>0.6 g/L performed with sensitivity and specificity of 95% and 91% respectively in 
differentiating TBM from viral meningitis. The suggested higher CSF protein cut-off 
(>1g/L) performed with less impressive diagnostic accuracy (sensitivity 76% and 
specificity 95%) but it must be taken in to account that only viral meningitis and non-
meningitis were considered as alternative diagnoses in my study. The uniform TBM 
research case definition included CSF protein cut-off of >1g/L, clear CSF macroscopic 
appearance, moderately elevated leucocyte count and the presence of lymphocyte 
predominance to assist with the distinction between TBM and bacterial meningitis [6]. 
 
Many other CSF biomarkers have been identified in TBM, but diagnostic utility is rarely 
described [17]. Studies evaluating CSF interferon gamma release assays (IGRA) 
demonstrated good diagnostic accuracy [18-21], but difficulty in obtaining CSF 
volumes that will provide sufficient cells for analysis is a limitation in children 
(typically 5-10ml CSF is required) [22, 23]. A recent study from a co-worker using a 
CSF proteinomics approach reveals the potential value of CSF interleukin-13, vascular 
endothelial growth factor and cathelicidin LL-37 as biomarkers when differentiating 
TBM from other forms of meningitis [24]. There is potential for the use of CSF lactate in 
children with TBM. CSF lactate has been shown to be a good biomarker to distinguish 
bacterial from aseptic meningitis [25], and remains unaffected by serum lactate 
concentration, reflecting the severity of cerebral hypoxia [26]. 
 
My study on the value of CSF chemistry in the diagnosis of TBM was limited by the 
small number of patients with serum glucose determination. Low numbers of TBM and 
HIV co-infection (4%) precluded separate analysis of the value of CSF glucose and 
protein levels in this subgroup. This low incidence of HIV co-infection in TBM concurs 
with other reported studies on TBM [27]. 
 
CHEST X-RAY FINDINGS IN CHILDHOOD TBM 
 
Stellenbosch University  https://scholar.sun.ac.za
General	discussion	and	future	perspectives					141	
	
The finding of a chest X-ray suggestive of pulmonary TB in a child that presents with 
meningitis implies an increased likelihood of TBM [6]. Previous studies have confirmed 
evidence of active pulmonary TB on chest X-ray in 70-84% of children with TBM [28]. 
My findings differ from these in that I found chest X-ray findings highly suggestive of 
pulmonary TB in only 46% of children with TBM while 11% had evidence suggestive 
of miliary TB. The need to treat calculation showed that only 1 in 4.39 children ≤3 
years of age with TBM are likely to have ‘certain TB’ on chest X-ray [29]. Possible 
explantions of the lower proportion of‘certain’ TB could be the minimization of over-
reporting Chest X-ray findings by using two reviewers. Another possible reason could 
be our low proportion of children (less than one third) with a positive tuberculin skin 
test, reflecting immature cell-mediated immunity in childhood, manifesting as 
decreased radiographic evidence of pulmonary TB and under-reporting of the chest X-
ray. Intra-thoracic lymph node disease was classified as either uncomplicated or 
complicated, according to a radiological classification of childhood intra-thoracic 
tuberculosis, using a structured approach to interpretation and recording chest X-ray 
findings [30]. Airway compression was defined as either compression of the trachea, 
left main bronchus or bronchus intermedius. Parenchymal changes were defined as 
either consolidation (including expansile pneumonia) or miliary. 
 
The poor diagnostic sensitivity of chest radiography in children with TBM implies that 
it cannot be used as a rule-out test, even in combination with TST and may impact 
scoring in future diagnostic rules and algorithms. With a normal chest X-ray, the 
diagnosis of TBM is even more reliant on a combination of clinical features, CSF 
findings, neuroimaging and microbiological confirmation. As expected complicated 
lymph node disease and airway compression were significantly more common in 
children ≤3 years, confirming that this is the predominant radiological finding in young 
children. TBM stage did not affect the radiographic picture. Lung CT is more sensitive 
than chest X-ray in detecting TB lymphadenopathy, but less sensitive in detecting 
parenchymal involvement in children under 3 years old. CT is also more expensive and 
delivers a much higher dose of radiation, mitigating its role in routine lung imaging in 
childhood [31]. Due to excellent contrast resolution, MRI has equivalent diagnostic 
performance to high resolution CT for the detection of pulmonary TB [32], but again 
cost rules out its routine use in children. 
 
NAA TESTING IN TBM 




UPDATED META-ANALYSIS OF COMMERCIAL NAA TESTS 
 
Definite diagnosis of TBM by CSF examination such as direct microscopy for acid-fast 
bacilli and M.tuberculosis culture are notoriously insensitive in the diagnosis of TBM 
[33]. The necessity of early, accurate and rapid TBM diagnosis is undisputable [34]. A 
2003 systematic review on the diagnostic accuracy of NAA tests found that significant 
heterogeneity affected the interpretation of in-house NAA tests. The pooled sensitivity 
and specificity of commercial NAA tests was 56% and 98%, respectively, suggesting a 
role for commercial NAA tests in confirmation, but not exclusion, of TBM diagnosis 
[33]. Since 2003, newer commercial NAA tests have emerged, with attention focused 
on Xpert MTB/RIF®. My recent meta-analysis of commercial NAA tests found an 
improved summary sensitivity of 64% and confirmed the previous excellent specificity 
of 98% [33,35]. Summary sensitivity of commercial NAA tests remains suboptimal and 
is unlikely to greatly enhance early accurate diagnosis. Conversely the excellent 
specificity suggests that commercial NAA tests may be regarded as definitive in the 
correct clinical setting [6].  
 
In 2013, the WHO recommended Xpert MTB/RIF® as the preferential initial 
investigation in all adults and pediatric TBM suspects [36]. My meta-analysis of 5 
studies reporting Xpert MTB/RIF® on CSF, 1 retrospective and 4 prospective, found 
summary sensitivity of 70% and specificity of 97% [34,35,37-40]. Despite sub-optimal 
sensitivity, the rapid turnaround time of NAA tests compared to culture enhances its 
role in the early accurate diagnosis of TBM. Future studies need to confirm excellent 
sensitivity, specificity and negative predictive value in order to justify the use of Xpert 
MTB/ RIF® as a “stand alone” test for diagnosis of TBM. A further benefit of NAA 
testing is the early detection of drug resistance. 
 
My recent updated meta-analysis supports the use of a commercial NAA test as 
evidence of a ‘definite’ TBM diagnosis in the right clinical context, as suggested by the 
uniform research case definition for TBM [6]. This meta-analysis is limited by the 
inconsistent use of reference standards in the different studies, with the sub-optimal 
sensitivity of microscopy for acid-fast bacilli and CSF culture for M.tuberculosis 
prompting the use of alternate clinical reference standards. There were multiple study 
exclusions, but careful assessment of study accuracy and reliability using the 
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QUADAS-2 tool strengthened the findings of the meta-analysis [41]. 
 
COMPARING DIFFERENT NAA TESTS PROSPECTIVELY 
 
In a follow-up study I found that more than one NAA test incrementally increased 
diagnostic accuracy on CSF in childhood TBM [42]. Although both the MTBDRplus® 
assay and Xpert MTB/RIF® were superior to liquid culture, sensitivity remained low 
compared to a rigorous predefined clinical case definition. The MTBDRplus® assay 
performed with an encouraging sensitivity of 33% (98% specificity) against a TBM case 
definition and sensitivity of 98% (98% specificity) against microbiologically-confirmed 
TBM. There are no other studies describing the use of the MTBDRplus® assay in CSF 
samples of either adults or children with TBM. Xpert MTB/RIF® was 26% sensitive 
(100% specificity) against a TBM case definition and 39% sensitive (100% specificity) 
against microbiologically-confirmed TBM. Combining these two NAA tests provided a 
sensitivity of 49% (98% specificity) against a TBM case definition, which is insufficient 
to serve as a rule-out test and provides only limited clinical guidance [42]. However, a 
positive test provides rapid microbiological confirmation providing further support for 
the use of a positive commercial NAA test as evidence of ‘definite’ TBM in the uniform 
research case definition for TBM [6]. Apart from improving the potential for same day 
diagnosis which prevents unnecessary treatment delay and potential life-threatening 
consequences, NAA tests has the added benefit of early recognition of drug resistance. 
 
This study is limited by the relatively poor correlation between NAA tests and liquid 
culture. Although every attempt was made to collect the CSF sample prior to the 
initiation of empiric therapy, some children were referred from outside centers and 
received initial treatment prior to CSF collection. This could explain the relatively low 
culture yields achieved, but it cannot explain why only a minority of cases tested 
positive with both MTBDRplus® and Xpert MTB/RIF®. Discrepancy found in NAA test 
results may be partly due to random sampling variation in a condition known for its 
low bacilli count in CSF. Dividing the small mean CSF volume of 2.19 ml collected in 
this study into smaller volumes for four different tests could have resulted in false 
negative tests in instances where the bacterial load was below detection threshold. 
However, low CSF volumes are an unfortunate clinical reality in young children. 
Concentration steps could have helped to reach the Xpert MTB/RIF® assay’s detection 
threshold of approximately 100 bacteria/ml [38]. 




OTHER INVESTIGATIONS IN CHILDHOOD TBM 
 
In my update on the diagnosis and management of TBM in children I discuss other 
common investigations in the early diagnosis of TBM [23]. The tuberculin skin test 
(TST) performed with a sensitivity of 61% [10], however this is decreased in HIV co-
infection [43]. Further limitations of TST is high false-positivity in young infants that 
have received BCG vaccination, and failure to delineate active TB disease [44]. 
Neuroimaging criteria are an important component of the uniform research case 
definition for TBM and helps clear up diagnostic uncertainty after clinical assessment 
and CSF analysis. Computed tomography (CT) is most often used in resource poor 
countries and a combination of hyperdense exudates on pre-contrast CT, basal 
meningeal enhancement, infarctions and hydrocephalus is highly suggestive of TBM 
[7]. Magnetic resonance imaging (MRI) is superior to CT for TBM diagnosis, by 
detecting basal enhancement and granulomas in more patients, and prognosis, by 
detecting many more infarcts in strategic locations such as the brainstem [45]. MRI is 
an invaluable tool in children with TBM and acquired blindness due to optochiasmic 
arachnoiditis, and can guide urgent intervention leading to improvement of vision [46].  
 
STAGE 1 TBM 
A consistent theme in the different chapters of this thesis is the small numbers of stage 
1 TBM in most studies due to the difficulty of early clinical diagnosis of TBM.  Ideally, 
in a thesis of this nature, early diagnosis of TBM should have been aimed at early 
identification of stage 1 TBM. However, this was unfortunately not possible mainly 
because my study was hospital-based and most cases of early, stage 1 TBM present at 
primary-care level. This is a major limitation of this study but opens the way for future 
studies in this regard. Early diagnosis of stage 1 childhood TBM, which is characterized 
by non-specific clinical features including the absence of meningism, is inseparably 
linked to improved surveillance of childhood TB. Since most of the clinical signs of 
stage 1 TBM relates to underlying pulmonary TB, a sound surveillance system could 
improve estimates and monitoring of both the TB and TBM burdens in young children 
[47]. In order to improve diagnosis of stage 1 TBM, awareness among health care 
workers must be improved especially at the primary-level healthcare setting, the point 
of first contact for many patients. Integrated Management of Childhood Illness (IMCI) a 
strategy developed by the World Health Organization (WHO) and the United Nations 
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Childrens Fund (UNICEF) is aimed at early detection of serious illnesses in young 
children under 5 in resource-limited settings. This allows early referral and thus a 
reduction in morbidity and mortality. IMCI is potentially a valuable tool in detecting 
early TB and TBM as it is practiced at primary healthcare level. A further strategy to 
improve the detection of childhood TB and TBM is household contact tracing which 
has the potential, when combined with preventive therapy, to reduce the burden of TB 
[48]. The failure to provide TB prophylaxis with isoniazid therapy to paediatric 
contacts is unacceptable as this can prevent the progression from infection with 
M.tuberculosis to active TB in a large proportion of children [49].
 
Because the early clinical presentation of TBM is non-specific, poor weight gain, or 
weight loss, reflected by crossing of weight centiles, should alert healthcare workers at 
first contact level with the patient to the possibility  of TBM [50]. The same applies to 
the presence of a persistent non-remitting cough for longer than 2 weeks [51]. It should 
be highlighted that in my different studies not a single patient with TBM was white. If 
ancestry is used as a proxy for socioeconomic status and level of nutrition, the affinity 
of TBM to affect black and mixed ancestry children is glaring and an indication that 
socio-economic inequalities need to be addressed urgently and that available financial 




TBM is the most feared consequence of M.tuberculosis infection in young children. 
The epidemiology of TBM is poorly understood because of sub-optimal diagnosis and 
under-reporting of childhood TB [52]. Standardization of TBM diagnosis and treatment 
is problematic. In order to progress, researchers have to speak the same language as to 
what constitutes a diagnosis of TBM. The uniform research case definition of TBM was 
an attempt to reach expert consensus on diagnosis. Both my studies testing the utility of 
the uniform research case definition reveal excellent diagnostic accuracy and 
consideration of the uniform case definition as an alternative research reference 
standard in children. Having a conceptual reference standard is acceptable, but for 
those working in the field, research has to lead to meaningful improvement of clinical 
well-being. Both my studies were performed in a clinical setting, and had superior 
diagnostic performance to existing diagnostics. I envisage robust multi-centre 
prospective studies in both adults and children in order for the uniform case definition 
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to transcend research to clinical practice in TB endemic settings. 
 
Prospective research should include validation of the components of the uniform case 
definition which were not addressed in this dissertation. I have shown that the CSF 
glucose and protein cut-off deserve inclusion in the uniform case definition. However, 
the diagnostic value of chest X-ray findings needs further investigation due to the lower 
proportion of children with TBM and radiological evidence of pulmonary TB in my 
study than previously reported. There are therefore research opportunities to evaluate 
the clinical, neuroimaging and supporting criteria in the uniform case definition. 
Provided that large numbers can be obtained, statistic modeling can be used to validate 
the uniform research case definition as a whole. Once supporting prospective research 
in both children and adults reveals validity and clinical applicability of the uniform 
research case definition, designing a smartphone application for identification of  
‘probable’ or ‘possible’ TBM is a possibility. This is achievable as the rollout of cheaper 
smartphones and mobile networks is the fastest growing in resource-constrained 
settings.  
 
The 2013 WHO recommendation that Xpert MTB/RIF® can be used as the preferential 
initial investigation in all adults and pediatric TBM suspects [36][53], underlines the 
need for more research in this area. I showed that Xpert MTB/RIF® performed with 
lower sensitivity, 26%, when compared to MTBDRplus® assay, 33%, and Xpert 
MTB/RIF® and MTBDRplus® combined, 49% [42]. My future research will include 
analyzing the performance of Xpert MTB/RIF® on bigger CSF samples, if feasible on a 
minimum volume of 5ml, with an additional concentration step in order to try and 
improve the diagnostic accuracy. 
 
In conclusion, the proposed uniform research case definition provided excellent 
diagnostic accuracy compared to microbiologically-confirmed TBM, when tested both 
retrospectively and prospectively and is recommended as the ‘standard’ definition of 
TBM for research purposes. Clinical vigilance is advised in early (stage 1) TBM as the 
uniform research case definition performs with decreased sensitivity in this group. 
Similarly clinical vigilance is strongly advocated in the setting of a normal chest X-ray 
as less than half of the childhood TBM cases had chest X-ray findings highly suggestive 
of pulmonary TB. When differentiating childhood TBM from other forms of meningitis, 
the optimal lower limit of CSF glucose concentration is 2.2 mmol/L and upper limit of 
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CSF protein is 1g/L (100mg/dL). It is recommended that serum glucose concentration is 
determined at the same time as CSF glucose concentration, as the CSF:serum glucose 
ratio improves diagnostic sensitivity. Meta-analysis of newer commercial NAA tests, 
including Xpert MTB/RIF®, found a suboptimal summary sensitivity of 64% which is 
unlikely to enhance early accurate diagnosis. However, the excellent summary 
specificity of 98% suggests that commercial NAA tests may be regarded as definitive in 
the correct clinical setting. The low sensitivity of commercial NAA tests was confirmed 
when testing the MTBDRplus® and Xpert MTB/RIF® assays on fresh CSF smaples, 
individually and in combination. However, routine commercial NAA testing is strongly 
recommended, as rapid microbiological confirmation ensures early TBM diagnosis, 
preventing unnecessary treatment delay and potential life-threatening consequences, 
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Due to the sub-optimal performance of definite diagnostic tests, the early 
identification of paediatric TBM suspects relies on a thorough assessment of all the 
evidence derived from a careful history, clinical examination and relevant 
investigations. Rapid diagnosis is needed for early treatment initiation but 
microbiological confirmation is difficult at stage 1 disease because a lumbar puncture 
is generally only done once signs of meningitis have developed (stage 2 and 3 TBM). 
With this thesis, I aim to investigate mechanisms of improving the early and/or more 
accurate diagnosis of childhood TBM.  
 
PART I 
In chapter 2 I provide an update on the diagnosis and management of TBM in 
children, based on local experience, which can be transposed to similar settings. 
Highlights include firstly that short (6 months) intensified therapy in children with drug 
susceptible TBM is safe and effective, with a good outcome and low mortality. 
Secondly, home-based TBM treatment after initial in-hospital stabilization is feasible 
in carefully selected patients under close supervision. Thirdly, treatment of 
tuberculous hydrocephalus depends on the level of cerebrospinal fluid (CSF) 
obstruction. Communicating hydrocephalus can be successfully treated with medical 
therapy with normalization of intracranial pressure occurring within days in the 
majority children and non-communicating hydrocephalus requires neurosurgical 
intervention. Fourthly, thalidomide is the local drug of choice in children who 
develop life-threatening TB mass lesions (IRIS) despite corticosteroids. 
 
PART II 
In clinical practice, TBM diagnosis is most often based on a combination of clinical, 
laboratory and radiological findings. A uniform research case definition utilizing these 
criteria was proposed by an international panel of experts as a means of improving 
diagnostic standardization in order to answer critical research questions, categorizing 
patients as definite, probable, or possible TBM. Part 2 of my thesis focuses on the 
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3.1 I retrospectively evaluate the diagnostic performance of probable and possible 
TBM criteria in children with culture-confirmed TBM and culture-confirmed bacterial 
meningitis. The proposed uniform research case definition provided excellent 
diagnostic accuracy compared to microbiologically-confirmed TBM, when a 
‘probable’ TBM score was used. When a ‘possible’ TBM score was used, not a single 
TBM case would have been missed, but clinical utility was minimal given the low 
specificity achieved. In order to strengthen my findings I prospectively assessed the 
diagnostic accuracy of the uniform TBM research case definition (see chapter 3.2). 
Excellent diagnostic accuracy was obtained for a diagnosis of TBM when compared to 
bacterial and viral meningitis controls. The high specificity of a probable TBM score 
justifies its use as an alternative reference standard to microbiological confirmation in 
future studies. In both studies poor sensitivity was obtained when a probable TBM 
score was used to diagnose early (stage 1) TBM, emphasizing a very high clinical 
index of suspicion of TBM in young children with recent TB exposure and persistent 
non-specific signs. 
 
CSF findings are essential to early diagnosis of TBM. Cut-off values for CSF glucose in 
TBM lack evidence. A CSF protein cut-off of >1g/L (100mg/dL) differentiated between 
cases of TBM and other forms of meningitis. My study on the diagnostic value of 
cerebrospinal fluid chemistry results in childhood TBM found that the optimal lower 
limit of CSF glucose concentration as a diagnostic aid for TBM was 2.2 mmol/L (see 
chapter 3.3). Absolute CSF glucose differentiated non-TBM from TBM cases with 
sensitivity of 68% and specificity of 96%, excluding its use as a ‘rule-out’ test. 
Simultaneous determination of serum and CSF glucose was seldom performed but my 
findings suggest that the CSF:serum glucose ratio may further improve diagnostic 
sensitivity.. CSF protein cut-off of >1g/L as well as CSF macroscopic appearance, cell 
counts and the presence of lymphocyte predominance are required to assist the 
distinction between TBM and bacterial meningitis.  
 
Previous studies suggest that chest X-ray findings consistent with active pulmonary TB 
are observed in 70% to 84% of children with TBM. In my study (chapter 3.4) only 
46% of cases with TBM had chest radiograph findings highly suggestive of pulmonary 
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TB. A need to treat calculation showed that only 1 in 4.39 children ≤3 years of age 
with TBM are likely to have ‘certain TB’ on chest X-ray.  
 
PART III 
Microbiological confirmation of TBM remains the gold-standard of diagnosis, but is 
challenging in young children due to the paucibacillary nature of disease, low CSF 
volumes available for diagnostic analysis and sub-optimal sensitivity of direct 
microscopy for acid-fast bacilli and M.tuberculosis culture on CSF. Several new 
commercially available NAA tests have been developed for the rapid diagnosis of TB. 
In part III of the thesis my meta-analysis of newer commercial NAA tests found a 
summary sensitivity of 64% and specificity of 98%. Summary sensitivity of 
commercial NAA tests remains suboptimal and is unlikely to greatly enhance early 
accurate diagnosis. However, the excellent specificity suggests that commercial NAA 
tests may be regarded as definitive in the correct clinical setting. In 2013, the WHO 
recommended Xpert MTB/RIF® as the preferential initial investigation in all adults and 
pediatric TBM suspects. My sub-analysis of 5 studies reporting Xpert MTB/RIF® on 
CSF, found summary sensitivity of 70% and specificity of 97%.  
 
In chapter 4.2 I aim to assess the utility of MTBDRplus® and Xpert MTB/RIF® to 
diagnose TBM in a clinical setting, alone and/or in combination. The main finding was 
the incremental increase in diagnostic accuracy achieved with combined use of these 
commercial NAA tests performed on CSF. Although both NAA tests were superior to 
liquid culture, sensitivity remained low compared to a rigorous predefined clinical 
case definition. The MTBDRplus® assay performed with sensitivity of 33% (98% 
specificity), Xpert MTB/RIF® was 26% sensitive (100% specificity) and combining 
positive results from both these tests provided a sensitivity of 49% (98% specificity) 
against a TBM case definition. This is insufficient to serve as a rule-out test and 
provides limited clinical guidance. However, microbiological confirmation provided 
by a positive test prevents unnecessary treatment delay and potential life-threatening 
consequences. The additional advantage of a positive NAA test is that of early 
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A major limitation of this study was the failure to improve diagnosis of stage 1 
childhood TBM, mainly because it was hospital-based. Good surveillance at primary 
healthcare level, identifying children with poor weight-gain (or weight loss) and 
persistent non-remitting cough for longer than 2 weeks, could improve the detection 
of both childhood TB and early TBM. IMCI is potentially a valuable tool to increase 
awareness of TBM among healthcare workers, and in detecting early TB and TBM, as 
it is practiced at the healthcare level of first contact. Household contact tracing and 
prophylaxis with isoniazid therapy, as well as more general measures such as 
improving nutrition, housing and poverty relief, are valuable measures in preventing 
TBM in young children. 





Die vroeë identifisering van kinders met vermoedelike TBM berus op 'n deeglike 
geskiedenis, kliniese ondersoek en toepaslike spesiale ondersoeke weens die lae 
sensitiwiteit van definitiewe mikrobiologiese diagnose huidiglik. Vroeë diagnose is 
noodsaaklik vir spoedige inisiasie van behandeling. Mikrobiologiese bevestiging is 
selfs meer problematies in stadium 1 TBM omdat  lumbale punksie gewoonlik slegs 
gedoen word in kinders met kliniese tekens van meningisme (stadium 2 en 3 TBM). 
Met hierdie tesis, beoog ek om meganismes te ondersoek wat vroeë en/of meer 
akkurate diagnose van pediatriese TBM kan verbeter.  
 
DEEL I 
In hoofstuk 2 word die plaaslike diagnose en behandeling van kinder TBM beskryf wat 
in soortgelyke omgewings toegepas kan word. Hoogtepunte sluit in, eerstens, dat kort 
(6 maande) intensiewe terapie in kinders met middel-sensitiewe TBM veilig en 
doeltreffend is, met goeie uitkoms en ‘n lae sterftesyfer. Tweedens, tuis-gebaseerde 
TBM behandeling na aanvanklike binnepasient stabilisering is haalbaar in noukeurig 
geselekteerde pasiënte onder streng toesig. Derdens, die behandeling van 
tuberkuleuse hidrokefalus word bepaal deur die vlak van serebrospinale vog (SSV) 
obstruksie. Kommunikerende hidrokefalus kan suksesvol met mediese terapie 
behandel word, met normalisering van intrakraniale druk wat plaasvind binne dae in 
die meerderheid van kinders. Nie-kommunikerende hidrokefalus vereis 
neurochirurgiese intervensie. Vierdens, thalidomied is die plaaslike middel van keuse 




In kliniese praktyk, word TBM dikwels gediagnoseer op grond van 'n kombinasie van 
kliniese, laboratorium en radiologiese bevindings. 'n Eenvormige gevalsdefinisie, 
gebaseer op die bogenoemde kriteria  is  voorgestel deur 'n internasionale paneel van 
kundiges om die diagnostiese standaard vir navorsingsdoeleindes te verbeter. 
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TBM. Deel 2 van my tesis fokus op die diagnostiese nut van hierdie voorgestelde 
eenvormige  gevalsdefinisie kriteria vir TBM. In hoofstuk 3.1 evalueer ek retrospektief 
die diagnostiese akkuraatheid van waarskynlike en moontlike TBM kriteria in kinders 
met kultuur-bevestigde TBM en kultuur-bevestigde bakteriële meningitis. Die 
voorgestelde gevalsdefinisie het uitstekend vergelyk met mikrobiologies-bevestigde 
TBM wanneer 'n 'waarskynlike' TBM telling gebruik is. Wanneer 'n ‘moontlike’ TBM 
telling gebruik is, soos bepaal deur die gevalsdefinisie, was daar nie 'n enkele geval 
van TBM  gemis nie, maar kliniese nut was minimaal gegewe die lae spesifisiteit. Om 
my bevindinge te versterk het ek ook die diagnostiese akkuraatheid van die 
voorgestelde TBM gevalsdefinisie prospektiewelik ondersoek (sien hoofstuk 3.2). Die 
gevalsdefinisie het diagnosties uitstekend vergelyk met bakteriële en virale meningitis 
kontroles. Die hoë spesifisiteit van 'n ‘waarskynlike’ TBM telling soos verkry met 
behulp van die gevalsdefinisie regverdig die gebruik daarvan as 'n alternatiewe 
verwysingsstandaard tot mikrobiologiese bevestiging in toekomstige studies. In beide 
studies (retrospektief en prospektief) was swak sensitiwiteit verkry wanneer 'n 
‘waarskynlike’ TBM telling gebruik was vir vroeë (stadium 1) TBM diagnose. Hierdie 
bevinding bevestig weereens die belang van ‘n hoe indeks van suspisie van TBM in 
jong kinders met onlangse blootstelling aan TB en persisterende non-spesifieke 
kliniese simptome en tekens.  SSV bevindinge is noodsaaklik vir die vroeë diagnose 
van TBM, maar die bewyse vir afsnywaardes vir SSV glukose in TBM is gebrekkig. ‘n 
SSV proteïen afsnywaarde van >1g/L (100mg/dL) is wel bewys om te onderskei tussen 
gevalle van TBM en ander vorme van meningitis. My studie wat die diagnostiese 
waarde van SSV chemie uitslae in kinder TBM beskryf het bevind dat die optimale 
ondergrens van SSV glukose konsentrasie as 'n diagnostiese hulpmiddel vir TBM 2.2 
mmol/L was (sien hoofstuk 3.3). Absolute SSV glukose konsentrasie onderskei nie-TBM 
van TBM gevalle met sensitiwiteit van 68% en spesifisiteit van 96%, wat die gebruik 
daarvan as 'n eliminasie toets uitsluit. Gelyktydige bepaling van serum en SSV glukose 
was selde uitgevoer, maar ek het bevind dat die SSV tot serum glucose verhouding 
diagnostiese sensitiwiteit kan verbeter. ‘n SSV proteïen afsnywaarde van >1g/L asook 
ander kenmerke van SSV soos makroskopiese voorkoms, seltelling en die seltipe 
(oorwegend  limfosiete)  is van waarde in die onderskeiding  van  TBM en bakteriële 
meningitis.




Vorige studies het bevind dat 70% tot 84% van kinders met TBM borskas X-straal 
bevindinge het van aktiewe long TB. In my studie (hoofstuk 3.4), het slegs 46%, van 
kinders met TBM borskas X-straal bevindinge hoogs suggestief van long TB getoon. 'n 
Behoefte tot behandeling berekening (‘need to treat’) toon dat slegs 1 in 4.39 kinders 
≤3 jaar oud met TBM waarskynlik 'definitiewe  long TB' op borskas X-straal sal hê. 
 
DEEL III 
Mikrobiologiese bevestiging van TBM bly die goud-standaard van diagnose, maar stel 
hoë eise in jong kinders as gevolg van die lae basillêre tellings wat kenmerkend van 
TBM is, lae SSV volumes beskikbaar vir diagnostiese analise en sub-optimale 
sensitiwiteit van direkte mikroskopie vir suur-vaste basille en M.tuberculosis kultuur 
op SSV. Verskeie nuwe kommersieël beskikbare nukleiensuur amplifikasie (NSA) 
toetse is ontwikkel vir die spoedige diagnose van TB. In deel III van die tesis, het ‘n 
meta-analise van nuwe kommersiële NSA toetse ‘n opsommings sensitiwiteit van 64% 
en spesifisiteit van 98% bevind. Sensitiwiteit van kommersiële NSA toetse bly dus 
suboptimaal en daarom ‘n onwaarskynlike modaliteit vir verbetering van vroeë 
akkurate diagnose van TBM; die uitstekende spesifisiteit dui egter daarop dat ‘n 
positiewe kommersiële NSA toets as definitief van TBM beskou kan word in die 
korrekte kliniese omstandighede. In 2013 het die WGO Xpert MTB/RIF® as die 
voorkeur aanvanklike ondersoek aanbeveel in alle volwassenes en kinders met 
verdagte TBM. Vyf studies wat Xpert MTB/RIF® op SSV beskryf het opsommings 
sensitiwiteit van 70% en spesifisiteit van 97% bevind. 
 
In hoofstuk 4.2 stel ek my ten doel om die nut van MTBDRplus® en Xpert MTB/RIF®, 
onafhanklik en/of in kombinasie, vir die diagnose van TBM in 'n kliniese omgewing te 
evalueer. Die belangrikste bevinding van die studie was dat die gebruik van beide 
bogenoemde kommersiële NSA toetse op SSV die diagnostiese akkuraatheid verhoog 
het. Beide NSA toetse het beter sensitiwiteit getoon as SSV kultuur, maar was minder 
sensitief as ‘n streng gedefinieërde kliniese gevalsdefinisie. Die onderskeie sensitiwiteit 
en spesifisiteit was 33% en 98% vir die MTBDRplus® toets, 26% en 100% vir die 
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die TBM gevalsdefinisie. Dit is dus onvoldoende as 'n eliminasie toets en bied 
beperkte kliniese leiding, maar 'n positiewe toets bied vinnige mikrobiologiese 
bevestiging wat onnodige behandelingsvertraging en potensiële lewensgevaarlike 
nagevolge voorkom. ‘n Addisionele voordeel van ‘n positiewe NSA toets is die vroeë 
herkenning van mikrobakteriele weerstandigheid. 
 
'n Beperking van hierdie tesis is die feit dat diagnose van stadium 1 TBM in kinders 
nie verbeter is nie. ‘n Hoë indeks van suspisie, veral in kinders met swak 
gewigstoename (of gewigsverlies ) en kinders wat vir langer as 2 weke hoes, kan die 
diagnose van kinder TB en vroeë TBM verbeter. IMCI, wat op primêre sorg beoefen 
word, is potensieël 'n waardevolle hulpmiddel om gesondheidswerkers meer bewus te 
maak van TBM, en dus die diagnose van vroeë TB en TBM te verbeter. Die opsporing 
van huishoudelike TB kontakte sowel as profilakse met isoniasied, en meer algemene 
maatreëls soos die verbetering van behuising en die verligting van armoede, moet 
toenemend as 'n voorkomende strategie teen TBM aangewend word. 
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ACA Anterior carotid artery
AFB Acid-fast bacilli
ART Antiretroviral therapy
AUC Area under the curve
BI Bronchus intermedius
BCG Bacille Calmette-Guerin
CFU Colony forming unit
CI Confidence interval




CXR Chest radiograph/ Chset X-ray
DOR Diagnostic odds ratio
EPI Expanded program of vaccination
GCS Glasgow Coma Scale
HIV Human immunodeficiency virus
ICA Internal carotid artery
ICP Intracranial pressure
IGRA Interferon gamma release assay
IRIS Immune reconstitution inflammatory syndrome
IQR Interquartile range
LAD Lymphadenopathy
LMB Left main bronchus
MCA Middle carotid artery
MDG Millennium Development Goals
MGIT Mycobateria Growth Indicator Tube
MRA Magnetic resonance angiography
MRI Magnetic resonance imaging
M.tb Mycobacterium tuberculosis
M.tuberculosis Mycobacterium tuberculosis
NAAT Nucleic acid amplification test
NHLS National Health Laboratory Service
NON-COMM Non-communicating
NPV Negative predictive value
OR Odds ratio
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OR-QNRT Original quantitative nested real-time
PAS Para-aminosalicylic acid
PCR Polymerase chain reaction
PPV Positive predictive value
QUADAS-2 Quality Assessment of Diagnostic Accuracy Studies-2
ROC Receiver operating characteristic
SIADH Syndrome of inappropriate anti-diuretic hormone
SROC Summary receiver operating characteristic
TB Tuberculosis
TBM Tuberculous meningitis
TNF-α Tumor necrosis factor alpha
TST Tuberculin skin test
US Ultrasound
VPS Ventriculo-peritoneal shunt
WHO World Health Organization
WR-QNRT Wide-range quantitative nested real-time
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